University of Kentucky

UKnowledge
Theses and Dissertations--Social Work

College of Social Work

2012

EXAMINING CHRONIC NON-CANCER PAIN AMONG A SAMPLE OF
INDIVIDUALS IN OPIOID TREATMENT PROGRAMS
Erin Stevenson
University of Kentucky, erin.stevenson@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Stevenson, Erin, "EXAMINING CHRONIC NON-CANCER PAIN AMONG A SAMPLE OF INDIVIDUALS IN
OPIOID TREATMENT PROGRAMS" (2012). Theses and Dissertations--Social Work. 2.
https://uknowledge.uky.edu/csw_etds/2

This Doctoral Dissertation is brought to you for free and open access by the College of Social Work at UKnowledge.
It has been accepted for inclusion in Theses and Dissertations--Social Work by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Erin Stevenson, Student
Dr. Melanie D. Otis, Major Professor
Dr. David Royse, Director of Graduate Studies

EXAMINING CHRONIC NON-CANCER PAIN AMONG A SAMPLE OF INDIVIDUALS IN
OPIOID TREATMENT PROGRAMS

DISSERTATION
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in the
College of Social Work
at the University of Kentucky
By
Erin Stevenson, M.S.W., C.S.W.
Lexington, Kentucky
Director: Dr. Melanie D. Otis, Associate Professor of Social Work
Lexington, Kentucky
2012

Copyright © Erin Stevenson 2012

ABSTRACT OF DISSERTATION
EXAMINING CHRONIC NON-CANCER PAIN AMONG A SAMPLE OF INDIVIDUALS IN
OPIOID TREATMENT PROGRAMS
National rates of chronic non-cancer pain (CNCP) are rising alongside increasing reports of
prescription opioid abuse and mortality. Associations between the rise in CNCP and in opioid
abuse seem logical, yet research on CNCP among individuals with opioid dependence is
currently limited due to the complicated nature of comorbid conditions in research and
treatment. This study aims to expand the CNCP knowledge base by responding to the question:
Do individuals with CNCP participating in an opiate treatment program have better or worse
treatment outcomes than individuals without CNCP?
This study used a secondary dataset including 483 adults from Kentucky’s Opiate Recovery
Treatment Outcome Study. Individuals in the sample met DSM-IV-TR criteria for opioid
dependence and were in treatment at a licensed opiate treatment program (OTP). Analysis
compared cases with and without CNCP on national treatment outcome measures including
substance use, recovery support, education, employment, mental health symptoms, and
criminal justice system involvement.
Results indicated no differences at follow-up between the CNCP (n=163) and non-CNCP (n=320)
individuals on substance abstinence, recovery supports, education level, or criminal justice
system involvement. At baseline and follow-up there were more unemployed individuals and
individuals receiving disability benefits in the CNCP group than the non-CNCP group. Reported
anxiety and depression symptoms increased at follow-up, while use of prescription medicine for
mental health symptoms declined for both groups (non-significant differences). The only
predictors for CNCP cases in this sample were tobacco use and presence of a chronic medical
condition.
Recommendations include expansion of smoking cessation programs in substance abuse
treatment settings. Future research might examine integrated treatment and medical home
health models to better address biopsychosocial components of clients with comorbid
conditions like opioid dependence and CNCP.
KEYWORDS: chronic non-cancer pain (CNCP), opioid dependence, opiate treatment programs
(OTPs), chronic medical conditions, tobacco
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CHAPTER 1. INTRODUCTION
Individuals experiencing physical non-cancer related pain that persists or recurs for
three months or longer are considered to have chronic-non-cancer pain or CNCP (International
Association for the Study of Pain Society [IASP], 2011). CNCP prevalence rates are on the rise
worldwide (Haanpaa et al., 2009) with 1 in 10 adults newly diagnosed each year (IASP, 2011).
Recent estimates from the Institute of Medicine indicate CNCP affects over 116 million adults
annually (2011). These numbers are expected to continue rising in the United States due to a
variety of issues including high rates of obesity, diabetes, arthritis, and an increasingly aging
population (Institute of Medicine [IOM], 2011). Though the natural aging process itself is not
associated with pain, the odds of developing painful health conditions does increase with age
(Tunks, Crook, & Weir, 2008) and United States census estimates show almost 60% of the
population will be age 50 or older by the year 2025 (U.S. Census Bureau, 2010).
Opioid analgesics are frequently prescribed for acute and chronic pain relief, despite
their high abuse liability potential (Katz, 2010). A review of 24 studies found less than 1% of
legitimate opioid analgesic users without prior substance abuse history ever abused or
developed opioid dependence to prescribed pain medication (Fishbain, Cole, Lewis, Rosomoff, &
Rosomoff, 2008), however. Nevertheless, two-thirds of a nationally representative sample of
clients in substance abuse treatment reported their initial use of opioids, which led to their
current opioid dependence, was through a legitimate opioid analgesic prescription for pain
(Cicero, Lynskey, Todorov, Inciardi, & Surratt, 2008). In fact, between 1992 and 2009 the rate of
substance abuse treatment admissions reporting opioid abuse quadrupled while rates of
reported use for other drug categories stayed the same or dropped slightly (SAMHSA, 2010).
The rise in prevalence of CNCP parallels this rapid rise in prescription painkiller abuse and opioid
dependence (Cicero, Inciardi, & Munoz, 2005; SAMHSA, 2003b; SAMHSA, 2010) and highlights
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an area of research needed in regards to CNCP among individuals who are already addicted to
opioids and are in substance abuse treatment.
The literature currently provides limited information regarding the overlap between
CNCP and opioid dependence (Manchikanti et al., 2006; Strain, 2002). Studies among opioid
dependent individuals in methadone maintenance treatment found 37% to 66% of clients
reported CNCP (Barry et al., 2009; Rosenblum et al., 2003). Other studies found 24% of
residential drug treatment patients (Rosenblum et al., 2003) and 29% of individuals in
outpatient substance abuse treatment (Sheu et al., 2008) reported CNCP. Self-medication of
pain was a primary reason clients gave for abuse of prescription medications (Khantzian, 1998;
Sheu et al., 2008). Guidance on how best to provide effective treatment for individuals in opioid
dependence treatment programs (OTPs) with comorbid CNCP is a gap in the current literature.
Yet, it is an important area to address as these conditions continue to expand their influence
and may have a negative association to recovery. Research protocols including samples with a
variety of comorbidities like CNCP are currently limited, thus a good first step is to examine
CNCP in relation to opioid dependence treatment outcomes.
Purpose of this Dissertation
The concurrent rise in CNCP and opioid abuse rates triggered a dissertation that
explores CNCP amongst a secondary client-level dataset from Kentucky’s opiate treatment
programs (OTPs). The study examines treatment outcomes for a sample of 483 individuals who
were clients in licensed OTPs in Kentucky between March 2007 and December 2010. Admission
to the OTP required that all individuals meet clinical criteria for opioid dependence (DSM-IV-TR
definition). All clients in state OTPs are offered the opportunity to participate in the Kentucky
Opiate Replacement Treatment Outcome Study (KORTOS) from which the secondary dataset is
derived. KORTOS examines long-term outcomes and treatment effects among clients in
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maintenance methadone or buprenorphine treatment at OTPs, thus the range of exposure to
treatment varies within the dataset. It is important to note there are strict regulations guiding
treatment protocols across all federally licensed OTPs. These guidelines require annual medical
check-ups, random observed drug screens, random take-home medication checks to ensure
clients are not diverting take-home medication doses, and substance abuse counseling (Center
for Substance Abuse Treatment [CSAT], 2005). OTP clients across the state of Kentucky have
very similar cross-site treatment experiences due to the strict Federal and state oversight of the
treatment program protocols.
Within the dataset analyzed for this paper, 37% of clients reported the presence of
CNCP (i.e., chronic physical pain persisting or recurring for three months or longer and not
related to cancer [IASP,2011]). Research provides some evidence of a correlation between
CNCP and opioid dependence (Hojsted, Nielsen, Guldstrand, Frich, & Sjogren, 2010;
Manchikanti, Fellows, Damron, Pampati, & McManus, 2005), but to my knowledge there have
been no studies to date that address the impact of the comorbidity of CNCP and opioid
dependence on outcomes for individuals receiving maintenance treatment with methadone or
buprenorphine medication at a licensed OTP. Thus, the purpose of this exploratory study is to
examine treatment outcomes specifically based on the presence or absence of CNCP. Outcomes
will focus on national measures that compare OTP client self-reported status from baseline to
follow-up regarding the following areas of interest:
1. Abstinence from alcohol use;
2. Abstinence from illicit drug use;
3. New or maintained employment;
4. Decreased mental health symptoms;
5. Decreased criminal justice system involvement; and
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6. Recovery support use.
Study Aims
The study’s primary goal is to expand the research regarding CNCP by examining
outcomes among opioid dependence treatment clients. The dataset used for this study was
compiled by staff at the University of Kentucky who followed a research protocol that started
the process of locating and contacting clients for a follow-up telephone interview two months
prior to the client’s follow-up eligibility date calculated as baseline date plus 180 days. The
window for follow-up remained open two months after the eligibility date in order to allow
sufficient time to locate the client and complete the 30-minute follow-up phone interview.
Individuals had been in treatment for an average of 15 months at follow-up.
Specifically, this study aims to examine characteristics of the sample by comparing
individuals with and without CNCP on key variables including: sex, age, race/ethnicity,
geographical location for treatment (Appalachian, non-Appalachian), length of time in
treatment, dose level, education level, employment status, substance use history, and mental
health symptoms.
In addition, the study aims to explore the relationship between CNCP and treatment
outcomes. The outcome most relevant to OTPs is abstinence from or reduction in illegal drug
use and alcohol use (CSAT, 2005). In addition, the study will examine changes by individual pain
group status from baseline to follow-up while controlling for age, gender, race/ethnicity,
geographical location of treatment, and presence of chronic medical conditions. Key follow-up
variables will include employment status, mental health symptoms, abstinence from drug use,
abstinence from alcohol use, and connection with recovery supports (i.e., narcotics anonymous
(NA), methadone anonymous (MA), family and friends who are supportive of recovery). Each of
these outcomes can help provide a measure of the individual’s ability to participate in and
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contribute to family and/or work communities in a stable way while also participating in opioid
maintenance treatment.
Conceptual Framework of the Study
The literature indicates biological, psychologial, and social conditions can influence the
likelihood of an individual developing CNCP and/or opioid dependence. Though research is
minimal and in no way definitive, it is clear that biopsychosocial factors play a part in the
process of developing these conditions (Strain, 2002; IOM, 2011). Thus, this study relies on the
biopsychosocial framework as a guide for its research questions and data analyses. The
biopsychosocial framework is not a stand-alone testable theory, but is rather a combination of
concepts that provides a useful heuristic for the examination of the complications inherent in
both opioid dependence and chronic pain. The use of a wider structure such as offered by the
biopsychosocial framework is essential to help us understand these disorders and attempt to
capture and weave together the physical, mental, and emotional aspects of the disorders
involved (Gatchel & Kishino, 2011; Gatchel, Peng, Peters, Fuchs & Turk, 2007). The following
paragraphs will expand on the inter-relatedness of the biopsychosocial framework in relation to
CNCP and opioid dependence.
Biopsychosocial framework and CNCP.
The concept of pain with which most people are keenly aware is the individual
psychological and emotional reaction to a negative physical sensation. In the early 1900’s,
scientists began examining the wide range of individual differences found among persons with
medically similar painful conditions, but who expressed very different ranges of pain ratings and
reactions. This discovery triggered scientific exploration of potential pain centers in the body
theorized as interacting with neural structures in the brain in order to guide how a person’s
mind translates and reacts to pain (Bonica & Loeser, 2001).
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In 1965, Melzack and Wall published their seminal work on the gate control theory of
pain, which identified the transmission of pain signals across the dorsal horn area at the top of
the spinal cord and into the central nervous system. Specialized nerve cells with temporal and
spatial patterning were acknowledged and the basis of the theory was that the brain had the
ability to gate or control impulses from the nervous system regarding pain. The implication of
this theory was particularly significant for pain control research and new treatment methods
quickly expanded based on the theory. One method developed to mediate pain was called
transcutaneous electrical nerve stimulation (TENS) which was a mechanism used to block
transmission of pain messages across the dorsal horn in the brain and thus reduce the
individuals’ perception of painful stimuli (Patel, 2010).
Over the next few decades, the biological aspects of pain were linked to the
psychological and social aspects including such phenomena as loss of work and strained family
relationships due to CNCP (Gatchel et al., 2007). In fact, diagnosing conjoint depression with
CNCP is very difficult because of the shared symptomology between diagnoses including sleep
disturbances, fatigue, and attention/memory issues (Sharp & Keefe, 2006). Thus, since the
spectrum of consequences of CNCP encompass not only the biological elements of a person, but
also social and psychological elements, the biopsychosocial framework has become the most
applicable framework for understanding and researching CNCP (Gatchel et al., 2007).
Biopsychosocial framework and opioid dependence.
The primary variable of interest in this study is CNCP, yet everyone in the sample has in
common opioid dependence. Consequently, it is also important to understand opioid
dependence within the context of the biopsychosocial framework. The American Society of
Addiction Medicine defines substance abuse and dependence as “a chronic recurring brain
disease” characterized by compulsive alcohol or drug use despite evidence of harmful effects
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(12 April 2011, www.asam.org; National Institute on Drug Abuse, 2010). In the not so distant
past, chemical dependence was viewed as moral weakness (Brown, 2006; O’Brien & McClellan,
1996), an attempt to self-medicate untreated mental health issues (Mueser, Drake, Turner, &
McGovern, 2006), or simply a failure by individuals to control their behavior (O’Brien &
McClellan, 1996; Straussner & Attia, 2002). In 1914, the Harrison Act set in motion the
criminalization of drug use and dependence in the United States by penalizing physicians for
maintaining opiate dependent clients, often morphine dependent as this was before synthetic
opioids were widely available, to prevent them from going into withdrawal. Many women at
the turn of the century were prescribed opiates like paregoric or opium derivatives for nervous
conditions and the 1914 law began a forced shift in thinking about whether or not this reliance
on drugs was acceptable in society (Campbell, 2010). Ironically, at the turn of the century, it was
morally and socially unacceptable for women to drink, yet they were encouraged to take alcohol
and opiate-based medications for all manner of aches, pains, and complaints (Brown, 2006). For
men, drinking together was a social event and a strong part of work and business culture. In
fact, the initial Alcoholics Anonymous (AA) meetings in 1935 were for men only which points
towards the beginning of a shift in cultural values surrounding alcohol use (Brown, 2006).
During this period, psychoanalysts described substance abuse in terms of an individual failing to
control impulses or to act responsibly (Straussner & Attia, 2002). Drug and alcohol use
problems were viewed as a personal or family problem and as a moral flaw leading to
degenerate and dangerous behavior. This was a particularly strong criticism made by the upper
classes towards individuals with lower socioeconomic resources and the rising number of
immigrants at the turn of the century (Campbell, 2010). The criminalization of drug or alcohol
dependence even led to forced sterilization of some women (Straussner & Attia, 2002).
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Further attempts to control drug and alcohol use was the establishment of treatment
and research facilities. In 1935, the Federal prison in Lexington, Kentucky established the
Narcotic Treatment Farm. The Lexington research facility was a human laboratory developed to
examine heroin and morphine dependence and to develop appropriate treatment for addiction.
The center had joint oversight both by the United States Public Health Service and the Federal
Department for Corrections. In 1938, a similar facility was established in Fort Worth, Texas. For
many decades, these were the only alcohol and drug dependence treatment and research
facilities that worked with human subjects (Campbell, 2010).
Early biological studies of addictive behavior were also conducted on alcohol and
morphine addicted monkeys and found that once an animal habituated to use of a drug, the
body’s natural desire is to maintain homeostasis, including maintaining levels of drugs in the
system (Campbell, 2010). Around 1960, Morton Jellinek publicized a disease model for abuse
and dependence on drugs and/or alcohol, which helped to ease stigma attached to substance
abuse and brought a renewed focus on understanding the biology behind drug and alcohol
dependence and effective treatment (Brown, 2006). Today, most behavioral health
professionals accept that abuse and dependence on drugs and/or alcohol is a chronic relapsing
brain disease caused by damaged reward-based circuits in the brain (Koob, 2006; 2011) and
influenced by psychological and social factors (Gatchel & Kishino, 2011). In fact, changes in
brain activity can be traced to even minor levels of opioid use (Younger et al., 2011). Brain scans
and post-mortem examinations of opioid dependent brains shows negative correlation between
years of drug use and volume of the prefrontal cortex, an area of the brain, which is heavily
involved in decision-making (Garcia-Sevilla et al., 1997; Liu, Matochik, Cadet, & London, 1998).
The central nervous system (CNS) plays a key role in an individuals’ decision-making abilities and
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the damaged CNS found among long-term drug users is outwardly reflected in their poor social
decisions and ongoing drug use, despite negative consequences (Lyvers, 2000).
The currently accepted standard for substance abuse research and treatment is a
biopsychosocial framework that includes the biological, psychological, and social life
circumstances that increase an individual’s vulnerability to substance abuse and play a role in
recovery and/or relapse behaviors (Gatchel & Kishino, 2011; Koob, 2011). Neuroscientific and
medical research contributes information on the biological perspective of chemical dependence,
while psychology provides insight into the mind’s perception of the body’s need for drugs to
cope with daily living. Sociological and behavioral research contributes information on the
social influences of environment and social network (i.e., family, friends, intimate partners, work
cohorts) in initiating and perpetuating chemical dependence. These factors weave together to
form a biopsychosocial framework for understanding abuse and dependence on drugs and
alcohol.
Biopsychosocial framework within this study.
For this study, opioid dependence treatment outcomes will be examined among OTP
clients, comparing individuals with and without CNCP (i.e., chronic pain persisting or recurring
for 3 months or longer as reported during the baseline interview). Figure 1 displays the
conceptual framework for this exploratory study using the biopsychosocial framework.
Predisposing factors include characteristics like age, sex, chronic medical conditions, mental
health and substance use history. The clinical characteristic examined in this study is CNCP. The
intervention for this sample is treatment with either methadone or buprenorphine medication
provided within a Federally regulated OTP. The fact that the treatment is provided in an OTP is
important to note because of the strict guidelines and protocol for dosing, counseling, and
monitoring that occur at these programs under Federal and state oversight (CSAT, 2005).
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Outcomes are the “successes” that clients hope to achieve as they progress through treatment
including reduced drug and alcohol use, employment, improved recovery support connections,
and decreased mental health symptoms.
Figure 1. Conceptual framework

Predisposing
Factors
Biological (i.e. sex,
age, chronic medical
conditions, substance
abuse - opioid
dependence)
Psychological (i.e.
mental health,
perception of control
over CNCP)

Clinical
Characteristic

Intervention

Outcomes
Alcohol and drug use
abstinence
Recovery support

Opiate Treatment
Program services
with Methadone or
Buprenorphine
maintenance

Co-occurring chronic
non-cancer pain

Social (i.e., recovery
support, employment,
education, geography)

Maintained or new
employment and
education
Decreased criminal
justice system
involvement
Decreased mental
health symptoms

Predisposing factors.
Both CNCP and opioid dependence have biological, psychological, and social
components (Bruns & Disorbio, 2005) that interact with each other in a variety of ways for each
person. An individual’s biologically determined factors of sex, age, and physical health may be
linked to an increased likelihood of CNCP, drug or alcohol abuse, depression, or anxiety. For
example, research indicates females in the general population are twice as likely as males to
develop chronic pain and females have higher rates of depression than men (Tsang et al., 2008).
In addition, the likelihood of developing physical health problems and painful conditions
increase in prevalence as a person ages (Tunks et al., 2008). Race (a biological factor) is
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correlated with lack of employment (a social factor) which is in turn linked to poor mental health
(a psychological factor) (Crum, 2009).
Mental health conditions like depression or anxiety are correlated with an increased risk
of developing opioid dependence and/or CNCP. Depression and anxiety are also correlated
with having a history of sexual, physical, or emotional abuse, which in turn increases an
indiviudal’s risk of developing drug or alcohol dependence and/or CNCP (Sansone, Whitecar &
Wiederman, 2009). Substance abuse has been linked to a history of psychological problems,
physical/sexual abuse (Engstrom, El-Bassel, Go, & Gilbert, 2008), and pain perception (Gatchel &
Kishino, 2011). Specifically, opioid dependence is correlated with depression (Becker, Sullivan,
Tetrault, Desai, & Fiellin, 2008) and tobacco use is related to signficantly poorer opioid
treatment outcomes (Ziedonis et al., 2009). Even a person’s perception of their ability to control
their pain is related to the interference or impairment CNCP has in a person’s life (Gatchel &
Kishino, 2011; McCracken & Vowles, 2008).
An individual with CNCP who lives in a rural or geographically isolated area will likely
have limited resources for pain management support (Hamilton et al., 2008) or treatment of
drug dependence (Havens et al., 2007). Social factors such as socioeconomic levels of income
and support are hamperd by limited access to resources and economic development
opportunities in many rural areas (Hamilton et al., 2008). Limited peer support is correlated
with negative treatment outcomes and includes the difficulty small town or rural individuals
may have in establishing new connections separate from their old drug using or trafficking
friends (Skinner, Haggerty, Fleming, Catalano, & Gainey, 2011). Additionally, community-level
economic issues make employment more difficult to maintain and improve in rural or
geographically isolated areas like Appalachia compared to more urban or metropolitan areas
(Hamilton et al., 2008). For example, the United States declared a recession between 2007 and
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2009. December 2011 Bureau of Labor Statistics data show rural areas in the state still below
national averages in available jobs with about 3.7% fewer jobs available in rural areas. To be
effective, treatment must take into account all of these different and intertwining
biopsychosocial combinations present in each individual. Notably, in the dataset for this study,
less than 1% of the cases are non-white, thus the issue of race cannot be fully examined here.
Co-occurring CNCP.
This study focuses on the intersection between opioid dependence and chronic noncancer pain (CNCP) as it relates to treatment outcomes. Though it is physiological phenomenon,
in this study chronic non-cancer pain (CNCP) is self-reported and is not captured through clinical
tests. Individuals met clinical criteria for opiate dependence and reported CNCP at baseline in
order to be considered as having co-occurring CNCP and opioid dependence in this study.
Intervention.
The intervention in this conceptual model is the treatment provided to the client
through the OTP. Federally licensed OTPs must follow the regulatory requirements of the
Substance Abuse and Mental Health Administrative Services, Center for Substance Abuse
Treatment, and the Office of Drug Control Policy. In addition they must follow state regulations
(Kentucky Narcotic Treatment Agency Regulations 908 KAR 1:340) or accrediting body protocols
(i.e., Joint Commission for Accreditation of Healthcare Organizations, Commission on
Accreditation of Rehabilitation Facilities). Kentucky regulations are among the most stringent in
the country and go above and beyond Federal guidelines. Admittance for treatment requires
proof that the person has been addicted to opioids for at least one year. All new clients receive
a full physical and are medically monitored as they are inducted to find the appropriate
medication dose for their body’s metabolism of methadone or buprenorphine. Daily in-person
medication dosing is required at all OTPS, along with weekly random observed urine drug
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screens, and weekly counseling sessions for the first 180 days of treatment. If the client has
been compliant with the treatment plan, including negative drug screens, the client may earn
the right to have one take-home dose per week. Weekly drug screens and counseling continue
through the sixth month of treatment and may continue longer or be reinstated depending on
client compliance with regulations and drug screens (908 KAR 1:340).
The majority of OTP clients in Kentucky take methadone, as opposed to buprenorphine
(Stevenson, Cole, Walker, Logan, & Mateyoke-Scrivner, 2011). Methadone is a synthetic opioid
agonist that binds with and occupies all the opioid receptor sites in the brain hindering other
substances from activating those receptors (CSAT, 2005). This means use of methadone reduces
or eliminates cravings and withdrawal symptoms, and at the same time does not create
euphoria when dosed properly. Methadone can be prescribed at higher doses (60-120mg
average), but is only taken daily because it has a half-life in the body of up to 48 hours.
Buprenorphine is a partial agonist that also binds with opioid receptors, but has a ceiling of 32
mg at which it hits maximum effectiveness (TIP 43, CSAT, 2005). The 32mg dose of
buprenorphine is comparable to about 120 mg of methadone (CSAT, 2005). Since methadone is
a full agonist medication, there is no ceiling effect. This allows for higher doses, but also a
greater potential for diversion, misuse, and abuse. Therapeutic threshold for methadone dose
is at or above 80 mg daily (Pollack & D’Aunno, 2008), while recent studies relate methadone
doses around 100 mg per day to better treatment outcomes and fewer relapse episodes (Fareed
et al., 2009). Buprenorphine is a more expensive treatment than methadone, but it is generally
covered by insurance and Medicaid, while methadone is not currently covered except for use in
pain control (Jones et al., 2009).
Outcomes.
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Generally, CNCP treatment focuses on reduction of pain and the impact pain has in the
individual’s ability to participate in daily life (i.e., work, home, family). The sample of individuals
with CNCP for this study is from an opioid dependence treatment setting. Therefore, problems
associated with CNCP are not addressed directly. The primary goal of treatment provided by an
OTP is to help clients achieve abstinence or reduction in illegal drug use and alcohol use (CSAT,
2005). Other positive outcomes include acquisition of or maintenance of employment,
reduction of mental health symptoms like depression or anxiety, reduction in criminal justice
system involvement, and connections with recovery support (i.e., Narcotics Anonymous (NA),
Methadone Anonymous (MA), family and friends who are supportive of the person’s recovery
efforts). Each of these outcomes is a measure of client stability and helps to demonstrate an
improvement in the individual’s positive engagement with family, work, and community. These
areas may become the focus of individual substance abuse treatment counseling sessions or
may result in referrals to other service providers outside of the OTP. The literature does not
currently address whether or not these outcomes are influenced by the presence of CNCP.
Description of this Exploratory Study
The current study is exploratory in nature. Based on an extensive search of the
literature, to my knowledge, no research with a sample of OTP clients has explored the impact
of CNCP on client-level opioid dependence treatment outcomes. This study proposes an
examination of the effect of CNCP among OTP maintenance clients. The study has one primary
research question:
Do individuals with CNCP participating in an opiate treatment program (OTP) have
better or worse treatment outcomes than those without CNCP (i.e., drug or alcohol use,
employment, mental health symptoms, criminal justice involvement, and connection
with recovery support networks?
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Current research literature does not appear to answer this question and yet such information
would be vital in treatment planning, case management, and family/client education. According
to Federal regulation, all licensed OTPs must provide clients with regular counseling, an initial
and annual medical screening and referrals, and regular testing for illicit drug use (i.e., urine,
saliva screens) in addition to opioid dependence treatment medication (i.e., methadone or
buprenorphine) (CSAT, 2005; CSAT, 2004). If the OTP identifies the client as having comorbid
physical health problems like hepatitis, diabetes, or CNCP, the client is referred to medical
treatment outside the OTP. Similarly, mental health problems that cannot be addressed during
the client’s required counseling sessions during treatment are referred to mental health care
providers outside of the OTP. Extant research on substance abuse treatment indicates
outcomes are commonly worse for individuals with comorbid mental health problems,
particularly depression and/or anxiety (Laudet, Magura, Vogel, & Knight, 2000; Skinner et al.,
2011). This referral system perpetuates a uni-dimensional approach to treatment, despite
evidence suggesting recovery occurs best within integrated treatment provision (Clark, Power,
Le Fauve, & Lopez, 2008).
This study theorizes that individuals in the sample with CNCP will exhibit poorer
treatment outcomes at follow-up compared to the individuals without CNCP. Best practices for
treating comorbid physical and mental health conditions are to provide integrated treatment
services. Since the focus of opioid dependence treatment programs is not on mental health or
pain management, it may be that clients in OTPs struggling with CNCP as well as depression or
anxiety do not receive the holistic assistance needed to help the individual. This study attempts
to provide insights into treatment outcomes for individuals who have CNCP while in opioid
dependence treatment programs in order to begin to fill the information gap regarding this
condition.
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CHAPTER 2. LITERATURE REVIEW
Scope of the Problem
The Institute of Medicine (2011) states CNCP affects 116 million U.S. adults annually.
The numbers are rising globally with one in ten adults newly diagnosed with CNCP each year
(IASP, 2011). Federal and State government expenditures for medical needs of those with
chronic pain were estimated at $99 billion in 2008 (IOM, 2011). In conjunction with the rising
number of adults with CNCP, the numbers of legitimate opioid prescriptions for CNCP have
increased in the past decade, with prescriptions obtained through general practitioners and
specialized pain management clinics (Stannard, 2011). Per capita, Kentucky had the fourth
highest number of filled prescriptions (17.1) in 2009 compared to the lowest number (6.4) in
Alaska (www.statehealthfacts.org). Though these figures include both opioid and non-opioid
prescriptions, the high volume of prescription medications per capita in Kentucky means there is
an increased potential for accidental overdose and misuse of medications. Despite the fact that
many individuals have legitimate opioid prescriptions for treatment of CNCP (Zacny et al., 2003),
there have been coinciding increases across the U.S. in emergency room visits for overdose.
These overdose numbers are correlated with the increased number of filled prescriptions and
increased non-medical use of prescription opioids (SAMHSA, 2003b).
Alongside the increase in legitimate opioid prescriptions in the U.S., there has also been
a significant increase in misuse of prescription painkillers with the largest percentage reported
among the 18-24 year old population (SAMHSA, 2003a). A 2009 general population U.S. survey
found that 5 million adults reported non-medical prescription opioid use in the past year and
opioid dependence related treatment admissions were at their highest in ten years (SAMHSA,
2010). Comparing state by state, Kentucky has one of the highest percentages of individuals
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seeking treatment for opioid abuse at 24% of admissions in 2009 compared to only 7% of
admissions nationwide (SAMHSA, 2011a).
Despite the increases in CNCP and prescription opioid abuse and the distinct
correlations between these disorders, data and journal articles available on individuals in opioid
dependence treatment with CNCP is currently limited. A trend in the past has been to exclude
individuals with an opioid dependence history from medical studies and similarly to exclude
patients with chronic pain from opioid treatment samples in an effort to exclude the
confounding effects of the comorbid conditions (Angelino, Clark, & Treisman, 2005). This
literature review will summarize current research that defines, describes, and provides insights
into CNCP.
Defining CNCP
Most people understand pain to be a noxious stimulus experienced by the body that is
by nature unpleasant and uncomfortable. Pain can be classified using distinctions based on the
temporality or length of time the pain has been endured, primarily divided between pain that is
acute (i.e., short-term) and pain that is chronic (Johannes, Le, Zhou, Johnston, & Dworkin, 2010;
Portenoy, Payne, & Passik, 2005). Acute pain occurs suddenly in response to an injury such as a
twisted ankle, burned finger, or broken arm. In most cases, the source of acute pain is known
and treatment is available to help heal the injury. Acute pain is short lived and intensity of the
pain decreases as healing occurs (Field & Swarm, 2008). On the other hand, chronic pain is
persistent or recurring pain that lasts beyond the expected healing period for an injury. Most
medical and research studies define 3 months as the marker at which point pain moves into the
category considered chronic (Jamison, Butler, Budman, Edwards, & Wasan, 2010). Cancerrelated pain is often considered medically different from non-cancer pain in that the cause of
the pain is understood and a course of treatment is typically available. Pain that is not acute, or
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is not rooted in a diagnosed cancer is termed chronic non-cancer pain or CNCP. This pain is
much more complex than either acute or cancer-based pain because of its enduring quality and
its long-term interference with daily functioning and overall physical and emotional health (Field
& Swarm, 2008; Portenoy et al., 2005).
CNCP prevalence.
Prevalence rates for CNCP range from 19% to 66% depending on the survey methods
and sample, though all of these studies used the same definition of CNCP which is pain
persisting or recurring for 3 months or longer, not related to cancer (Breivik, Collett, Ventafridda,
Cohen, & Gallacher, 2008; Portenoy, Ugarte, Fuller, & Haas, 2004; Tsang et al., 2008). A large
European study found 6-month CNCP prevalence rates of 19% among adults in the general
population who responded to a random digit-dialed phone survey (Breivik et al., 2008). Tsang
and colleagues (2008) combined data from 18 adult population surveys and found past 12month CNCP prevalence rates of 41.1% in developing countries and 37.3% in developed
countries. A 2003 telephone survey with adults in the U.S. found one-third of individuals had
experienced chronic pain in the past year (Portenoy et al., 2004). Despite extensive searches, no
literature was found that could provide state-by-state prevalence or estimates of CNCP. The
Centers for Disease Control (CDC) report annually on state-level risks for chronic diseases like
diabetes, pulmonary disorders, and musculoskeletal conditions that may lead to disability and
CNCP (2008). Reviewing Kentucky’s risk factors for chronic diseases compared to the general
U.S., state data reflect higher rates of being overweight or obese (69.1% KY vs. 63.0% U.S.),
cigarette smoking (28.2% vs. 19.8%), and lack of preventive health care or health coverage (19%
vs. 17%) among Kentucky adults (CDC, 2008). Though CNCP is not directly identified in the CDC
reports, it is understood that poor health and disability are correlated with the development of
CNCP (Katz, 2010).
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Causes of pain are diverse and may include multiple injuries and damage to tissue or
nerves. Among a general population survey of adults in the U.S. with CNCP in the past 3
months, 25% reported low back pain while 13% reported neck pain with similar prevalence rates
among racial groups and by sex (Lawrence et al., 2008). Other examples of CNCP sources
include diabetes, HIV/AIDs, shingles, migraine, trauma from an accident or surgery, and
endometriosis. Locations of CNCP in the body are also diverse and may shift around the body in
the case of nerve damage, or may hover in one area like low back, knees, chronic headache, or
neck pain. In a recent analysis of the general U.S. population, over 26% of adults reported
arthritis and respondents with a BMI of 30 or greater were 1.9 times more likely to report
arthritis compared to adults with a lower BMI (Wilson, Zakkak & Lanier, 2009). Using
standardized prevalence rates adjusted for age another study examined specific chronic pain
conditions in the past 12 months as reported by survey respondents (N=42,249) across both
developing (n=10) and developed (n=7) countries. Respondents reported CNCP conditions of
back pain (20.0%), arthritis or joint pain (16.5%), headache (14.4%), and other unspecified
chronic pain (6.9%) (Tsang et al., 2008). A European sample of adults with CNCP in the general
population reported that 66% of respondents rated their pain as moderately severe (5-7 on a
scale from 0=no pain to 10=worst possible), while another 34% reported very severe pain (8-10
on scale) (Breivik et al., 2008). In the same sample, 59% of respondents reported they had
struggled with CNCP for a range of 2 and 15 years, and 40% stated their pain was inadequately
managed by their physician (Breivik et al., 2008).
Biology of CNCP.
As stated previously, the origin of an individual incidence of CNCP may be a single
accident or injury or condition, or it may have multiple origins, or the origin may be unknown
(Field & Swarm, 2008). Despite the wide variance in origin, CNCP is usually identified as having
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one of the following primary modes of pain transmission within the body: nociceptive, central,
or neuropathic. Nociceptive pain refers to tissue damage and is usually responsive to opioids
and over-the-counter medications like aspirin or acetaminophen for pain control (Field &
Swarm, 2008). Central pain includes pain due to a damaged central nervous system (brain and
spinal cord) such as a brain injury incurred by many returning war veterans. Neuropathic pain
refers to damage in either peripheral or central nerves such as occurs with multiple sclerosis,
diabetes, and fibromyalgia. This type of pain is very difficult to treat and the opioid class of
drugs rarely provides long-term analgesia (Dworkin et al., 2007). Compared to central or
nociceptive pain, neuropathic pain correlates with a significantly lower quality of life and with a
higher degree of impairment in day-to-day activities (Doth, Hansson, Jensen & Taylor, 2010).
Over the past decade, CNCP has been labeled an illness in itself due to the complicated
mass of symptoms it encompasses within the biological, psychological, and social realms of an
individual’s life (Gatchel & Kishino, 2011; Turk, Wilson, & Cahana, 2011). The process by which
our bodies recognize and respond to pain begins with the biological impact when the body
sustains an injury, wound, or illness that causes tissue discomfort or inflammation. The process
of the body as it responds to the injurious stimuli is called nociception (Patel, 2010). Nociception
triggers the sending of a signal about the stimuli to the affected nerve tissues through
neurotransmitter messengers, which then travel through the central nervous system to the
brain (Gazzaniga, 1989). The injury is typically not labeled pain until the information is
processed by the brain upon receipt of the message from the nerve tissues, though pain can
begin to occur without nociception or obvious tissue damage in patients with CNCP due to
permanent damage to the nervous system (Patel, 2010). CNCP is very complex in nature
because of the heavy involvement of the brain and nervous system in its detection, moderation,
and the resulting response signals the brain sends back to the body.

20

Endogenous opioids.
A discussion of the biochemistry of CNCP naturally leads to one of the body’s key
internal mechanisms for moderating pain: the endogenous opioid system. Endogenous opioids
include enkephalins, endorphins, and dynorphins, which all work by readily binding to opioid
receptors and helping naturally modulate pain in the body (Patel, 2010). Nociceptive or
inflammatory pain triggers release of endogenous opioids that help to inhibit and control pain at
the mu receptor as an agonist (Harvey & Dickenson, 2010). This innate pain relieving system
consists of neurons and opioid neurotransmitters that bind with three types of receptor cells –
the mu, kappa, and delta receptors (Holden, Jeong, & Forrest, 2005) and opioid-based drugs
bind with these same three receptor sites to provide analgesia. Chemokines, a type of protein
cell, moderates pain, tissue inflammation, and analgesia by regulating the migration of
endogenous opioid cells into the inflamed area of tissue after injury or strong stimuli occurs.
The chemokines cells connect to the mu, kappa, and delta receptor sites to provide analgesia.
The use of synthetic opioids for analgesia (i.e., oxycontin, hydrocodone) is important for acute
pain relief. All opioids register a “reward” signal in the brain, which in effect encourages the
person to continue taking the pain relieving medications. The same occurrence happens when
opioids are taken for their euphoric effects. Repeated opioid use strengthens the connections
to receptors, which has led researchers to theorize an association with opioid dependence
where this reward mechanism is continually triggered by opioid use (Fields, 2007; Koob &
LeMoal, 2008). The question of whether or not the nervous system has a mechanism to
differentiate between opioids for pain relief versus opioid use to stave off withdrawal due to
opioid dependence is not clear. There is some evidence of a psychological as well as a
physiological component to how the body responds to drugs.
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The body’s natural endogenous opioid system is one key in understanding opioid
dependence problems. Opioids connect with the mu, gamma, and delta receptors in the brain
by mimicking its naturally occurring chemicals and fitting into existing neurotransmitter sites
(Hyman & Malenka, 2001). When an individual ingests an opioid drug like oxycontin, the
synthetic opioid fills the slots in opioid receptors, encourages the body’s dopamine production,
and contributes to a feeling of euphoria and pleasure (Savage & Horvath, 2009). Compared to
the body’s naturally occurring endogenous opioids, synthetic versions can fill up to 10 times
more receptors, which explains why these chemicals are useful for pain management, but also
very highly addictive (Savage & Horvath, 2009).
Defining Opioid Dependence
The current definition of prescription opioid abuse is a chronic brain disease
characterized by intentional use of a prescription opioid for purposes outside of a medical
condition (Compton and Volkow, 2006). Opioid dependence may manifest in a variety of ways,
but the common strand with all substance-related disorders defined by the Diagnostic and
Statistical Manual of Mental Disorders is: When an individual persists in use of alcohol or other
drugs despite problems related to use of the substance, substance dependence may be
diagnosed. Compulsive and repetitive use may result in tolerance to the effect of the drug and
withdrawal symptoms when use is reduced or stopped (DSM IV-TR; American Psychiatric
Association, 2000).
In addition to the clinical criteria, other behavioral flags associated with opioid
dependence are often present. For example, when compared to individuals who do not abuse
drugs, research indicates drug dependent individuals are more likely to spend time in jail, lose
custody of children due to neglect or abuse charges, be charged with a DUI (driving under the
influence of drugs and/or alcohol), or have other ongoing involvement with the criminal justice
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system (Gossop, Marsden, Stewart, & Rolfe, 2000). The drug dependent individual is also more
likely to be unemployed or have more difficulty maintaining paid employment than the nondependent individual (Henkel, 2011). When a person is informed that continued opioid abuse
may lead to jail time, loss of child custody rights, or loss of a job and this information does not
deter the individual from continuing to abuse opioids, opioid dependence is likely present.
Prevalence of opioid dependence.
In 2009, the National Survey on Drug Use and Health, which annually surveys a
representative sample of the general U.S. population, reported 5 million adult respondents had
abused prescription opioids in the past year (SAMHSA, 2010). Figure 2 displays the rate of
prescription opiate abuse across Kentucky (SAMHSA, 2010). The highest rates are reported in
northern and central Kentucky with 6.17 % to 6.85% of individuals having reported abuse of
prescription pain relievers in the past year.
Figure 2. Percentages of persons in general population reporting past year nonmedical pain reliever use
across Kentucky

Source: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health 2006- 2008.
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Opiates are natural chemical derivatives of the poppy plant and opioids are the
synthetic version of these natural compounds; the term opioid refers to both the natural and
synthetic varieties of opium (Albertson, 2007). Prescription opioids include methadone,
codeine, hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone,
pentazocine, propoxyphene, tramadol, and any other drug with morphine-like effects (SAMHSA,
2011b). According to National Treatment Episode Dataset (TEDS), abuse of prescription pain
relievers which are primarily the opioid class of drugs was reported by 2.5% of substance abuse
treatment admissions in 1999 (SAMHSA, 2011a). Ten years later in 2009, this number increased
to 11.5% of admissions (SAMHSA, 2011a). In Kentucky, the percentage of opioid users in
treatment jumped from 3.7% in 1999 to 32% in 2009. Compared to other alcohol and drug use
rates, opioid use has increased dramatically. Table 1 displays the percentage of substance abuse
treatment admissions between 1999 and 2009 by drug types and compares the United States to
Kentucky on major drug classes.
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Table 1
Comparison between the United States and Kentucky on Percentage of Individuals Reporting Use of Specific Drugs or Alcohol When
Seeking Substance Abuse Treatment between 1999 and 2009

Year

Opioids

Percent in Treatment Reporting Use of:
Alcohol
Marijuana
Cocaine
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United States:

Kentucky:

Benzodiazepine

Total population
(% in treatment)

Total population
(% in treatment)

U.S.

KY

U.S.

KY

U.S.

KY

U.S.

KY

U.S.

KY

2009

307,006,550 (63.9)

4,314,113 (49.8)

11.5

32.0

60.7

54.6

38.1

40.1

24.3

21.6

3.9

15.1

2008

304,374,846 (65.6)

4,287,931 (51.7)

9.9

27.9

60.9

58.6

37.2

42.2

27.8

27.3

3.3

13.3

2007

301,579,895 (63.2)

4,256,278 (56.6)

8.5

22.0

61.2

60.2

36.5

43.0

30.7

31.3

2.9

11.4

2006

298,593,212 (63.8)

4,219,374 (58.5)

7.4

18.2

60.8

62.4

36.4

43.5

31.8

32.2

2.6

11.2

2005

295,753,151 (63.9)

4,182,293 (54.3)

6.5

15.2

61.0

64.3

36.9

44.6

31.6

31.0

2.3

9.5

2004

293,045,739 (61.7)

4,147,970 (49.0)

5.9

10.7

62.2

49.3

36.3

34.8

31.1

17.7

2.2

7.7

2003

290,326,418 (64.1)

4,118,627 (74.4)

5.1

9.0

63.6

54.4

35.8

34.4

30.8

19.5

2.0

6.9

2002

287,803,914 (65.5)

4,091,330 (64.1)

4.5

6.8

65.1

52.1

35.6

32.7

30.2

17.3

1.9

6.1

2001

285,081,556 (62.0)

4,069,191 (62.3)

3.8

5.9

66.4

51.5

35.4

31.8

30.2

14.4

1.8

6.2

2000

282,171,957 (62.0)

4,048,903 (45.6)

2.9

4.6

68.1

49.4

34.7

28.6

31.2

14.0

1.6

4.9

1999

277,840,888 (61.7)

4,018,053 (40.1)

2.5

3.7

70.2

49.2

34.7

27.4

32.5

14.3

1.5

4.4

* excludes heroin since Kentucky’s primary problem is prescription opiate abuse. Table created using U.S. Census data (census.gov) and
TEDS admission public data concatenated 1999-2009 files retrieved from http://dx.doi.org/10.3886/ICPSR25221.v4.

Among a nationally representative sample of 1408 methadone treatment clients, 66%
reported their initial use of opioids, which led to their current opioid dependence, was through
a legitimate opioid analgesic prescription for pain (Cicero et al., 2008). Table 2 displays the
number of prescriptions in 2009 filled by retail pharmacies, including new prescriptions and
refills of both brand name and generic drugs (Retrieved from http://www.statehealthfacts.org).
These data include prescriptions for opioid medications, but are not exclusively opioids.
Southern states like Kentucky are at the top of the list. West Virginia had the highest number of
prescriptions filled per capita at 18.92 compared to Alaska with only 6.43. Whether or not the
high prescriptions per capita are due to unusual prescribing practices or an increased burden of
disease in the southern states is not clear.
Table 2
Average per Capita Number of Prescriptions Filled at Retail Pharmacies in 2009
Top Five
Prescriptions Bottom Five
Prescriptions
States
per capita States
per capita
West Virginia
18.92 D.C.
8.65
Tennessee
17.33 California
8.45
Alabama
17.13 New Mexico
7.69
Kentucky
17.10 Colorado
7.58
Arkansas
16.70 Alaska
6.43
(Table created using data retrieved from www.statehealthfacts.org)
Concern with prescribing practices led researchers to examine particular opiate use
trends related to the newer medication, buprenorphine (SAMHSA, 2011b). In 2000, the Drug
Addiction Treatment Act (DATA) allowed private physicians to dispense buprenorphine-based
opioids approved for treatment in their offices instead of being required to dispense through
the oversight of a licensed opioid treatment program (OTP). Trends in prescription opioid abuse
rose along with the new prescribing regulations for buprenorphine-based medications
(SAMHSA, 2011b). Though physicians must complete special training, obtain a federal waiver to
prescribe and dispense buprenorphine, and maintain caps on the maximum number of patients
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for which they prescribe medications, buprenorphine remains a Schedule III controlled
substance. The increased abuse of opioids and increased availability of prescription opioids
seem linked with one another (Compton & Volkow, 2006; Gilson, Ryan, Joranson, & Dahl, 2004).
Monitoring of prescription drugs.
The use of prescription pain medication has been monitored in a variety of ways since
1970 when the Controlled Substances Act gave the duty of monitoring controlled substances to
the Drug Enforcement Agency (DEA). The DEA set up a schedule of drugs based on the abuse
and diversion liability or danger associated with each drug (DEA, 2011). Most opioids are
Schedule II, meaning their abuse and opioid dependence liability are very high, but there is
medical value to allowing physicians to prescribe opioids. Schedule I drugs such as heroin have
been deemed to have no medical benefit and thus cannot be prescribed. Schedule II-IV drugs
are rated based on addictive liability and potential for abuse; the higher the number, the less
dangerous the drug has been deemed by the DEA. All physicians who prescribe and/or dispense
controlled substances must register with the DEA (2011). Pharmacists and physicians have
shared responsibility for the legal implications of prescribing controlled substances, such as
opioids. In 2005, the National All Schedules Prescription Electronic Reporting Act (NASPER) was
signed into law and provided funding to states for development of prescription drug monitoring
databases that could cross-reference with other states (Public Law No: 109-60. H.R. 1132).
Kentucky was one of the first to develop a statewide All Schedule Prescription Electronic
Reporting program (KASPER) which provides regular data to the DEA on prescribing practices in
the state.
The DEA also monitored OTPs until 2001 when this role was shifted to SAMHSA. OTPs
have always been highly regulated at both the Federal and state levels because the medicine
primarily dispensed by OTPs is methadone (schedule II). The other regular dispensers of
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methadone are physicians who treat chronic pain. The regulation and oversight of physicians
who prescribe pain medications and of Pain Management Clinics is conducted state-by-state
with the help of Medical Licensure Boards and state Medical Associations.
This means that physicians, pharmacists, and substance abuse treatment professionals
have three different monitoring agencies providing guidelines, protocols, and monitoring tools
regarding controlled substance use. In 2006, hearings were held to examine the reports that
prescription drug abuse was rising at an alarming rate. Fingers were pointed at OTPS, pain
management clinics, and the prescribing physicians as being at fault, while conclusions reported
in the Federal Register (2006) indicated all of the above were part of the problem. The
significant increase in percentage of emergency room visits for prescription opioid overdose
over the past decade (SAMHSA, 2010) along with a 48% increase in prescriptions written for
opioids between 2000 and 2009 has drawn further legislative attention (White House, 2011).
Concerns are bolstered by continuing increases in the number of opioid addicted individuals as
well as significant increases in new opioid abusers (i.e., new initiates). State and Federal bills are
being proposed suggesting increases in control over pain management clinics and prescriptions
for pain medication.
The Researched Abuse, Diversion, and Addiction-related Surveillance (RADARS) system
used by physicians and emergency facilities for documenting the abuse of prescription drugs
tracked the increasing trend of opioid abuse, with oxycontin and hydrocodone as the most often
reported substances by survey respondents (Cicero et al., 2005). Data from RADARS also point
to the widespread nature of prescription drug abuse, including opioids by tracking zip codes
where abuse cases are reported. In 2004, RADARS data indicated 60% of zip codes across the
U.S. had at least one case of prescription drug abuse (Cicero et al., 2005).
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Biology of Opioid Dependence
Over the past decade, data supporting the biological origin of abuse and dependence on
drugs and/or alcohol has helped shift focus away from moral and societal explanations for drug
and alcohol abuse (National Institute on Drug Abuse [NIDA], 2005). The currently accepted
definition of abuse and dependence on drugs and/or alcohol is a chronic relapsing brain disease
(ASAM, 2011; NIDA, 2005, 2010). The data tying abuse and dependence on drugs and/or
alcohol to brain and nervous system malfunctions has been framed within the context of the
disease model and has helped to link substance abuse with research agendas that include other
chronic illnesses like diabetes, arthritis, asthma and chronic non-cancer pain (Campbell, 2010).
Research using animal models has helped scientists understand a wide range of phenomena
including opioid dependence patterns in humans. For example, lab animals allowed to selfadminister opioids will readily do so, but when mu opioid receptors in the brain are chemically
blocked, as with methadone or buprenorphine, self-administration of the opioids stops
(Gardner, 2011; Koob, 2011). These lab animal cases of drug self-administration behaviors help
illustrate the strength of the drug dependence process, while also showing how the body’s drug
cravings can be tamed with medication.
Chronic opioid abuse damages the nervous system’s drug reward mechanism and
redirects the CNS and brain from focusing on obtaining the euphoric effects of opioids to
focusing on avoiding the dysphoric post-use state (Gardner, 2011). This process strengthens an
anti-reward CNS pathway, which heightens sensitivity to past drug use, and makes the individual
prone to relapse triggered through biopsychosocial means (i.e. people, places, and things that
remind the individual of drugs or drug use) (Gardner, 2011; Koob, 2011). The transition from
taking drugs for the euphoric effect to taking drugs to meet a compulsive biological need to
prevent the extreme discomfort of opioid withdrawal is due to neural changes in the brain
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caused by drug abuse. CNS damage from substance abuse helps explain why opioid abuse may
persist despite obvious threats to one’s livelihood, health, familial, and societal connections
(Everitt & Robbins, 2005; Volkow & Li, 2004). In fact, opioid dependent individuals are more
likely to have used multiple substances in the past year compared to individuals whose primary
drug of abuse was not an opioid, and therefore opioid addicted individuals have a higher risk of
increased neural damage over time (Gossop, Marsden, Stewart, & Kidd, 2003).
Further evidence of how opioid dependence impairs the brain’s ability to function with
memory and motor changes is seen not just in behavior patterns, but has also been isolated on
magnetic resonance imaging or MRI scans (Volkow & Li, 2004). In fact, MRI brain studies have
identified a connection between the changes to the endogenous opioid system and regular use
of drugs including marijuana, alcohol, opioids, and nicotine (Maldanado, Valverde, &
Berrendero, 2006; Trigo, Martin-Garcia, Berrendero, Robledo & Maldanado, 2010). The brain
chemistry behind opioid dependence is complicated and the tangled neurochemical changes
from opioid abuse present incredible barriers to maintaining long-term abstinence from opioid
abuse (Gardner, 2011; Lyvers, 2000). Passetti, Clark, Mehta, Joyce & King (2008) studied these
brain changes by exploring decision-making skills among 37 opioid dependent individuals who
were clients in a community-based treatment program. At baseline, and then 3 months into
treatment, participants performed decision-making tests (Iowa Gambling Task and Cambridge
Gamble). Poor decision-making abilities were correlated with lower abstinence rates at the 3month follow-up time period. The researchers indicated that neural connections, particularly in
the anterior cingulate gyrus, which are necessary for accurate decision-making, are damaged by
opioid abuse. Thus, use of pre-treatment screening could help specifically target individuals
who need more help with decision-making and coping skills in order to maintain abstinence
from opioids (Passetti et al., 2008).
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While these studies raise a number of concerns, the good news is that brain pathways
can recover with prolonged abstinence from drug use (Volkow & Li, 2004). Literature indicates
genetics, environment, and the neurological changes that occur with substance abuse may all
impact an individual’s ability to sustain drug and alcohol abstinence over time (Erickson &
White, 2009). These data also suggest a link between neural dysregulation existing prior to
opioid dependence that may have influenced a person's attraction to abusing specific drug
classes. In particular, the effect of opiate abuse on neural pathways in conjunction with the
development of CNCP is not yet clear. Targeting these potential problems will be a key future
research area to prevent opioid dependence problems and augment faulty neurochemistry
(Erickson & White, 2009).
Comorbidity of CNCP with Opioid Dependence
The drug treatment field has a special interest in understanding CNCP, as the rising
prevalence rates for prescription painkiller abuse repeatedly make the headlines (Chou,
Ballantyne, Fanciullo, Fine, & Miaskowski, 2009; SAMHSA, 2010). Developing a clear
understanding of substance abuse and dependence behaviors is also important in settings like
pain management clinics, which do not typically treat opioid dependence (CSAT, 2005). In 2001,
the American Pain Society, American Society of Addiction Medicine, and American Academy of
Pain Medicine worked together to define key terms related to opioid dependence and pain
treatment and help move the research field forward in regards to CNCP and opioid dependence.
These professional organizations suggest pseudoaddiction may better describe patients with
undertreated chronic pain who exhibit what appear to be addictive behaviors like aggressively
seeking higher doses, obtaining prescriptions from two or more doctors at the same time, and
running out of medicine significantly ahead of schedule (American Pain Society, 2001; Passik,
Kirsh, & Webster, 2011). In contrast, individuals with a true opioid dependence exhibit
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observable patterns of behavior including craving, compulsive and uncontrolled substance use,
and a desire to use a medication for more than pain relief. When pain is effectively managed,
these pseudoaddiction behaviors disappear (American Pain Society, 2001; IASP, 2011).
Though research on chronic pain has expanded over the past decade, there is still
limited information about individuals with both a history of opioid dependence and CNCP.
Many pain clinics exclude clients who have a history of opioid dependence from their clinical
populations, and individuals with a history of opioid dependence are generally omitted from
research studies on CNCP due to the complicating nature of substance abuse (Angelino et al.,
2005). Comorbid CNCP and drug/alcohol dependence have been identified in 37% to 61% of
methadone treatment samples (Jamison, Kauffman, & Katz, 2000; Rosenblum et al., 2003)
compared to 29-66% found in general substance abuse treatment samples (Barry et al., 2009;
Sheu et al., 2008). Among chronic pain management samples, it is estimated that 18-41% of
clients have substance abuse problems (Manchikanti et al., 2005), though development of
opioid dependence when using opioids medically for analgesia occurs in less than 1% of
individuals who do not have a prior history of drug or alcohol abuse or dependence (Fishbain et
al., 2008). The literature indicates CNCP is also prevalent among clients from psychological
treatment samples and studies have linked mood disorders, unemployment, increasing age, and
severity of pain to poorer treatment outcome (Tunks et al., 2008).
Risk factors related to development of CNCP.
Research separately indicates potential risk factors for developing CNCP and opioid
dependence, but currently no research presents risk factors for their comorbid presentation.
Sex, race, ethnicity, age, and physical or mental health conditions are predisposing factors to the
development of CNCP, as well as to development of opioid dependence. The following section
describes the currently available empirical data on risk factors for developing CNCP.
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Sex. Women are twice as likely as men to develop CNCP during their lifetime (Tsang, et
al., 2008). The literature indicates similar increased risk for women in regards to opioid
dependence (Green, Serrano, Licari, Budman, & Butler, 2009), which is particularly important to
note since opioid medication is commonly used to treat pain. Overall, women start using
prescription drugs illicitly at lower doses than men do, but women escalate to abuse and
dependence faster and are at greater risk of relapse after substance abuse treatment (Becker &
Hu, 2008). Furthermore, a higher percentage of women than men report depression in their
lifetime (Tsang, et al., 2008) and mental health disorders have been correlated with prescription
opioid abuse for women (Tetrault et al., 2008) and with the development of CNCP for both sexes
(Becker et al., 2008). It appears that being male or female has a role in the development of
CNCP, though the literature does not indicate whether this is due to biological, cultural, or
psychological aspects of one sex or the other.
Race/ethnicity. The sample for this study overwhelmingly report being white, nonhispanic (95%); therefore, little can be examined in regards to race/ethnicity and CNCP among
the study sample. Other research has indicated race or ethnicity in conjunction with low
socioeconomic status has been found to increase the odds of an individual developing CNCP
(Johannes et al., 2010; Rashiq & Dick, 2009). In one U.S. study, white subjects reported longer
pain duration, but lower pain severity ratings compared to other racial groups (Portenoy et al.,
2004), but in a Canadian sample, whites were less likely than other racial groups to have CNCP
(Rashiq & Dick, 2009). On the other hand, non-white race and lower socioeconomic status have
been correlated to lower rates of employment (Crum, 2009). Future studies should include a
sample which incorporates a wider range of race and ethnicities in order to further examine
race/ethnicity in relation to CNCP.
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Age. It is common knowledge that the odds of developing painful conditions increase as
a person ages. Increasing age is correlated with increased physical health problems, but also
with decreased substance abuse (Rashiq & Dick, 2009). Thus, individuals with CNCP who are in
substance abuse treatment may have better outcomes as they age, though whether or not
untreated CNCP will negatively impact outcomes needs further exploration.
Physical and mental health.
Pain is an internal warning system native to our bodies and one of the most primitive
systems we have. Part of coping with CNCP is learning to ignore the pain-alert system wiring
since it is no longer useful in regards to long-term pain (Eccleston, 2010). Research primarily
focused on pain management clinic samples identifies substance abuse history and mental
health problems as the key predictors of future opioid dependence problems for individuals
with CNCP (Edlund, Steffick, Hudson, Harris, & Sullivan, 2007). A study of 6,000 women in the
general population found significantly more daily tobacco smokers reported CNCP than nonsmokers (Mitchell et al., 2011) indicating a link between legal drug use in the form of tobacco
with presence of CNCP. Sensitivity and pain-related anxiety also help to perpetuate CNCP
(Gonzalez, Zvolensky, Hogan, McLeish, & Weibust, 2011). Having a history of sexual, physical, or
emotional abuse increases a person’s likelihood of developing CNCP and particularly
fibromyalgia which occurs most frequently among women (Sansone et al., 2009). Finally, a
person’s perception of their ability to control or moderate their pain can have a significant
impact on development and recurrence of CNCP (Dersh, Gatchel, Mayer, Polatin, & Temple,
2006; Gatchel & Kishino, 2011).
Coping and perception of pain are extremely tricky when part of the body is in high-alert
mode due to painful stimuli. The person’s perception of the ability to cope with and control the
pain has an impact on how well the person can manage CNCP (Turner, Holtzman, & Mancl,
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2007). Particularly, individuals who are catastrophic thinkers may perceive themselves as having
less control over their pain and have more difficulty coping on a day-to-day basis (Chapman &
Turner, 2001). Similarly, highly anxious individuals have an increased attention to pain,
increased negative affect from pain, and are harder to distract from pain (Verhoeven et al.,
2010). In addition to the level of control a person feels over their pain and their reactions to
painful stimuli, other emotional factors influence CNCP (Turner et al., 2007). Through fast
magnetic resonance imaging (fMRI) studies of the brain, scientists identified the role of the
prefrontal cortex in processing emotions surrounding pain (Gatchel & Kishino, 2011). In
addition, fMRI’s identify the anterior cingulate gyrus as part of the limbic system which helps
moderate mood and pain perception in regards to CNCP (Luu & Posner, 2003).
This understanding of the chemistry of pain and emotion can help guide development of
treatment to target the specific body/mind areas impacted by pain and help explain why many
other psychological processes interact with CNCP. Emotional reactions to long-term,
unremitting pain and its implications for daily living are subjective and can vary greatly from
person to person. Most reactions are negative and include depression, anger, and hopelessness
(Disorbio, Bruns, & Barolat, 2006) with an estimated 40-50% of individuals with CNCP reporting
depression due to their painful conditions (Dersh et al., 2006). Anxiety and fear of more pain
can lead to substance use problems and avoidance of physical or social activities, though this
reaction negatively affects the overall functionality of an individual with CNCP and may in fact
increase pain levels over time by decreasing mobility and support (Gatchel, 2005; Gatchel et al.,
2007; Gatchel & Kishino, 2011). Figure 3 depicts the inter-connectedness of CNCP, stress,
substance use, and psychological problems. This diagram illustrates how CNCP triggers
depression, anxiety, sleep problems, and daily coping difficulties such as substance abuse, which
then leads to an increase in pain and a continuance of the cycle.
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Figure 3. Illustration of inter-relationship of chronic pain and stress

Socio-cultural. The development of CNCP is influenced by heritable and environmental
components, though research shows that neither are completely deterministic (Agrawal &
Lynskey, 2008). CNCP prevalence rates in developing and developed countries vary only slightly
with lower rates reported in the developing nations. This could be due to lack of available
healthcare or that different cultures are more likely to care for family members at home and
thus do not publicly report their painful conditions (LeResche, 2001). Social exclusion by the
person with CNCP may occur due to the person’s social circle moving away from the individual
because CNCP is such a large part of the individual’s life (Tollefson, Piggot & Fitzgerald, 2008).
Women have higher pain prevalence rates compared to men, thus socially ingrained messages
may make it less acceptable for men to report pain or coping difficulties than for women
(LeResche, 2001; Tsang et al., 2008). In addition, family, friends, and coworkers may make
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moral judgments about the individuals’ reaction to their painful condition including doubt about
the validity of pain, particularly if there is no specific diagnosis or visible cause (Giddings, & Roy,
2008). Others might question the level of assistance requested to help the individual cope, or
about the emotional state of the patient, assigning blame for the chronicity of the condition to
something the individual has or has not done to help themselves (Tollefson et al., 2008).
CNCP affects a person’s ability to perform regular household chores, attend to work
duties, enjoy leisure activities, and concentrate on day-to-day events. Estimated social costs of
chronic pain in lost workdays, health care, disability and other expenses are approximately $210
billion per year for the United States (National Research Council, 2001). Ongoing pain that
individuals experience with CNCP can affect a person’s mood leading to depression, anxiety,
lethargy, increased substance abuse risk, and a general inability to cope with daily living
activities (Turk et al., 2011). This is illustrated in a study of 4,839 individuals reporting past 6month CNCP where 61% had difficulty maintaining employment, 19% had lost their job, and 13%
had switched jobs due to chronic pain (Breivik et al., 2008). Individuals who continue to use
drugs and alcohol 12-months after treatment have significantly lower rates of employment and
household income compared to individuals who maintain abstinence post-treatment (Walker,
Cole, Logan, Mateyoke-Scrivner, & Stevenson, 2011).
High economic costs of CNCP affect the individual, her/his family, and society (Field &
Swarm, 2008), and this is likely increased two-fold for those clients who also have comorbid
CNCP. As previously noted, relationships and social connections may be limited by CNCP as
many individuals recede from social circles when pain makes daily activities difficult (Disorbio et
al., 2006). Yet, many of the same social issues occur within the lives of someone struggling with
opioid dependence where social context can affect perpetuation of drug and alcohol abuse. On
one hand, families and social networks that are drug- free and supportive of recovery act as a
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protective factor from drug and alcohol use (Davidson et al., 2010). On the other hand, a social
atmosphere in which drug use is accepted as part of the environment is a risk factor for
substance abuse and relapse (Davidson et al., 2010; McCrady, 2006). For example, social
bonding around drinking at bars and baseball games is common. In a family or neighborhood
struggling with poverty, abuse, or other stressors, substance abuse is more likely to flourish
(Moos, 2006). In fact, reaching a point where someone with a substance use problem is ready
to change is heavily influenced by surrounding cultural acceptance or ignorance of drug and
alcohol problems (Carlson, 2006) and by the support or resistance of family and friends
(McRady, 2006). Low socioeconomic status and a family history of substance abuse increase the
risk of an individual developing alcohol or drug dependence (Crum, 2009) while unemployment
decreases socioeconomic resources and increases risk for relapse from substance abuse
recovery (Henkel, 2011).
Cultural roles, family, and social responsibilities, for women in particular, make
participating in behavioral health treatment difficult, and many residential treatment facilities
do not have childcare or other resources while a woman participates in treatment (Straussner &
Attia, 2002). Learning to cope with CNCP through individual and small group therapy along with
peer support has been shown to aid functionality (Wetherall et al., 2011). Similarly,
participation in peer-based recovery groups like Alcoholics Anonymous (AA) or Narcotics
Anonymous (NA) positively impacts recovery and maintenance of abstinence from drug and
alcohol use, particularly for women (Grella, Scott, Foss, & Dennis, 2008; Timko, Finney, & Moos,
2005). Online support groups for CNCP are fairly new, but have been growing in number and
offer a confidential place to share CNCP issues and talk with peers who struggle with similar
health problems (i.e., www.dailystrength.org; www.cpsginc.org ).
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CNCP Treatment
Myths and stereotypes surround CNCP and the medications used to treat pain
symptoms. Some patients do not report pain or report when pain medication is not working
because they harbor a stoic no pain, no gain mentality. Others feel that being a good patient
means not complaining or that if they discuss the pain, surgery will be required or treatment will
become more complicated (IOM, 2011). Even if an individual does seek help for their pain
symptoms, many rural areas have shortages of physicians and professionals versed in pain
management techniques. This may affect military personnel returning from war with painful
conditions who cannot afford treatment outside of the Veteran’s Administration (VA) healthcare
system (VA), but do not have access to VA or other services in their rural hometown to which
they are returning after active duty (Tanielian & Jaycox, 2008). Unresolved and persistent acute
pain becomes chronic pain and this is a growing issue for the returning veterans for whom
becoming opioid dependent may be a growing issue as needs outpace resources for combat
veterans (Clark, Bair, Buckenmaier, Gironda, & Walker, 2007).
The goal of CNCP treatment is to reduce the severity of the pain and to increase
functioning for individuals with CNCP. It is accepted practice to differentiate between palliative
care for cancer or end-of-life issues compared to rehabilitative pain management. Currently the
literature provides only minimal support for long-term use of opioid medications in treating
CNCP (Chou et al., 2009; Katz, 2010). This is also an issue in regards to continuity in criteria used
for prescribing pain medications. Some physicians fear prescribing controlled substances
because of the DEA’s regulation of the drugs. The DEA (2011) affirms that there is no one
guideline that would fit all patients and that prescribing should be on a case-by-case basis.
Thus, the DEA monitors prescribing of controlled substances with this in mind and does not
specifically target or single out pain management physicians for audit any more than they do
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OTPs or buprenorphine prescribing physicians. Pharmacological treatment is considered best
practice for palliative care while non-pharmacological treatment like behavioral therapy,
vocational rehabilitation, and physical therapy are best for treating long-term chronic pain
(Robinson, Leo, Wallach, McGough, & Schatman, 2010). The goal is not to “cure” or eliminate
the pain entirely as that is not possible for most CNCP. As illness and CNCP persist over time for
an individual, the stress of dealing with pain and the ongoing cycle of pain and stress may create
ingrained patterns of coping behaviors. These patterns of coping behavior can help and hinder
reactions to CNCP. For example, the standard expectation for medical treatment of patients
with acute pain mindfulness training to help disrupt the underlying cognitive workings that help
maintain the biopsychosocial substance dependence and provide coping skills to prevent relapse
(Bowen, Witkiewitz, Dillworth, & Marlatt, 2007; Garland, Boettiger, & Howard, 2011).
Varieties of pharmacotherapies are available for treating substance dependence. For
nicotine dependence, bupropion has proven to help increase quit rates among smokers
compared to a placebo (O’Malley & Kosten, 2006). For alcohol dependence, clinically monitored
benzodiazepine use has helped individuals manage withdrawal symptoms and a monthly
naltrexone injection was approved in 2010 (CSAT, 2009). Similarly, disulfiram, naltrexone, and
acamprosate have proven effective for alcohol withdrawal and detoxification (O’Malley &
Kosten, 2006). There are also several opioid replacement treatment medications approved by
the U.S. Food and Drug Administration (FDA) that bind with the body’s opioid receptors, stop
withdrawal symptoms, and reduce the likelihood an individual will relapse (CSAT, 2005). The
primary medications used for opioid dependence treatment are methadone and buprenorphine.
In order to be admitted into a formal opioid treatment program (OTP) with a
maintenance therapy medication like methadone, individuals must meet the DSM IV-TR criteria
for opioid dependence and have failed past treatment attempts in standard abstinence-based
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treatment (CSAT, 2005; Federal Register, 2006). OTPs are heavily regulated by both federal and
state drug control policy agencies because the primary opioid dependence treatment
medications are controlled substances (Federal Register, 2006). Specifically in Kentucky, 908
KAR 1:340 defines the OTP regulations that govern operation and dispensing of the replacement
therapy drugs. The Controlled Substances Schedule created by the Drug Enforcement Agency
(DEA; Federal regulation 21 CFR Sections 1308.11-1308.15) defines whether substances have an
approved medical use and rates the drug according to its abuse and dependence potential on
this Schedule. Drugs with the highest danger for abuse are assigned a Level I while the drugs
with the lowest danger are assigned a Level V (DEA, 2011). For example, buprenorphine (brand
names of Subutex and Suboxone) is a Schedule III drug, methadone and morphine are Schedule
II, and heroin and MDMA are Schedule I drugs not approved for any medical purpose and with a
high risk of abuse (DEA, 2011). Regulations allow methadone (Schedule II) to be administered
only in a specially licensed clinic approved by the Substance Abuse and Mental Health Services
Administration. Methadone must be taken daily with a clinical staff person witnessing the client
swallowing the medication at the clinic for the first 90 days of treatment. After that period, if a
client meets compliance with all rules at the clinic and consistently has negative drug screens,
approval for take home doses may begin.
Methadone was first approved to treat opioid dependence in the 1960’s as a longacting (8-59 hour) highly potent full mu-opioid agonist therapy (CSAT, 2005). In 1993, the FDA
approved another long-acting mu-opioid agonist called levo-alpha-acetyl methadol (LAAM) with
a similar drug profile to methadone except that it only needed to be administered three times a
week instead of daily (CSAT, 2005). No pharmaceutical company currently manufactures LAAM.
A partial mu-opioid agonist called buprenorphine was formulated with naloxone to make it less
abusable (Suboxone) and FDA approved in 2002 for opioid dependence treatment (Crum, 2009).
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Initially, buprenorphine was developed as a prescription painkiller, but researchers found it also
worked for opioid dependence. The most research is available on methadone since it has been
around the longest time, but data are rapidly being gathered on the newer formulations of
opioid dependence pharmacotherapies. Physicians in standard office settings can write a 30day buprenorphine prescription that is filled by a retail pharmacy (Federal Register, 2006).
Methadone and buprenorphine can also be prescribed through a pain management clinic, but
the purpose of use in these settings is reduction of pain rather than prevention of withdrawal
symptoms.
Background on Opioid Treatment Programs (OTPs) in Kentucky.
Approximately 270,881 individuals in the United States are enrolled annually in an OTP
of which 98.5% take methadone (SAMHSA, 2010). Kentucky has 11 OTPs that serve the entire
state. Table 3 provides a comparison of the U.S., Kentucky, and surrounding states on the
number of certified OTPs, types of medication provided, and their primary payment
mechanisms. The majority of clients are taking methadone medication. Medicaid coverage for
methadone is limited in most states to only pain management treatment, not for opioid
dependence treatment, though most states have OTPs, which offer a sliding scale fee or
treatment at no charge. The issue is where OTPs are located since most public non-profit
agencies are in large urban areas of the state, not in a rural county. Table 3 also shows the wide
range of service availability versus OTP capacity. Tennessee had fewer OTPs than Kentucky, yet
serves almost 2.5 times more individuals. Illinois has 5 times more OTPs than Kentucky, yet
fewer clients are servedis that the source of pain is identified, cured, and the patient achieves a
full recovery. For CNCP, this goal must be modified since elimination of CNCP is not generally an
option. Rather than focusing on curing the patient, the model for CNCP must be a
biopsychosocial one with a goal of helping the patient to determine the best methods for
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reducing pain levels, coping with the pain, and improving functionality and quality of life.
Partners, friends, and other caregivers can be taught to help provide at-home support for
individuals with CNCP and communication between all those involved in the care of the patient
is critical to increasing the patient’s quality of life and functioning (Tollefson et al, 2008).
Research on best practices for CNCP has expanded over the past decade and includes
treatments with behavioral therapy, pharmacological therapy, physical, and occupational
therapy (Sanders, Harden & Vicente, 2005; Wetherall et al., 2011).
Opioid Dependence Treatment: An Overview
Overall, research literature indicates that medication-assisted treatment for opioid
dependence is an effective and cost-efficient method of treatment (Belenko, Patapis, & French,
2005; Connock et al., 2007; Harwood et al., 2002), especially when compared to the costs of
opioid abuse left untreated. Birnbaum et al., (2006) provided a detailed cost analysis related to
opioid abuse which estimated costs of $9.5 billion in 2005 or $10.6 in 2010 dollars (conversion
from Officer & Williamson, 2011). When this estimate is broken down, workplace costs
including employment, productivity, and wages accounted for 53% of the total; healthcare costs
including local, state, and private care accounted for 30%; and criminal justice costs accounted
for 17% of the total (Birnbaum et al., 2006). Specifically breaking out healthcare costs for
individuals who abuse opioids, an average year of healthcare (including emergency room visits)
can cost up to $17,600 compared to only $2,030 for a non-opioid abuser (White et al., 2005;
conversion from Officer & Williamson, 2011).
OTPs are required to include behavioral counseling as part of the medication-assisted
treatment protocol; however, buprenorphine prescribed for treatment through a physician’s
office does not always have this requirement (Veilleux, Colvin, Anderson, York, & Heinz, 2010).
The inclusion of behavioral therapies with medication-assisted treatment like methadone
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increases the number of individuals who are able to maintain abstinence at follow-up points
(Veilleux et al., 2010). With any substance dependence problem, comorbid mental health issues
complicate treatment and decrease the long-term positive outcomes for many patients
(Cacciola, Alterman, Rutherford, McKay, & Mulvaney, 2001). Recent research has shown brief
cognitive-behavioral treatment models can be as effective as longer, more intensive models by
teaching clients healthy skills for coping with daily stressors (Carroll & Rounsaville, 2006; Laudet,
2008a; Wetherall et al., 2011). Other behavioral therapies with data to support their efficacy
include brief motivational therapy, cognitive behavioral therapy, contingency management, and
social and family network therapy (Carroll & Rounsaville, 2006).
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Table 3
Comparison of U.S., Kentucky, and Surrounding States on OTP Features Using 2009 N-SSATS Data
U.S.

KY

TN

OH

WV

IN

IL

MO

Number of OTPs

1233

11

8

17

9

16

60

12

Percent public non-profit

45.6%

18.2%

0%

82.4%

0%

33.3%

55.0%

54.5%

Average daily client census*

321,130

1710

4856

6861

4939

7571

14708

3546

Methadone client census

277,104

1487

4844

4334

4690

7279

12035

3485

Buprenorphine client census

5647

129

12

137

249

56

102

61

Self-pay/cash

97.5%

90.9%

100.0%

94.1%

100.0%

100.0%

96.7%

91.7%

Private health insurance

50.9%

27.3%

12.5%

81.3%

77.8%

56.3%

51.7%

33.3%

Medicaid

64.5%

27.3%

0

76.5%

0%

6.7%

61.0%

45.5%

Sliding fee scale

48.4%

18.2%

0

76.5%

33.3%

31.3%

50.0%

50.0%

Treatment at no charge

32.8%

9.1%

0

76.5%

11.1%

12.5%

46.7%

50.0%

Federal military insurance

21.6%

27.3%

0

33.3%

25.0%

12.5%

25.9%

41.7%

Percent taking payment type:
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Table created using public use data files from 2009 SAMHSA National Survey of Substance Abuse Treatment Services (N-SSATS) retrieved from
http://oas.samhsa.gov/SAMHDA.htm *Daily census varies so it represents a snapshot in time and thus methadone plus buprenorphine client
census does not necessarily equal the total census.

Locations for OTPs across the state are displayed in Figure 4. Public non-profit agencies
are marked with a star (n=2). Sites are color-coded to denote which ones offer buprenorphine
versus methadone. Less than 2% of OTPs nationwide currently have clients taking
buprenorphine for maintenance treatment (CSAT, 2005).
Figure 4. Map of OTP locations across Kentucky by type of opiate replacement medication

In Kentucky, six of the eleven OTPs provide both methadone and buprenorphine
medication. The other five OTPs only provide methadone for treatment of opioid dependence.
The oldest clinic in the state is centrally located in Lexington, which is where the original
Narcotic Treatment Farm was located thus establishing Lexington as one of the primary sites for
provision of opioid dependence treatment in the state. Lexington has one of the only two public
non-profit treatment sites available in the state; the other location is about an hour north in
another major metropolitan area of the state, Louisville. Both public sites in Kentucky are
centrally located in metropolitan areas. Only about 3% of OTPs across the nation are in nonmetropolitan areas (SAMHSA, 2009), so it is unique that the majority of Kentucky’s OTPs (n=6)
are in rural towns, though they are all private for-profit clinics.
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Federal and state regulations guide how, when, and where new OTPs can operate
(CSAT, 2005). In Kentucky, these guidelines include a required public notice of intent to provide
treatment services, approval by the state narcotic treatment authority, accreditation by an
authorized entity (i.e., Commission on Accreditation of Rehabilitation Facilities, Joint
Commission on Healthcare Organizations). Medications must be secured in a safe to prevent
theft and security around the OTP premises must be assured. Many of the regulations were
developed specifically because the facilities provide methadone a Schedule II drug with high
liability for abuse, overdose, and diversion. Clients must purchase special locked containers in
which to secure their medications once they are allowed to have take-home doses.
According to the Federal buprenorphine education website
(http://www.buprenorphine.gov) there are 12,973 physicians and 1839 practices in the United
States that can prescribe buprenorphine for opioid dependence treatment. Table 4 displays a
count of physicians and behavioral health practices in Kentucky and surrounding states that
have obtained the necessary training for a Federal DATA 2000 waiver allowing them to prescribe
buprenorphine for opioid dependence treatment outside of an OTP. To my knowledge, there is
no public census of clients prescribed buprenorphine for opioid dependence treatment through
non-OTP sites.
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Table 4
Count of Authorized Buprenorphine Prescribers and Practices Offering Buprenorphine for Opioid
Dependence Treatment in Kentucky and Surrounding States
State

Physicians that can prescribe
Practices offering
buprenorphine (n)
buprenorphine+ (n)
United States
12,973
1,839
Kentucky
201
23
Tennessee
272
24
Ohio
383
48
West Virginia
96
17
Indiana
181
54
Illinois
306
64
Missouri
119
13
[Data retrieved from http://www.buprenorphine.gov]
+ includes OTPs and public/private physician practices
Summary of Literature Review
Both CNCP and opioid dependence are biologically complex (Banta-Green, Merrill,
Doyle, Boudreau, & Calsyn, 2009; Zacny et al., 2003) and encompass social and psychological
aspects of an individual (Gatchel and Kishino, 2011). Rates of CNCP are increasing with 1 in 10
individuals newly diagnosed annually (IASP, 2011). Pain treatment includes opioid medications
when appropriate, though increasing opioid abuse nationwide raises concerns for prescribing
practices. Current research is limited regarding CNCP among individuals with opioid
dependence (Angelino et al., 2005; Clark, Stoller, & Brooner, 2008). Historically, research
studies on CNCP have excluded individuals with opioid dependence, while most substance abuse
research has not addressed CNCP, and the majority of research does not provide specific
information on the comorbid effects of CNCP and opioid dependence (Angelino et al., 2005;
Portenoy et al., 2005). Developing a clear understanding of the relationship between CNCP and
opioid dependence is important to clinicians and essential to individuals seeking treatment. To
begin to address the issue, this study proposes an examination of the effect of CNCP in relation
to treatment outcomes among clients in opioid treatment programs.

48

CHAPTER 3. METHODOLOGY
Research Question and Design
The goal of this study is to build the knowledge base around CNCP by examining
outcomes for a statewide sample of 483 individuals who met DSM IV-TR criteria for opioid
dependence with methadone or buprenorphine at a federally licensed opioid treatment
program (OTP) in Kentucky between March 2007 and December 2010. The primary research
question the study attempts to answer is this: How does the presence of CNCP among clients in
a community-based OTP affect treatment outcomes? Are outcomes at follow-up significantly
different for clients with CNCP compared to clients without CNCP regarding abstinence from
drug use, employment, mental health symptoms, criminal justice system involvement, and
connection with recovery support networks?
The study will examine characteristics of the sample at treatment baseline by comparing
individuals with and without CNCP (dependent dichotomous variable) using frequencies,
crosstabs, t-tests, and bivariate correlations between key variables including: sex, age,
race/ethnicity, geographical location for treatment (Appalachian, non-Appalachian), education
level, employment status, criminal justice system involvement, methadone or buprenorphine
dose level, time in treatment, substance use history, and mental health symptoms.
In addition, the study aims to explore the relationship between CNCP and treatment
outcomes. The outcome most relevant to OTPs is abstinence from or reduction in illegal drug
use and alcohol use (CSAT, 2005). In addition, the study will examine changes by individual pain
group status from baseline to follow-up. Key follow-up variables will include abstinence from
drug use, abstinence from alcohol use, employment status, criminal justice system involvement,
mental health symptoms, and connection with recovery supports (i.e., narcotics anonymous
(NA), methadone anonymous (MA), family and friends who are supportive of recovery).
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Description of Data Source for Analyses
A secondary dataset from the Kentucky Opiate Replacement Treatment Outcome Study
(KORTOS) was used for analyses. Baseline data were collected in face-to-face interviews at the
OTP and follow-up data were collected during phone interviews conducted by independent
evaluators. The sample of 483 cases includes 163 individuals (33.7% of sample) who reported
experiencing chronic pain at baseline (i.e. pain persisting or recurring for 3 months or longer
over the past year). KORTOS is a statewide data collection system that follows clients through
maintenance treatment for opioid dependence. Treatment typically includes methadone or
buprenorphine medication, substance abuse counseling, and annual medical check-ins with a
physician on an outpatient basis. In 2007, Kentucky’s Division of Behavioral Health,
Developmental, and Intellectual Disabilities initiated data collection for KORTOS in collaboration
with the Center on Drug & Alcohol Research at the University of Kentucky (UK CDAR). The
Division of Behavioral Health requires data collection of all state-licensed Kentucky OTPs that
span the state from east to west. For these analyses, ten of the eleven OTPs are represented
since one clinic had just opened and was not yet providing data for KORTOS at the time of data
collection for this sample.
Baseline data for KORTOS were collected in face-to-face interviews by OTP staff during
the initial clinical assessment phase of treatment, reading questions from a structured interview
online, and entering client responses into the web-based data collection program. Baseline
questions focus on circumstances prior to entry into treatment, unless otherwise specified (i.e.,
current events, date of birth). Baseline data are obtained as part of the treatment process
covered under the OTP’s standard consent for treatment. At the end of the baseline interview,
clinicians describe the follow-up telephone interview and ask if the client is willing to volunteer
for the second part of the outcome study. Clients who volunteer must provide locator
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information including phone numbers of two relatives or friends who could help UK CDAR locate
the client for the interview in about 6-months post-baseline. Data along with informed consent
releases for follow-up are electronically transmitted to UK CDAR and stored as encrypted files
on secure servers.
Over the past several years, approximately 30% of the 1,000 clients who were admitted
to treatment at a Kentucky OTP volunteered to participate in the KORTOS follow-up study.
Anecdotally, OTP staff relay the primary reason provided by clients who do not choose to
participate in the follow-up study is fear of having personal information and substance use
history accessed by researchers. This trend continues, despite assurances provided in the
informed consent process regarding the study’s Certificate of Confidentiality from the Federal
government that prohibits access to identifying information in relation to survey response,
which includes probation or parole officers or subpoenas.
Follow-up data were collected by UK CDAR staff through telephone interviews for the
sample of clients who were still active at an OTP and who gave informed consent at baseline to
participate in the follow-up interview. These interviews are independent of the treatment
agency with the goal of tracking the ongoing progress of clients receiving medication-assisted
maintenance treatment in the state. The follow-up interviews include questions matching much
of the baseline interview and focus on current substance use, employment, education, mental
health status, criminal justice system involvement, and use of recovery supports. Individuals
report the current medication type and dose in milligrams per day of methadone or
buprenorphine during the follow-up interview.
Measures and Instrumentation
The statewide sample of secondary data used for these analyses includes 483 baseline
and follow-up records collected between March 2007 and December 2010 from individuals in
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maintenance opioid dependence treatment at ten of the eleven state-licensed OTPs in
Kentucky. Secondary data for this study was provided to the researcher with permission of the
Kentucky Division for Behavioral Health, Developmental, and Intellectual Disabilities and the
state Narcotic Treatment Authority. The data collection instruments for KORTOS are based on
the Addiction Severity Index, 5th edition (ASI; McLellan et al., 1992). Multiple studies over the
past 20 years have evaluated and support the ASI’s test-retest reliability, concurrent, predictive,
and discriminate validity for identifying abuse and dependence levels across genders, racial
groups, and treatment setting samples including inpatient (i.e., hospitals), prisoners, outpatient,
residential, (Alterman, Bovasso, Cacciola, & McDermott, 2001; Alterman et al., 2001; McLellan
et al., 1985). Comparable results were also found with methadone treatment clients (Bovasso,
Alterman, Cacciola, & Cook, 2001). In 1985, McLellan and colleagues conducted a cross-site
evaluation of the ASI and reported concurrent reliability concordance scores at an average of .89
between interviewers. Test-retest reliability was measured over a 3-day interval with no
significant differences in interviewer ratings even with varied interviewers conducting the tests.
Discriminant validity tests on the ASI questions have found expected between group
differences and report moderate internal consistency for subscales of between .65-.89
(Cronbach’s alpha) and weak correlations between subscales (<.05; Leonhard, Mulvey,
Gastfriend, & Shwartz, 2000). Thus, the subscale scores are not included in this study. On the
other hand, the composite scores for alcohol and drug dependence measures matched to DSMIV diagnoses had 85% concordance between the two diagnoses (Rikoon, Cacciola, Carise,
Alterman, & McLellan, 2006). When comparisons between clinical diagnoses and ASI composite
scores were made with a sample of adults in substance abuse treatment in Kentucky, the ASI
score identified more alcohol dependence than was identified by the actual client diagnoses, but
similar numbers of drug dependence (Walker et al., 2011). Topics derived from the ASI included
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in the KORTOS data collection interviews include substance use, employment, caretaking roles,
mental health, physical health, and involvement in recovery support groups. Calculation of ASI
composite scores for drug or alcohol dependence, but not for the subscales (i.e., employment,
mental health) is maintained in the KORTOS study.
Chronic pain measures were derived from the Brief Pain Inventory (BPI; Cleeland, 1991).
Reliability of the BPI has been compared to that of studies with cancer patients and arthritis
patients (.70 or higher; Keller et al., 2004). The BPI has high discriminate ability for rating pain
severity and is sensitive to changes over time (Guyatt’s statistics = .46 to 1.14) making it a good
measure for research as well as clinical diagnoses (Keller et al., 2004). Williams, Smith, and
Fehnel (2006) evaluated the BPI interference scale with osteoarthritis pain patients and found
high reliability (Cronbach’s alpha = .82) and discriminant validity (t41=-.71, p<.05).
Outcome variables.
Description of the specific measures included for this study are detailed in the following
segments along with the type of variables and levels of measurement (nominal, ordinal, or
ratio). As described previously, all data were collected as part of a structured interview with
clients of OTPs and were self-reported by the client to the interviewer who recorded the client
responses. Outcome measures of interest for this study include substance use, employment
status, education status, criminal justice system involvement, recovery support, and mental
health symptoms.
Alcohol and drug use abstinence.
Information on substance use was self-reported by clients during structured interviews
at baseline and follow-up using questions adapted from the ASI. Abstinence from alcohol and
drug use are measured with continuous ratio measures for the number of days of use in the past
30 days to capture recent use patterns. In addition, number of months of use in the past 12-

53

months was captured at baseline to examine patterns of use over the long term for tobacco,
alcohol, and the major drug classes (cocaine, opioids, marijuana, barbiturates, tranquilizers,
amphetamines, inhalants). Variables were also recoded into dichotomous yes/no responses for
any use in the past 30 days.
The ASI alcohol and drug dependence scale was utilized as well, which allows for
calculation of a severity score for individual alcohol and drug use. This calculation includes the
addition of responses to the amount of money spent on alcohol in the past 30 days, and the
number of days the client experienced alcohol problems and days of drug problems (i.e.,
craving, withdrawal, want to quit but unable) in the past 30 days. Also, questions asked the
client to rate (ordinal measure: 0=not at all to 4=extremely) how troubled or bothered he/she
was by drug problems, by alcohol problems, and how important treatment is now to him/her for
alcohol problems and for drug problems. A formula developed by McClellan et al. (1992)
calculates an alcohol dependence score and a drug dependence score based on the composite
of answers to these questions. The recommended ASI composite cutoff scores (CS) at which a
clinical diagnosis of dependence is considered likely is set at 0.17 for alcohol and 0.16 for drug
use (Rikoon et al., 2006). These composite scores will be used in the analyses for this study.
Specifically, abstinence from alcohol abuse (as opposed to legal use) is measured by the
number of days in the past 30 days (interval measure: 0-30) that a client reports being
intoxicated from drinking alcohol. Since alcohol use is legal, the primary concern for this sample
is with problem drinking as indicated by intoxication. The ASI questions about the number of
days a client was intoxicated from alcohol are included in both the baseline and follow-up
interviews allowing for calculation of percentage change in alcohol intoxication from baseline to
follow-up.
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Employment.
Current employment status was measured at baseline and follow-up using structured
interview questions adapted from the ASI. The nominal variable included these response
options: full-time (35 or more hours per week, includes service/military), part-time (less than 35
hours per week, includes occasional/seasonal employment), or currently unemployed (includes
student, retired, disabled).
Education.
Current education completion was measured at baseline and follow-up using ASI
questions. Individuals select their highest level of education completion from 0=no formal
education to 20=graduate level degree.
Mental health symptoms.
Mental health information focused on depression and anxiety, two factors that the
literature identifies as strong correlates with both CNCP and with opioid dependence.
Questions from the ASI were used to ask clients at baseline and follow-up: 1.) Have you had a
significant period (that was not related to your drug or alcohol use) in which you experienced
serious anxiety in the past 30 days? (dichotomous measure: Yes/No). 2.) Have you had a
significant period (that was not related to your drug or alcohol use) in which you experienced
serious depression in the past 30 days? (dichotomous measure: Yes/No). 3). Have you been
prescribed medication for any psychological/emotional problem within the past 30 days?
(dichotomous measure: Yes/No).
Criminal justice system involvement.
Using measures adapted from the ASI, criminal justice system involvement was
measured with questions about arrests and parole, probation, or drug court involvement.
Clients were asked at baseline and at follow-up: Are you currently on probation? (nominal
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measure: Yes/No); Are you currently on parole? (nominal measure: Yes/No); Are you currently
involved in a drug court program? (nominal measure: Yes/No). At baseline clients were asked:
Were you arrested in the past 12-months? (nominal measure: Yes/No). This was changed to:
Were you arrested in the past 6-months? (nominal measure: Yes/No) at follow-up to cover the
time period between baseline and follow-up.
Recovery support.
To evaluate recovery support for each client, questions were asked about self-help
group attendance. Clients were asked at baseline and follow-up: How many AA/NA/MA
meetings have you attended in the past 30 days? The data collection program capped the
number of meetings that could be entered at 100 since the researchers estimated that clients
could potentially attend an average of 3 meetings per day (ratio measure: 0-100). Since AA/NA
meetings are abstinence focused and generally non-supportive of medication assisted treatment
provided by OTPS, this measure may be a limitation to examining true recovery support for this
sample.
Predictor variable.
Chronic non-cancer pain (CNCP).
Using the definition of chronic pain established by the International Association for the
Study of Pain, the following question was asked of all clients: We all have pain like headaches
and sprains, but sometimes the pain from an injury or illness can last longer, beyond the usual
healing time that is expected, and the pain becomes chronic. In the past 12-months, have you
had any chronic physical pain? By chronic I mean pain that has lasted more than 3 months,
beyond the usual healing time for an injury or illness. (Nominal measure: Yes/No). Clients who
answer “yes” to this question about chronic pain and do not identify cancer as one of their
chronic health conditions (previous question) are considered to have chronic non-cancer pain
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(CNCP). Cancer pain and its treatment are considered a completely different medical condition
than chronic non-cancer pain. This study focuses on non-cancer pain, thus any clients from the
sample that reported cancer as a current medical condition were excluded from the CNCP
group; no clients met this criteria in this sample.
Individuals reporting CNCP were asked a series of questions adapted from the BPI. Rate
your level of pain at the present moment (ordinal measure: 0=no pain at all to 10=worst possible
pain); Rate the degree to which bodily pain has interfered with your normal work, including
household duties, in the past 30 days (ordinal measure: 0=not at all to 4=extremely interfered).
To examine control individuals feel over their CNCP, a question was asked: Rate the level
of control you feel you have over your pain. (ordinal measure: 1=no control at all to 6=a great
deal of control). Though this question is not on the BPI, the literature indicates perceived level
of control over pain is a strong indicator of how a patient will respond to the chronicity of pain
(Turner et al., 2007).
Clients who stated they had chronic pain were also asked about use of prescription
drugs for which they did not have a prescription. This helps capture an indication of selfmedication for CNCP. The question read: Do you take any prescription painkillers for your pain
(whether or not you have a prescription from a doctor)? (nominal measure: Yes/No). If the
individual reports any painkiller use, they were asked: Do you have a personal prescription for all
the pain medications you have taken? (nominal measure: Yes/No).
Socio-demographic characteristics.
Questions on socio-demographic characteristics asked at baseline were adapted from
the standardized Government Performance and Reporting Act of 1993 (GPRA; Public Law 10362) monitoring tool. This data collection instrument is used with all Center for Substance Abuse
Treatment (CSAT) and Substance Abuse and Mental Health Services Administration (SAMHSA)
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funded grants (KORTOS is funded through federal block grant dollars which funnel through CSAT
and SAMHSA to the state government entities). This study includes the following:
A. Sex: a nominal measure with responses that include male=1, female=2;
B. Race/ethnicity: nominal measure with responses that include Non-Hispanic white=1,
Non-Hispanic black=2, Other= 3 (i.e., American Indian, Alaskan native, Asian or
Pacific Islander, Hispanic-Mexican, Hispanic- Puerto Rican, Hispanic-Cuban, other
Hispanic);
C. Client birthdate (month/day/year), in order to calculate current age at baseline;
D. Current marital status: nominal measure including responses for married=1,
divorced=2, widowed=3, separated=4, never married=5, and cohabiting=6;
E. Geographical location of OTP: a variable was created to identify if the treatment
location was in an Appalachian or non-Appalachian setting based on the zip code of
each OTP (www.census.gov);
F. Physical health: Clients were asked to identify whether or not they had any chronic
physical health conditions diagnosed by a physician (nominal measure: Yes/No). If
the client responded affirmatively to any chronic health problems, he/she was asked
to select from a list of chronic conditions (based on World Health Organization
major chronic disease categories): cancer, cardiovascular disease, arthritis, HIV,
asthma, hepatitis B or C, severe dental problems (gum disease, bad teeth), and
diabetes.
Opioid dependence treatment medication and dose.
Clients also reported at follow-up which maintenance treatment medicine they were
currently taking (i.e., methadone or buprenorphine-based formulations of Suboxone, or
Subutex) and the current dose in milligrams per day. Dose fluctuates during the first month of
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treatment while clients move from an initial dose of about 10mg to their maintenance dose
which prevents withdrawal and limits craving symptoms. Dose in this report is the maintenance
dose recorded by the clients at follow-up. High, medium, and low dose methadone were
calculated to allow for comparison between methadone dosing which may range from 20-150
milligrams per day versus buprenorphine dosing which ranges from 2-32 milligrams per day.
Medication dose was grouped using standard equivalency recommendations to match low dose
methadone (20-49mg) and low dose buprenorphine (2-6mg), moderate dose methadone (50-80
mg) with moderate dose buprenorphine (7-15mg) and high dose methadone (81-150mg) with
high dose buprenorphine (16-32 mg) (Mattick, Kimber, Breen, & Davoli, 2002).
Human Subjects Protection
Study protocols, which include human subject protection measures and data safety
guidelines, were approved by both the University of Kentucky Institutional Review Board (IRB)
and the Kentucky Cabinet for Health and Family Services IRB (see Appendix A). All clients
entering one of the eleven state-licensed OTPs in Kentucky were eligible to be included in the
baseline interview dataset and consent for these baseline data is covered by the OTP’s consent
to treatment and HIPAA guidelines. Ten of the eleven OTPs were included in this dataset, since
one site had just opened and was not yet providing data for KORTOS at the time of data
collection for this sample. On average, about 30% of clients volunteer for the follow-up study;
data analyses from the 2010 KORTOS annual report reflect no significant differences between
clients who agree to follow-up and those who do not (Stevenson et al., 2011). The secondary
dataset used for this study has been de-identified. Matching of baseline to follow-up records is
accomplished by using the unique number assigned to each client’s record and maintained from
baseline to follow-up to match responses in the data files and maintain that no duplication in
client cases occurred in the dataset.
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Data Entry and Data Cleaning
Data were entered into an online electronic data collection program by OTP staff at
baseline. The baseline data program requires all fields be filled before moving forward with the
question sequence, which ensures minimal missing data. Follow-up interview data are recorded
on a paper form during the phone interview and then data are entered into an electronic
database by UK CDAR staff. Initial data cleaning was conducted by the follow-up interviewers in
PASW 19 by running frequencies and correcting any errant or invalid appearing responses based
on the handwritten notes taken during the interview. Normal distributions were examined and
the baseline and follow-up databases were combined by the researcher using PASW 19 for the
detailed data cleaning prior to running analyses. Data were screened for outliers and
frequencies were examined for missing responses or miscoded items (i.e., response “3” when
only options available were 0-2) and corrected when possible. New variables were created by
recoding responses into comparison groups of clients with and without CNCP.
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CHAPTER 4. RESULTS
All analyses were conducted using the IBM PASW 19 statistical program. Univariate and
bivariate analyses were conducted to examine client characteristics based on the presence or
absence of CNCP. Analyses included crosstabs for categorical variables and ANOVAs for interval
or ratio variables. Baseline to follow-up changes in the percentage of individuals reporting
abstinence from alcohol and drugs, recovery support, employment status, educational
achievement, mental health symptoms, and involvement in the criminal justice system was
examined. Percent of change is calculated based on n values at baseline (n1) and follow-up (n2)
using the formula: [(n2 – n1)/n1)] X 100. A positive percent change indicates an increasing trend,
and a negative percent change indicates a decreasing trend. Change was considered statistically
significant if the probability of the finding was less than .05.
For categorical variables (i.e., count of individuals who were employed full-time or
alcohol abstinent), a z test for proportions was calculated to determine if the change was
statistically significant. In addition, analysis of change from baseline to follow-up for continuous
variables (i.e., number of arrests, number of days of illicit drug use) was conducted with paired
sample t-tests to determine if the change was statistically significant. Addiction Severity Index
(ASI) composite scores were calculated to determine substance use severity at baseline.
Severity is determined by using established cutoff scores (0.17 for alcohol and 0.16 for drug use)
which are correlated with DSM-IV diagnostic criteria for alcohol and/or drug dependence
(Rikoon et al., 2006).
The primary question on which these analyses focus is: Does the presence of CNCP
worsen or improve the outcomes for clients of opiate treatment programs (OTP)? Outcomes
examined to help answer this question include abstinence from illicit drug use, alcohol use and
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intoxication, recovery support use, employment status, mental health symptoms, and criminal
justice system involvement. The results section is organized as follows:
1. Description of the sample and examination of baseline statistics for key outcome
variables;
2. Examination of dose variance related to CNCP status, gender, and anxiety symptoms;
3. Examination of changes from baseline to follow-up on the key variables using crosstabs,
ANOVAs, t-test, z-test; and
4. Multivariate regression for odds of an individual having CNCP.
Socio-Demographic Characteristics of Sample
Slightly more individuals in the sample were male than female and over 97% reported
being non-Hispanic white. Results from crosstab and ANOVAs comparing demographics for the
sample by pain status groups are displayed in Table 5 with statistically significant group
differences noted for alpha of .05 or less. Individuals with CNCP were significantly older with an
average age of 35 years compared to 32 years on average for the non-CNCP group (p<.001).
Both groups reported a body mass index (BMI) in the overweight range, though t-test for means
indicates the non-CNCP group BMI at 27.7 is significantly higher than the BMI of 26.1 for the
CNCP group (p<.01). A higher percentage of individuals with CNCP were receiving OTP services
in Appalachian counties (37.4%) compared to the non-CNCP group (28.4%; p<.05). In addition, a
higher percentage of individuals with CNCP were widowed, divorced, or separated (34.3%)
compared to those without CNCP (23.9%; p<.01). A significantly higher percentage of
individuals with CNCP (73.6%) reported having children under the age of 18 compared to those
without CNCP (61.2%; p<.01). Among those with children, around 24% of individuals in either
group were involved with child protective services.
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Half of individuals with CNCP (50.3%) reported ever having a chronic medical condition
compared to only 7.8% of individuals without CNCP (p<.001). Though conditions can be chronic,
as in asthma or migraines, they do not always trouble an individual if a medical regimen is
followed and managed by the individual. A follow-up question was asked about current trouble
with the chronic condition, and among the 107 cases who reported lifetime chronic medical
problems, only 33 cases had current trouble. The majority of those cases with current medical
problems were among the CNCP group (n=31 vs. n=2). Among those with current medical
issues, about 67% of CNCP cases reported arthritis, 32% reported chronic dental issues,
between the two groups except for arthritis, which was reported by 67.4% of the CNCP group
compared to none of the non-CNCP group.
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Table 5
Socio-Demographics of the Sample at Baseline by Pain Status Group (N=483)
Characteristics
Male
Non-Hispanic White
Average age ***

Percentage or Mean
CNCP (n=163)
Non-CNCP (n=320)
54.0%
57.2%
97.5%
97.8%
34.8 (sd=9.6)
31.9 (sd=8.8)

Average Body Mass Index (BMI)**a

26.1 (sd=5.5)

27.7 (sd=5.9)

OTP services received in an Appalachian county*

37.4%

28.4%

Marital Status**b
Never married
Cohabiting/ married
Widowed/separated/divorced

5.1%
60.6%
34.3%

13.6%
62.6%
23.9%

73.6%

61.2%

24.1%

24.5%

Have children under the age of 18**
Among individuals with children (n=316), percent
with any child protective services involvement

Lifetime chronic medical problems***
50.3% (n=82)
7.8% (n=25)
Current chronic medical problems troubling the
37.8% (n=31)
8.0% (n=2)
client at baseline**
Arthritis*
67.4% (n=21)
0
Asthma
3.2% (n=1)
0
Diabetes
12.9% (n=4)
50.0% (n=1)
Heart problems
6.5% (n=2)
50.0% (n=1)
Hepatitis B or C
12.9% (n=4)
50.0% (n=1)
Severe dental problems
32.3% (n=10)
0
Cancer
0
0
HIV/AIDS
0
0
Receiving treatment for chronic medical
64.5% (n=20)
50.0% (n=1)
Problems
Taking a prescription medication for physical
54.8% (n=17)
50.0% (n=1)
health problems
*p<.05, **p<.01, ***p<.001
a- BMI categories defined as: lower than 20 –underweight; 20-24 optimal weight; 25-29
overweight; 30-39 obese; 40+ morbidly obese.
b -missing marital status data for 103 cases.
CNCP levels and ratings.
Individuals reporting CNCP were asked a series of additional pain-related questions.
Perception of pain control has an impact on ability to maintain daily tasks and has some
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implication for pain rating as well (Turner et al., 2007). Among the 163 individuals in the sample
with CNCP, the average pain level rating at baseline was 4.4 (sd=2.1) on a scale where 0=no pain
and 10=worst possible pain. A score of 4 or higher is considered a clinically significant pain level
requiring medical attention and 64.4% of cases with CNCP rated their pain at a clinically
significant level. The average rating of control individuals reported feeling over their pain was a
3.4 (sd=1.6) on a scale where 1=no control at all and 6=great deal of control. In addition, over
half of clients felt moderate to no control over their pain. When asked to rate the degree of
interference their pain has on normal daily activity in the past 30 days, 23.3% reported
considerable or extreme interference. The majority (60.7%) reported moderate to slight
interference, and about 16.0% reported no interference. No correlation was found between
pain level and perceived control over pain, neither were there correlations with gender and pain
ratings. Crosstabs were used to examine differences by gender in level of pain control and
degree of CNCP interference with daily activities. Figure 5 displays perceived level of control
over CNCP which was statistically different by gender as indicated in the crosstab results (X2=(5,
163)12.79, p<.05). Females reported higher levels of control over their pain than males
reported. There were no gender differences in reported interference of pain with daily
activities.
Figure 5. Percentage by Gender of Levels of Control Over CNCP (n=163)
36.0

34.1
24.0

Male
Female

27.3

19.3

18.7
12.0

Not at all

11.4

Slightly

Moderately

8.0 9.3

Considerably
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Extremely

Among individuals who reported taking prescription painkillers for CNCP (n=158), only 13.3%
reported having a legitimate prescription for their pain medication. Among the 86.7% who took
prescription painkillers without a prescription, there were no statistically significant differences
by gender. Individuals were also asked if they were currently taking a prescription for a physical
health condition, regardless of pain status. Of the CNCP cases 12.0% were taking a prescription
for a medical condition compared to 12.8% of non-CNCP cases.
Changes in Outcome Variables from Baseline to Follow-up
Key outcome variables were examined comparing individuals with CNCP to those
without CNCP regarding changes from baseline to follow-up. Outcome variables include
tobacco, alcohol, and drug use abstinence, recovery support involvement, education
completion, employment status, criminal justice system involvement, and mental health status.
Abstinence from tobacco, alcohol, and illicit drugs at baseline.
Table 6 displays crosstab results for abstinence from tobacco, alcohol, and illicit drugs
reported by individuals at baseline for the past 12 months and the past 30 days by pain status
group. There was no significant difference in abstinence from tobacco, alcohol, and illicit drugs
at baseline when comparing the two groups either for past 12 months use or more recent past
30 days use. Tobacco abstinence and prescription opioid abstinence remained stable over the
past year and during the preceding 30 days before OTP baseline, which reflects a regular use
pattern for both drugs among the sample. Alcohol abstinence increased from almost 41.1% of
individuals with CNCP reporting past 12 month abstinence to 68.7% reporting abstinence in the
past 30 days at baseline. A similar pattern occurred for the non-CNCP group and for both
groups in regards to intoxication from alcohol at both points in time.
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Table 6
Tobacco, Alcohol and Illicit Drug Use Abstinence in the Past 12 Months and Past 30 Days at
Baseline by Pain Status Group (N=483)
Substance Abstinence at
Baseline
Tobacco
Alcohol
Alcohol intoxication (among
cases who used any alcohol)
Prescription opioids
Non-prescribed methadone
Non-prescribed buprenorphine
Heroin
Marijuana
Cocaine
Hallucinogens
Stimulants
Barbiturates
Tranquilizers
Inhalants
*p<.05, **p<.01, ***p<.001

In the Past 12 Months

In the Past 30 Days

CNCP
(n=163)
12.9%
41.1%

Non-CNCP
(n=320)
13.8%
43.1%

CNCP
(n=163)
12.9%
68.7%

Non-CNCP
(n=320)
14.7%
74.4%

37.5%
4.9%
46.0%
83.4%
83.4%
47.9%
61.3%
96.9%
82.8%
91.4%
43.6%
95.1%

36.8%
6.2%
44.7%
81.6%
84.7%
47.5%
63.8%
95.3%
83.4%
92.8%
51.9%
90.9%

43.1%
11.0%
63.8%
92.0%
90.2%
60.7%
77.9%
99.4%
95.7%
94.5%
68.7%
100.0%

42.7%
10.9%
59.4%
93.4%
88.4%
60.3%
82.2%
98.8%
93.1%
96.9%
74.7%
99.4%

Dependence on alcohol and illicit drugs at baseline.
In addition to looking at abstinence from substance use, an Addiction Severity Index
composite score was calculated for each case. This composite score uses a specific formula,
which incorporates number of days of alcohol or drug use in the past month, rating of difficulty
with drug or alcohol use, and rating of need for treatment (not shown in a table). The highest
possible ASI composite score is 1.0 with client score values of 0.17 for alcohol and 0.16 for drug
use indicating alcohol or drug dependence (Rikoon et al., 2006). Composite scores are thus used
to identify individuals whose self-reported substance use met criteria indicating likely drug or
alcohol dependence. Almost 98% of the sample met ASI cutoff criteria for drug dependence. At
baseline, 97.4% of the CNCP group and 96.4% of the non-CNCP group had a composite score
that met criteria for drug dependence (ns). Much smaller percentages of both groups met
67

alcohol dependence criteria with 14.3% in the CNCP group and 11.5% in the non-CNCP group.
None of the group differences was statistically significant.
Recovery support at baseline.
Table 7 displays results for crosstabs examining differences in pain status group by
recovery support and mutual self-help group use at baseline. Only 17.8% of individuals with
CNCP and 18.1% of individuals without CNCP reported use of mutual self-help groups like
alcoholics or narcotics anonymous before baseline. Of those individuals who did report
attending any mutual help group meetings, the mean number of meetings attended was 5 for
the CNCP group and 6 for the non-CNCP group. The majority of individuals in both groups
reported having had contact in the past 30 days at baseline with friends and/or family who were
supportive of their recovery efforts.
Table 7
Recovery Support in the 30 Days before Baseline by Pain Status Group (N=483)
Recovery Support in the 30 Days before Baseline

Attended mutual self-help group meetings ( AA/NA)
Among those attending any meetings, mean
number of meetings attended
Had contact with friends/family supportive of your
recovery
*p<.05, **p<.01, ***p<.001

Percentage or Mean
Non-CNCP
CNCP (n=163)
(n=320)
17.8%
18.1%
5 (sd=7)

6 (sd=8)

87.1%

89.7%

Education and employment status at baseline.
Table 8 displays crosstab results of education and employment information for
individuals at baseline by pain status group. No significant differences were found by education
level with the majority of individuals reporting a high school degree or GED completed at
baseline. There were also no differences by pain status group in the percentage of individuals
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working full-time at baseline, though significantly more cases with CNCP were unemployed and
not looking for work (26.5% vs. 15.9%; p<.05).
Table 8
Education and Employment Status at Baseline by Pain Status Group (N=483)
Characteristics
Highest completed education levela
Less than HS diploma or GED
HS graduate/GED completed
Postsecondary education
Employment status
Full-time (includes military)
Part-time (<35 hrs, irregular)
Unemployed, looking for work
Unemployed, not looking for work*
Among those unemployed, not looking for
work: Receiving SSI/ SSDI income (n=94)
*p<.05, **p<.01, ***p<.001
a- missing education level data for 9 cases

CNCP (n=163)

Non-CNCP
(n=320)

18.2%
35.8%
45.9%

18.4%
36.2%
45.4%

51.5%
14.1%
8.0%
26.4%

57.5%
14.1%
12.5%
15.9%

48.8%

31.4%

Mental health symptoms at baseline.
Table 9 displays crosstab results comparing mental health symptoms at baseline by pain
status group. Similar percentages of cases in both pain status groups reported depression. A
significantly higher percentage of individuals with CNCP reported anxiety (21.9%) compared to
individuals without CNCP (12.6%; p<.01). In addition, more individuals with CNCP (16.5%)
reported taking prescription medications for mental health problems than those without CNCP
(9.1%; p<.05).
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Table 9
Mental Health Symptoms at Baseline by Pain Status Group (N=483)
Mental Health Symptoms, in the Past 30 Days
Not Related to Drug or Alcohol Use….
Depression symptoms
Anxiety symptoms**
Prescription medication for mental health
symptoms*
*p<.05, **p<.01, ***p<.001

CNCP
(n=163)
10.7%
21.9%
16.5%

Non-CNCP
(n=320)
6.7%
12.6%
9.1%

Criminal justice system involvement at baseline.
There were no differences by criminal justice system involvement between individuals
with and without CNCP at baseline (See Table 10). Less than 10% of individuals with CNCP
reported an arrest in the 12 months before baseline compared to 12.6% of those cases without
CNCP. Very few individuals in either group were involved with probation, parole, or drug courts.
Table 10
Criminal Justice System Involvement at Baseline by Pain Status Group (N=483)
Characteristics
Arrested in past 12 months
Currently on Probation
Currently on Parole
Currently Enrolled in Drug Court
*p<.05, **p<.01, ***p<.001

CNCP
(n=163)
9.3%
8.6%
2.5%
0.6%

Non-CNCP
(n=320)
12.6%
10.3%
0.6%
0.3%

Medication Dose and Time in Treatment at Follow-up
During the first few months of OTP services, individuals are titrated onto a dose of
either buprenorphine or methadone. The Center for Substance Abuse Treatment (CSAT)
provides dosing recommendations based on the type of medication provided to the client
(2005). Methadone is a full opiate agonist, while buprenorphine is a partial-agonist.
Methadone has a long half-life in the body and has an average dose of around 80-120
milligrams. Buprenorphine’s chemical make-up has a ceiling of effectiveness at 32 milligrams.
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The initial methadone dose is no more than 30 milligrams with dose titrated up by 10 milligram
increments until the physician determines the client’s symptoms of withdrawal and craving are
managed adequately (CSAT, 2005). For both medications, the prescribing physician determines
the client dose through monitoring client vital signs, withdrawal, and craving reports of the
client. CSAT notes there are wide variations in client dose response affected by weight,
metabolism, co-occurring conditions, and genetics.
Individuals self-reported the type of medication and stabilized dose in milligrams during
the follow-up interview. Though all individuals reported their type of medication, 1 CNCP and 3
non-CNCP cases declined to provide their dose, and 3 CNCP and 13 non-CNCP cases did not
know their dose. Comparisons using crosstabs and ANOVAs for pain status group by medication
type and dose in milligrams are displayed in Table 11. The majority of cases in the sample were
taking methadone, though a significantly higher percentage of individuals taking buprenorphine
were in the non-CNCP group. Among individuals taking methadone, the mean dose in
milligrams was higher for the CNCP group (82.2 mg) compared to the non-CNCP group (75.2
mg). This contrasts with individuals taking buprenorphine where those with CNCP had a lower
average dose (9.7 mg) compared to individuals without CNCP (14.0 mg). When dose levels for
methadone and buprenorphine were matched for high, moderate, and low dose amounts, there
were no statistically significant differences in dose level by pain status group.
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Table 11
Opiate Dependence Medication Type and Dose by Pain Status Group (N=483)
Medication for Opiate Dependence
Methadone
Among individuals taking methadone:
Average dose (mg) (n=422)a **
Buprenorphine *
Among individuals taking buprenorphine:
Average dose (mg) (n=43)b

Percentage or Mean
CNCP (n=163)
Non-CNCP
(n=320)
95.1%
89.1%
82.2 (sd=31.0)

75.2 (sd=23.7)

4.9%

10.9%

9.7 (sd=5.7)

14.0 (sd=10.4)

Matched Methadone/ Buprenorphine groups
High dose
35.9%
46.5%
Moderate dose
51.3%
40.9%
Low dose
12.8%
12.6%
*p<.05, **p<.01, ***p<.001
a -Four cases declined to provide their methadone dose; 14 cases did not know their methadone
dose.
b- Two cases did not know their buprenorphine dose.
Average length of time in treatment at the OTP for both pain status groups was about
the same with 17 months (sd=12.4) for individuals with CNCP and 15 months (sd=12.3) for those
without CNCP. Despite the variation in length of treatment, there was no significant correlation
between months in treatment and CNCP, gender, dose level, or presence of chronic medical
conditions.
As there were no significant buprenorphine dose differences among individuals with
CNCP and very few cases in the buprenorphine medication group, no further analyses were
conducted with buprenorphine-dosed cases. On the other hand, individuals taking methadone
medication did show variation. Thus, further analyses were conducted to examine dose
variation by key characteristics using a one-way analysis of covariance (ANCOVA). CNCP, sex,
and anxiety were the variables of interest examined in relation to variation in methadone dose
in milligrams. The assumption of homogeneity of variance and homogeneity of slope were met.
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Table 12 displays the mean dose for the predictor variables based on presence or absence of
CNCP for males and for cases with anxiety symptoms. The average dose for males with CNCP
was 89 mg which is significantly higher than males without CNCP (76 mg; p<.01). Individuals
with anxiety symptoms in addition to CNCP had a significantly higher mean dose (83 mg)
compared to individuals who had anxiety symptoms but did not report CNCP (73 mg; p<.01).
Table 12
Influence of CNCP Status on Average Methadone Dose in Relation to Sex and Anxiety Symptoms
(n=394)
Variables
Males**
CNCP
No CNCP

Mean (standard error)

95% Lower, Upper
Confidence Interval

88.65 mg (3.39)
75.81 mg (3.05)

69.81, 81.81
81.99, 95.31

Anxiety symptoms**
CNCP
82.86 mg (4.58)
73.85, 91.87
No CNCP
73.03mg (4.88)
63.44, 82.62
*p<.05, **p<.01, ***p<.001; Covariates evaluated at values: age=32.95, BMI=26.79
Displayed in Table 13 are the main and interaction results for the ANCOVA with
Bonferroni adjustment to reduce potential Type 1 error in relation to the number of
comparisons in the model. Main effects for presence of CNCP (F (1, 393)=3.89, p<.05) and being
male (F (1,393)=8.90, p<.01) had a statistically significant influence on methadone dose variation
for this sample. The interaction term for being male and having CNCP was found to significantly
influence methadone dose variation as well (F(1,393)=3.84, p<.05) .
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Table 13
ANCOVA of Current Methadone Dose Variance Related to Gender, Anxiety, and CNCP (n=394)
Source
Corrected Model**
Intercept***
BMI (covariate)
Age (covariate)
CNCP*
Anxiety in past 30 days
Male**
CNCP X Anxiety
CNCP X Male*
*p<.05, **p<.01, ***p<.001;
a
Adjusted R Squared = .04

Sum of Squares
16512.54
46823.41
784.51
1435.21
2764.40
1.67
6330.71
324.66
2731.42

df
7
1
1
1
1
1
1
1
1

Mean Square
2358.93
46823.41
784.51
1435.21
2764.40
1.67
6330.72
324.66
2731.42

F
3.32
65.80
1.10
2.02
3.89
.01
8.90
.46
3.84

Analyses of Outcome Variables
The goal of OTP services is to assist individuals in obtaining recovery from drug and
alcohol abuse and opioid dependence, as well as to improve positive participation in family,
work, and recovery support. The following tables provide outcome information by pain status
group for education, employment, criminal justice system involvement, mental health, and
recovery support as self-reported at follow-up by individuals in the sample. Changes from
baseline to follow-up are calculated when possible using a percent change formula [(n2n1)/n1x100] where n1 represents baseline data and n2 represents follow-up data.
Tobacco, alcohol, and drug use abstinence at follow-up.
In Table 14, crosstab results are displayed reflecting abstinence reported by the sample
in the past 30 days at follow-up by each substance type. There were no significant differences in
abstinence from alcohol, tobacco, or illicit drug use by pain group status. No one in either group
reported use of hallucinogens. Overall, the majority of clients abstained from illicit drug use at
follow-up. None of the cases reported use of hallucinogens at follow-up. No one in the CNCP
group and only one or two cases in the non-CNCP group reported use of non-prescribed
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buprenorphine or inhalants. Among individuals reporting any alcohol use, 64% of cases were
abstinent from intoxication in the CNCP group compared to about 69% of the non-CNCP cases.
Table 14
Tobacco, Alcohol, and Drug Abstinence 30 Days before Follow-up by Pain Status Group (N=483)
Substances
Tobacco
Alcohol
Alcohol to intoxication (among
cases reporting any alcohol use)
Marijuana
Prescription opioids
Non-prescribed methadone
Non-prescribed buprenorphine
Heroin
Cocaine
Hallucinogens
Stimulants
Barbiturates
Tranquilizers
Inhalants
*p<.05, **p<.01, ***p<.001

CNCP (n=163)
17.2%
84.7%

Non-CNCP (n=320)
14.7%
83.8%

64.0%

69.2%

90.8%
91.4%
96.9%
100.0%
97.5%
96.9%
100.0%
100.0%
98.8%
96.9%
100.0%

90.9%
92.8%
96.2%
99.7%
99.4%
98.1%
100.0%
98.1%
100.0%
96.9%
99.7%

Changes in substance abstinence from baseline to follow-up.
Table 15 displays the percent change in abstinence from baseline to follow-up by pain
status group for major drug classes, including prescription opioids. No significant changes
occurred in tobacco use, though there was a slight increase in tobacco abstinence for the CNCP
group from baseline (12.9%) to follow-up (17.2%). Past 30 day alcohol abstinence increased
significantly for both groups. The CNCP group went from 68.7% reporting abstinence at baseline
to 84.7% at follow-up, representing a 23.2% increase in alcohol abstinence (p<.001). Though
this is a statistically significant increase in abstinence from illicit drug use and specifically for
prescription opioid use, it is important to note that individuals had to meet opioid dependence
criteria for admittance to the OTP. In addition, all clients are required to participate in weekly
observed drug screens to monitor illicit drug use. Alcohol use, particularly intoxication, is
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discouraged but not prohibited; similarly, tobacco use is not monitored or discouraged by most
OTPs. Both groups show a significant increasing trend in opioid and illicit drug use abstinence
from baseline to follow-up.
Table 15
Percent Change in Past 30 Day Substance Abstinence from Baseline to Follow-up Comparing
CNCP and Non-CNCP Groups (N=483)
Abstinent at Baselinea Abstinent at Follow-upa

Percent
Changeb

Tobacco
CNCP (n=163)
Non-CNCP (n=320)

n

Valid %

n

Valid %

21
47

12.9%
14.7%

28
47

17.2%
14.7%

+33.3%
0.0%

Alcohol
CNCP (n=163)
Non-CNCP (n=320)

112
238

68.7%
74.4%

138
268

84.7%
83.8%

+23.2%***
+12.6%**

Alcohol to intoxication
CNCP (n=163)
Non-CNCP (n=320)

134
272

82.2%
85.0%

154
303

94.5%
94.7%

+14.9%***
+11.4%***

Prescription opioids
CNCP (n=163)
Non-CNCP (n=320)

18
35

11.0%
10.9%

149
297

91.4%
92.8%

+727.8%***
+748.6%***

Any illicit drug use
CNCP (n=163)
Non-CNCP (n=320)

8
5

4.9%
4.7%

132
270

81.0%
84.4%

+1550.0%***
+1700.0%***

*p < .05, **p < .01, ***p < .001.
a- Between group significant differences established using chi-square test.
b- Within group significant differences established using z test for proportions
Changes in recovery support at follow-up.
Recovery support measured through self-reported attendance at mutual-help group
meetings like alcoholics or narcotics anonymous (AA or NA) is displayed in Table 16. The
percent of individuals by pain group status reporting use of mutual help groups increased
significantly for both pain status groups. The number of meetings attended in the past 30 days
increased for both groups from 1 meeting at baseline to 2 meetings at follow-up.
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Table 16
Changes in Past 30 Day Recovery Support at Follow-up by Pain Status Group (N=483)
Recovery Support in the Past 30 Days

Percent or Mean
Baseline
Follow-up

Attended mutual self-help group meetings
(AA/NA)
CNCP (n=163)***
Non-CNCP (n=320)***
Number of mutual self-help group meetings
attended
CNCP
Non-CNCP
*p<.05, **p<.01, ***p<.001

17.8%
18.1%

35.6%
33.8%

(n=87)

(n=165)

5 (sd=7)
6 (sd=8)

7 (sd=7)
5 (sd=5)

Changes in education and employment at follow-up.
Education and employment status at follow-up is displayed by pain status group in Table
17. No education differences appeared by pain status group with both groups increasing their
education levels by follow-up (18.9% CNCP and 23.2% non-CNCP). A significantly higher
percentage of individuals with CNCP reported unemployment and not looking for work (30.1%)
compared to the non-CNCP group (17.2%). Within that group of individuals (n=104),
significantly more unemployed individuals with CNCP (61.2%) reported receiving disability
income compared to non-CNCP persons (25.5%). Allow it seems likely, the data do not include
variables to allow examination of whether or not a relationship exists between CNCP source and
disability qualifications. Gender differences by CNCP status and employment status were
examined with crosstabs. No differences were found for females, but males with CNCP were
less likely than males without CNCP to be employed at follow-up [X2=(1, 271)7.557, p<.005].
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Table 17
Education and Employment at Follow-up by Pain Status Group (N=483)
Education and employment at follow-up

Percentage or Mean
CNCP (n=163)
Non-CNCP
(n=320)

Highest completed education level-a
Less than HS diploma or GED
HS graduate/GED completed
Postsecondary education
Increased education from baseline to follow-up (n=474)a
Employment status
Full-time (includes military)
Part-time (<35 hrs, irregular)
Unemployed, looking for work
Unemployed, not looking for work**
Among those unemployed, not looking for
work (n=104):
Receiving SSI/ SSDI income ***
*p<.05, **p<.01, ***p<.001
a- missing education level data for baseline 9 cases

16.6%
33.1%
50.3%

14.1%
35.0%
50.9%

18.9%

23.2%

50.9%
12.3%
6.7%
30.1%

57.5%
14.4%
10.9%
17.2%

61.2%

25.5%

Table 18 examines the relationship between CNCP-status and changes in employment
status from baseline to follow-up. None of the changes for either group were statistically
significant as determined with a z-test for proportions.
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Table 18
Percent Change from Baseline to Follow-up in Employment by Pain Status Group (N=483)
Baselinea*

Employed fulltime
Employed part
time

CNCP (n=163)
Non-CNCP
(n=320)
CNCP (n=163)
Non-CNCP
(n=320)

Follow-Upa**

n
84

Valid %
51.5%

n
83

Valid %
50.9%

Percent
changeb
-1.19

184
23

57.5%
14.1%

184
20

57.5%
12.3%

----13.04

45

14.1%

46

14.4%

+2.22

Unemployed, not
looking for work

CNCP (n=163)
Non-CNCP
(n=320)

43

26.4%

49

30.1%

+13.95

51

15.9%

55

17.2%

+7.84

Unemployed,
looking for work

CNCP (n=163)
Non-CNCP
(n=320)

13

8.0%

11

6.7%

-15.38

40

12.5%

35

10.9%

-12.50

CNCP (n=49)
21
48.8%
30
61.2%
+42.86
Non-CNCP
(n=55)
16
31.4%
14
25.5%
-12.50
*At baseline, CNCP and Non-CNCP groups significantly differed from one another at p<.05.
**At follow-up, CNCP and Non-CNCP groups significantly differed from one another at p<.01.
a- Between group significant differences established using chi-square test.
b-Within group significant differences established using z test for proportions
c- Among only those unemployed, not looking for work
Receiving SSI/SSDI
incomec

Changes in mental health symptoms at follow-up.
Percent change in mental health symptoms self-reported at baseline and follow-up are
displayed in Table 19. Reported depression symptoms increased for both groups, though
neither group increased significantly according to z-tests for proportional differences. Anxiety
symptoms were reported by 12.6% of the non-CNCP group at baseline compared to 21.2% at
follow-up for a significant 83.8% increase (p<.001). Prescription medication taken for mental
health symptoms decreased for the CNCP group from 16.5% taking medication at baseline to
7.4% at follow-up representing a significant -53.9% decrease (p<.05). Though not statistically
significant when comparing both groups, the percentage of cases in each group reporting
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depression and anxiety symptoms increased at follow-up. On the other hand, reported use of
medication for mental health problems declined for both groups.
Table 19
Percent Change in Past 30 Day Mental Health Symptoms from Baseline to Follow-up by Pain
Status Group (N=483)

Depression
symptoms
Anxiety
symptomsc

CNCP (n=163)
Non- CNCP (n=320)
CNCP (n=163)
Non- CNCP (n=320)
CNCP (n=163)

Baselinea
n
Valid %
17
10.7%
20
6.7%
35
21.9%
37
12.6%
26
16.5%

Follow-upa
n
Valid %
23
14.1%
32
10.0%
46
28.2%
68
21.2%
12
7.4%

Percent
Changeb
+35.3%
+60.0%
+31.4%
+83.8%***
-53.9%*

Prescription
medication for Non- CNCP (n=320) 27
9.1%
18
5.6%
-33.3%
mental health
symptomsd
*p<.05, **p<.01, ***p<.001
a- Between group differences established using chi-square test.
b- Within group differences established using z test for proportions.
c- Anxiety symptoms significantly different between the CNCP and Non-CNCP groups at baseline
(p<.01).
d- Percent cases taking prescription medication for mental health symptoms were significantly
different between the CNCP and Non-CNCP groups at baseline (p<.05).
Changes in criminal justice system involvement at follow-up.
Table 20 displays the between group differences and percent of change from baseline to
follow-up in arrests, probation, parole, and drug court involvement. The low number of cases in
most categories means the percent change statistic should be interpreted with caution. For
example, drug court participation increased from 1 case at baseline to 2 cases at follow-up; a
100% increase though only one case was added to the already small count. Among the nonCNCP group, 12.6% of individuals had been arrested before baseline and 6.9% were arrested
before follow-up representing a 40.5% decrease in arrests (p<.05). There were no other
significant within group differences or between group differences.
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Table 20
Percent Change in Criminal Justice System Involvement from Baseline to Follow-up by Pain Status
Group (N=483)

Arrested
On Probation
On Parole

CNCP (n=163)

Baselinea
n
Valid %
13
9.3%

Follow-upa
n
Valid %
12
7.4%

Non- CNCP (n=320)
CNCP (n=163)
Non- CNCP (n=320)
CNCP (n=163)

37
14
33
4

12.6%
8.6%
10.3%
2.5%

22
12
32
2

6.9%
7.4%
10.0%
1.2%

-40.5%*
-14.3%
-3.0%
-50.0%

Non- CNCP (n=320)
CNCP (n=163)

2
1

0.6%
0.6%

3
0

0.9%
0.0%

+50.0%
-100.0%

Enrolled in Drug
Court
Non- CNCP (n=320) 1
0.3%
2
0.6%
*p<.05, **p<.01, ***p<.001
a- Between group significant differences established using chi-square test.
b- Within group significant differences established using z test for proportions.

Percent Changeb
-7.7%

+100.0%

Multivariate Regression
Based on results from the previous analyses, a multivariate logistic regression was
conducted to examine which socio-demographic and baseline health characteristics best
predicted CNCP among this sample. Predictor variables from baseline included presence of a
chronic medical condition (Yes/No), being unemployed (Yes/No), days of tobacco use (0-30),
days of alcohol use (0-30), and use of illicit drugs other than opioids (Yes/No). The regression
model included age, sex (Male, not Male), OTP region (Appalachian, not Appalachian), and BMI
as control variables. The logistic regression analysis results are displayed in Table 21. Upon
entry of the control variables, the model classified 78.1% of the cases correctly. The -2LL
dropped from 595.41 to 502.69 with a significant chi-square [X2= (7, 476) 114.91, p<.001] with a
non-significant Hosmer and Lemeshow test. In the next block, the predictor variables were
entered and the model prediction level did not change, though the -2LL dropped again to 496.26
and the chi-square significance remained at with a significant chi-square [X2= (10, 473) 121.35,
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p<.001]. Significant predictors of CNCP included chronic medical conditions (p<.001) and
tobacco smoking (p<.05). Presence of chronic medical conditions were related to an 11 times
increase in the odds of having CNCP, while each additional day of smoking in the 30 days before
baseline increased the odds of CNCP by one time.
Table 21
Logistic Regression Predicting Odds of CNCP by Socio-demographic and Health Characteristics at
OTP Baseline (N=483)
95% C.I.
Wald
Exp(B)
Lower
Upper
Age
1.42
1.02
0.99
1.04
Male
1.67
0.73
0.46
1.17
Appalachian OTP
1.50
1.35
0.84
2.19
BMI
2.92
1.04
0.99
1.08
Days between baseline and follow-up
2.37
1.00
1.00
1.00
Unemployed
0.15
0.91
0.54
1.51
Chronic medical condition
78.01***
11.27
6.58
19.29
Days of tobacco use in the past 30 days
4.08*
1.02
1.00
1.04
Days of alcohol use in the past 30 days
1.36
1.03
0.98
1.07
Use of any illicit drugs other than opioids
0.36
1.18
0.68
2.05
*p<.05, **p<.01, ***p<.001; reference category listed as variable name.
Nagelkirke R2 =.31
Predictors Variables

Summary of Results
This study examined the influence of comorbid CNCP on opioid dependence treatment
outcomes. Almost two-thirds of individuals in the sample with CNCP reported clinically
significant levels of pain and over half of cases reported feeling moderate to no control over
their pain symptoms. Six in ten of the cases with CNCP reported their pain moderately
interfered with daily living activities. Men reported significantly lower ratings of control over
their pain than did women. Though equal amounts of cases (12%) in the two pain status groups
reported taking a prescription for physical health needs, the majority of CNCP group cases (97%)
reported use of prescription painkillers for their pain. Among those 158 cases, only 13%
reported having a legitimate prescription for the medication they took. The overall picture of
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the 163 individuals in the sample with CNCP is one of significant pain levels, lack of control over
the pain symptoms, and an attempt to self-medicate with non-prescribed opioid medications.
In regards to treatment outcomes, there were no differences at follow-up between the
CNCP and non-CNCP groups on substance abstinence, recovery supports, education level, or
criminal justice system involvement. At baseline and follow-up there were more unemployed
individuals and individuals receiving disability benefits in the CNCP group than the non-CNCP
group. Reported anxiety and depression symptoms increased at follow-up and while use of
prescription medicine for mental health symptoms declined for both groups (non-significant
differences). The only predictors for CNCP cases in this sample were tobacco use and presence
of a chronic medical condition.
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CHAPTER 5. DISCUSSION
Individuals with CNCP were compared to individuals without CNCP on treatment
outcomes using a biopsychosocial framework. Prior literature indicated likely group differences
with more women than men reporting CNCP (Tsang et al., 2008), however, this did not hold true
for the study sample. In addition, individuals with CNCP in socially isolated non-metropolitan
treatment settings were expected to have worse outcomes compared to those in a metropolitan
treatment setting due to the limited resources and social networks often found in more rural
areas (Hamilton et al., 2008). Though significantly more individuals in the CNCP group were
from Appalachian OTPs, location was not correlated with any of the outcomes. Prior literature
also indicated higher methadone doses were likely among cases with CNCP (Peles, et al., 2005).
In this study’s sample, methadone-dosed cases with CNCP did have significantly higher doses
compared to the non-CNCP cases, as well as wider variation in dose levels. In addition, being
male was related to greater variance in methadone dose. The threshold for a therapeutic
methadone dose is at least 80 mg daily (Pollack & D’Aunno, 2008) and average dose for CNCP
cases in this sample was at or slightly above this threshold. A larger sample might allow for
examination of more detailed dose differences by gender, age, multi-drug use, and medication
type (methadone vs. buprenorphine) in future studies. Key differences in national outcome
measure results are discussed in the following sections.
Alcohol and Drug Abstinence
There were no statistically significant differences in substance use between the pain
status groups. At baseline, the majority of clients reported use of tobacco and prescription
opioids and over half of each pain status group reported use of alcohol to intoxication. Both
groups showed a decline in alcohol and drug use in the 30 days before starting OTP services
compared to use in the 12 months before entering treatment. This decline may indicate an
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attempt to cut down on drug or alcohol use as individuals prepared to enter treatment. It could
also be a reflection of occasional use (i.e., one holiday drink) being captured in the past 12
months measure and more current use captured in the past 30 days measure.
As would be expected due to opioid dependence as a requirement for OTP admission,
about 97% of both groups met Addiction Severity Index (ASI) composite score criteria for drug
dependence at baseline. Both groups showed significant increases in abstinence from illicit drug
use, particularly abstinence from opioids. Rates of abstinence from illicit drugs at follow-up
were around 80% with no statistically significant differences between pain status groups.
Specifically, prescription opioid abstinence was around 90% for both groups, thus presence of
CNCP did not appear to have an effect on an individual achieving abstinence from opioid use. It
may also be that the desire to stay in treatment and receive the daily dose of methadone to
stave off craving and withdrawal symptoms was powerful enough to help the client maintain
abstinence so they could stay in treatment.
Fewer individuals (14.3% CNCP; 11.5% non-CNCP) met ASI alcohol dependence criteria,
though alcohol use to intoxication was reported by 5 in 10 participants who used any alcohol at
follow-up. General population prevalence rates for alcohol use to intoxication range from 17.7%
to 37.3% (CDC, 2012), while 36.5% of adult treatment seekers in Kentucky reported alcohol
misuse and binge drinking in 2009 (TEDS, 2009). Drinking alcohol to intoxication among
individuals with CNCP who drank alcohol was reported at follow-up by over one-third of cases.
This may be an indication that individuals do not consider alcohol use to be as dangerous or as
harmful as illicit drug use. On the contrary, use of alcohol decreases inhibitions and may lead to
higher rates of relapse to other illicit drug use (Butler, 2008; Centers for Disease Control and
Prevention, [CDC] 2012). A Tufts Health Care Institute study indicated individuals with CNCP
who abuse alcohol in conjunction with prescription opioids are more likely also to abuse other
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illicit drugs compared to CNCP cases who do not abuse alcohol (Butler, 2008). This is particularly
concerning because alcohol is legal for adults and easily obtainable. Addressing binge drinking
with individuals in opioid dependence treatment is important for overall behavioral health and
recovery. Education about measurement of alcohol beverage size, effects of alcohol that
increase pain symptoms, and coping mechanisms that do not include alcohol use may be an
important additional treatment component to expand upon in order to further enhance
outcomes and prevent relapse for clients with CNCP.
Tobacco Abstinence
Another legal drug measured in this study was tobacco use. Tobacco abstinence at
follow-up increased slightly, though not significantly, for the CNCP group. Use of tobacco
correlates with increased physical health risks including coronary, respiratory, and reproductive
system damage (CDC, 2004). The issue of addressing legal, but physically damaging tobacco use
within substance dependence treatment is controversial (Baca & Yahne, 2009) and studies show
tobacco use remains stable in most outpatient treatment settings (Haas, Sorenson, Hall, Lin,
Delucchis, Sporer, et al., 2008). Current research indicates outcomes are enhanced by providing
smoking cessation programs alongside alcohol and illicit drug dependence treatment (Baca &
Yahne, 2009). OTPs could consider incorporating smoking cessation along with opioid
dependence treatment to help address the low rates of tobacco abstinence at follow-up and
improve the physical health of clients. This may be particularly challenging in Kentucky since the
state has historically derived a large proportion of its income from tobacco-related work and
tobacco sales. National rates of smoking among adults are around 18%; while in Kentucky, 25%
of adults currently use tobacco (CDC, 2008). Among this sample, 83% of CNCP cases were using
tobacco at follow-up, which is more than triple the state average. Federal policymakers who
manage OTP protocol should consider smoking cessation assistance as standard practice in
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order to support the overall health of OTP clients. The negative health consequences of
smoking for the individual as well as for family members should be discussed with clients and
smoking cessation tools provided in OTPs as a standard part of protocol. In addition, new
research findings point to increased pain levels and decreased healing capacity among daily
smokers (Ditre, Gonzalez, Simmons, Faul, Brandon, & Jacobsen, 2011), as well as smoking being
correlated to increased opioid use among individuals with CNCP (Hooten, Shi, Gazelka, &
Warner, 2011). Use of tobacco, in particular smoked tobacco, needs further examination among
individuals with CNCP and opioid dependence.
Recovery Support
Recovery support, especially from peers, is important for sustaining recovery and
preventing relapse into drug and alcohol abuse (Boisvert, Martin, Grosek, & Clarie, 2008; Laudet,
2008a). One method used for providing regular support is attendance at 12-step meetings like
Alcoholics Anonymous (AA) or Narcotics Anonymous (NA). Historically, AA/NA groups have not
accepted individuals receiving OTP services since the model is abstinence-based and individuals
on medication assisted treatment with methadone or buprenorphine are not considered
abstinent (Hettema & Sorenson, 2009). Methadone Anonymous (MA) was developed as a 12step model peer-based support group for individuals in methadone treatment; however, these
groups are mostly online and not available in many areas. The low attendance at meetings for
this sample was similar for both the CNCP and non-CNCP groups with about 1 to 2 meetings
reported in the past 30 days at both baseline and follow-up. Though meeting counts were low,
the percentage of individuals reporting any attendance in the past 30 days increased
significantly from baseline to follow-up for both groups. It may be that the attendance is low
because meetings that accept and support the OTP clients are limited. There is one MA meeting
listed online in Central Kentucky and one group in Western Kentucky, whereas AA and NA
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meetings are too numerous to count and span the whole state with daily meeting opportunities.
On the other hand, it may be that clients are getting peer and professional support through daily
attendance at the OTP and are using NA or AA meetings as supplementary to the OTP services.
Research indicates peer support in addition to a treatment program encourages long-term
recovery and improves treatment outcomes (Gossop, Stewart, & Marsden, 2008; Laudet,
2008b). Future studies should consider closer examination of a variety of supports considered
helpful and important to recovery for OTP clients with CNCP.
Education and Employment
Regular employment has a positive influence on recovery from illicit drug use (Walker et
al., 2011), while relapse is related to unemployment (Henkel, 2011). Not surprisingly, according
to the Bureau of Labor Statistics, education level also correlates with increased employment and
financial stability (2010). Educational attainment levels increased from 18.9% of the CNCP cases
at follow-up compared to 23.2% of the non-CNCP cases. Though not significant statistically,
fewer cases with CNCP pursued education and vocational enhancement by follow-up compared
to the non-CNCP cases. By follow-up significantly more individuals in the CNCP group remained
unemployed and not looking for work compared to the non-CNCP cases. Logically it would seem
enhanced education and employment increased the likelihood the non-CNCP cases were able to
maintain or gain employment, while lack of education or technical skills would go with
unemployment for the CNCP cases. It might be that the CNCP cases were involved in vocational
rehabilitation due to chronic medical problems and CNCP, though these specifics are not
available in the dataset. Notably, 61% of the unemployed CNCP cases reported receiving
disability income compared to 26% of the non-CNCP group who were unemployed. Though this
dataset did not include a variable to examine disability qualifications in relation to the source of
an individuals’ CNCP, this information should be examined in future studies.
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Correlations exist between chronic medical conditions like arthritis or diabetes and
reduced work performance, unemployment, and lost wages (Li, Gignac, & Anis, 2006). The low
rates of employment among the CNCP group may be related to the high prevalence of chronic
medical conditions. In the regression model predicting CNCP, the only variables with significant
predictive value were presence of chronic health problems and regular tobacco use. The most
noted physical health condition among the CNCP cases who reported current health trouble was
arthritis. Though the count of cases reporting arthritis is small compared to the overall sample
size, we do know prevalence of arthritis increases as BMI increases (Cheng, Hootman, Murphy,
Langmaid, & Helmick, 2010) and odds of having arthritis rises with age (CDC, 2010). In fact,
rates of arthritis in the United States are expected to increase over the next decade along with
an increasingly aging population (CDC, 2010). Rates of rheumatoid arthritis, which is a painful
autoimmune disease affecting joints, heart, liver, and kidneys, are trending upward, particularly
for women (Arthritis Foundation, 2010). This means that CNCP will also likely rise since chronic
pain is often a part of arthritic conditions.
In addition to existing chronic medical conditions, tobacco use greatly increases the risk
of chronic pulmonary and lung disorders (CDC, 2004). The high rates of regular smoking among
the OTP clients and specifically the clients with CNCP are of special concern. Thus, expanding
education and resources for tobacco cessation and physical health including non-opioid pain
management will be important in OTPs and other behavioral health treatment programs. In
general, managing painful chronic medical conditions without use of opioid medications should
be a priority as there is limited evidence to support long-term opioid use for a chronic illness like
arthritis (Whittle, Richards, Husni, & Buchbinder, 2011). Non-addictive anti-inflammatory pain
medications, physical therapy, and psychological coping techniques including meditation should
be examined as better long-term treatment solutions.
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Mental Health Symptoms
Prior research indicates an association between opioid dependence and depression
(Becker et al., 2008), while both depression and anxiety are associated with higher CNCP risk
(Sansone et al., 2009). Thus, it was expected among this study sample that a higher percentage
of opioid dependent individuals with CNCP would have depression or anxiety compared to
persons without CNCP. As anticipated, initial analysis did identify a correlation between opioid
dependence, anxiety, and CNCP. At baseline, the percentage of cases in the CNCP group
reporting anxiety, depression, or prescription medication for mental health symptoms was
significantly greater than percentages in the non-CNCP group. At follow-up, the percentage of
cases reporting depression and anxiety symptoms in both groups increased, and differences
were no longer statistically significant between groups. On the other hand, reported use of
prescription medication to treat mental health symptoms declined for both groups. This finding
is concerning since anxiety is related to non-compliance with treatment protocols and
worsening CNCP symptoms (Gonzalez et al., 2011). Moreover, prescription anti-anxiety or antidepression medications have positive effects on CNCP and treatment outcomes (SAMHSA, 2011;
TIP 54).
At the follow-up, the majority of clients had been in treatment over a year and should
have had time to begin seeing the aftermath of drug and alcohol abuse in their lives (i.e.,
negative impact on relationships with family and friends, ability to maintain employment,
financial and temporal cost of OTP services). In an integrated treatment model, mental health
would be addressed as part of the process of treatment. Thus, issues that arise as the client is
working to regain control over life without dependence on abuse of drugs and alcohol would be
addressed along the course of treatment with the help of a professional. In the OTPs, mental
health symptoms may not be regularly addressed in the treatment sessions and this may
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contribute to the increased reports of depression and anxiety in this sample. Many OTPs refer
clients for mental health counseling at other facilities, since the focus of an OTP is on substance
abuse treatment. The follow-up on attendance for referred counseling sessions and improved
mental health symptoms may not be as closely monitored in these cases. Comorbid mental
health, CNCP, and substance use problems decrease long-term outcomes for patients (Cacciola
et al., 2001). Yet, the literature indicates brief therapy and cognitive-behavioral models for
coping with anxiety are helpful and can be addressed concurrently with substance abuse
treatment programs (Carroll & Rounsaville, 2006; Wetherall et al., 2011).
Criminal Justice System Involvement
Random clinical trials of methadone maintenance treatment show reduced recidivism
and increased overall social functioning for participants (Sees, Delucci, Masson, Rosen, Clark,
Robillard, et al., 2000). In the past, criminal justice populations have not had access to opioid
replacement treatment in the form of methadone or buprenorphine maintenance in an OTP
setting. The low numbers of criminally involved clients in this study highlights this issue. There
were no significant differences among the less than 12% of cases in either group who reported
arrests, parole, probation, or drug court involvement at either baseline or follow-up. Both pain
status groups showed decreases in criminal justice system activity by follow-up, though the drop
in arrests for the non-CNCP group was cut significantly by half (13% to 7%). The larger issue
then is to discover what percentage of people in jail, prison, or detention centers are opioid
dependent and have CNCP. The current population of OTP clients excludes these cases and yet
prevalence data indicates the high probability of unaddressed CNCP and opioid dependent
individuals in corrections (Staton-Tindall, McNees, Walker, & Leukefeld, 2009).
Kentucky is unique in providing a wide range of diversion and substance abuse
treatment within the criminal justice system, but opioid dependent individuals who could
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benefit from OTP services are not allowed to participate because of current criminal justice
system regulations. Trends in the Criminal Justice Kentucky Treatment Outcome Study indicate
rising rates of incarcerated individuals with opioid abuse and dependence, particularly to
prescription painkillers (Staton-Tindall, et al., 2009). In a recent special issue of Substance
Abuse, the articles focused on a need for methadone maintenance treatment as a standard of
care for opioid dependent individuals, including those who are incarcerated, due to strong
evidence supporting its treatment effectiveness (Lee & Rich, 2012). As noted earlier, the rates
of CNCP continue to rise, thus the overlap between CNCP and opioid dependence is also likely to
increase. This means that the demand for OTP services among the criminal justice population
with CNCP will likely increase over the next few years. There needs to be ongoing conversation
between healthcare providers, corrections administration, and OTP professionals in order to
provide the best possible care and recovery opportunities for people with CNCP and opioid
dependence.
Study Limitations
There are three primary limitations to discuss in regards to the research. First, this
study is exploratory and therefore inherently arrives with some limitations. Secondly, analyses
are conducted with a secondary dataset, which relies mostly on client self-reported information.
Client selection bias may be an issue regarding who was willing to participate in the follow-up
interviews. Thirdly, the measure for CNCP was limited in its scope and may have under or over
identified cases for analysis. The following section details these study limitations.
Exploratory study.
Though there is substantial research regarding CNCP and a separate body of literature
regarding opioid dependence and treatment, there is limited research that addresses both
conditions simultaneously, thus the analyses for this paper were deemed exploratory. Though
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an exploratory study is limited in the generalizability of results or ability to make causal
statements, it does allow for initial examination of a sample of opioid addicted individuals who
have CNCP and provides a starting point for future research. The size of the sample and the
variety of available data points allowed for rich initial exploration of the issues regarding CNCP
and opioid dependence.
Self-report.
A secondary dataset was used for this study and data were derived from client selfreport, which leads to potential limitations in data validity. Though memories are inherently
biased, self-reported past year substance use, employment, and mental health has been found
to be generally reliable (Harrison, Martin, Enev, & Harrington, 2007; Shannon, Mathias, Marsh,
Dougherty, & Liguori, 2007). It is common accepted practice for behavioral health studies to
rely on self-reported client level information for day-to-day activities. In fact self-reported
prescription analgesic use has been found to be generally accurate comparing the verbal naming
of medications taken compared to identifying medications based on images of the drugs (Smith,
Rosenblum, Parrino, Fong, & Colucci, 2010). Though clients may be prone to adjust responses in
order to please or appease clinical staff, there was little reason for the clients in this sample to
modify responses. At baseline, the client is encouraged to be honest about their responses
because the nature of requesting treatment implies the client has serious drug use and other
issues which need addressing. There were very few criminal justice system and child protective
services referred clients, thus these individual who might be afraid to talk openly of their
problems due to fear of negative consequences. In addition, though the baseline interview is at
the beginning of treatment services for alcohol and drug dependence, all interviews are
conducted after clients have obtained initial sobriety (post-detox).
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Selection bias affects the study sample in a number of ways. The sample represents
clients who are self-referred to an OTP in Kentucky with the funds to pay out of pocket for most
of the services, and transportation to and from treatment on a daily basis. The average monthly
cost of treatment is around $500 and this price, which is not covered by most insurance,
excludes individuals who do not have funds to cover OTP services. In addition, the sample
excludes the majority of clients who may have been involved with criminal justice or child
protection services because those systems do not currently endorse methadone or
buprenorphine medication-assisted treatment in Kentucky. Hence, this sample is made up of
individuals with limited criminal justice system involvement, funds to pay for treatment, and
transportation to attend daily treatment sessions.
This is not a random sample and clients are not randomized into/out of treatment
protocols; therefore, external validity and representativeness of clients is a limitation. The
sample is drawn from a majority of clients at OTPs in the state, with every client entering
treatment during the study period being offered the opportunity to participate in the study.
About one-third of the baseline interview clients agreed to participate in a follow-up interview,
and of those clients, about 70% were successfully interviewed. Therefore, this secondary
dataset encompasses only a small portion of the overall OTP population. When comparing
baseline interview data for demographic and substance use between cases who did and did not
complete a follow-up interview found no significant differences. The wider population of OTP
clients with CNCP is not fully understood at this time, but may include higher numbers of CNCP
cases, heroin dependence instead of prescription opioid dependence as in this sample (Jamison
et al., 2000; Peles et al., 2005; Rosenblum et al., 2003).
Dataset measures.
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The majority of the dataset measures were based in the Addiction Severity Index (ASI),
which has been extensively validated as a reliable tool for measuring substance use and related
problems among a wide range of samples (Rikoon et al., 2006). There may an issue with the
question used to identify CNCP cases in the study. Clients who self-reported “yes” to the
primary question at baseline about chronic non-cancer pain that has recurred or persisted for 3
months or longer in the past year are considered to have CNCP for this study. It may be that
clients with chronic pain do not self-report symptoms at baseline because their drug of choice –
opioids – has masked the pain symptoms. If data were available, it might reveal an increase in
reports of CNCP and pain symptoms at follow-up, which is not necessarily due to actual
increased pain, but to increased awareness of pain now that the client is no longer abusing
opioid medications. On the other hand, it may be that individuals are reporting CNCP at
baseline in order to support opioid dependent behaviors in hopes of getting a regular source of
opioids through the OTP. Future research will benefit from identifying the myriad factors that
contribute to variation in CNCP. For example, understanding more about the relationship
between age of onset for CNCP and age of first illicit drug use and opioid dependence would
help to illuminate the underlying mechanisms of these intertwining conditions (Field & Swarm,
2008). In addition, CNCP can take many forms including recurrent versus unremitting pain,
neuropathic, central, or nociceptive pain, and may or may not have a known source (i.e., car
accident, arthritis, migraine, and endometriosis). A wider range of variables regarding CNCP will
be helpful in future studies and can better elucidate the picture of clients with CNCP and opioid
dependence.
Conclusions
Recent literature suggests there should be significant differences between individuals
with CNCP in opioid treatment programs compared to individuals without CNCP (Bruns &
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Disorbio, 2005; Gatchel & Kishino, 2011). Individuals with CNCP are four times more likely to
have depression, anxiety, and other comorbid conditions compared to individuals without CNCP
(Gureje, Simon, & von Korff, 2001). In particular, women and individuals with a history of
victimization have higher rates of emotional distress and pain which correlates with poorer
substance abuse treatment outcomes (El-Bassel, Gilber, Wu, Go, & Hill, 2005). Studies
examining outcomes for individuals with CNCP who report substance use disorders while
receiving pain management services are limited, but indicate opioid dependence has a negative
effect on pain treatment outcomes (IASP, 2011). Conversely, the results from this study point to
similar outcomes both for clients with and without CNCP, including substance abstinence,
recovery support, employment, mental health, and criminal justice involvement. Even gender
differences dissolved in this sample despite extant literature that correlates being female with
higher rates of CNCP, opioid abuse, depression, and anxiety (Becker et al., 2008; Gatchel &
Kishino, 2011; Tsang et al., 2008). In fact, childhood sexual abuse and partner violence, which
correlate with CNCP, are common among women in other research using methadone treatment
samples (Engstrom et al., 2008; Gatchel & Kishino, 2011). The lack of gender and other
differences in treatment outcomes may be due to the sample being only a small sub-set of the
wider population of OTP clients. The individuals in the follow-up study had to have at a
minimum a working landline or cell phone, money to continue paying for OTP services, and a
willingness to be in the follow-up research study. This means among the clients excluded from
the survey are those who did not stay in treatment at the OTP, or were unmotivated to
participate in survey research. Nevertheless, this study presents interesting findings about this
subset of individuals with CNCP who are in opioid dependence treatment which merit further
examination.
Tobacco use and physical health.
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In this study, predictors of CNCP included tobacco use and chronic medical conditions.
Both predictors remained statistically significant regardless of client age, length of time in
treatment, use of alcohol, or use of illicit drugs other than opioids. Half of the CNCP cases
reported lifetime chronic medical problems compared to only 8% of the non-CNCP cases, and 8
in 10 individuals with CNCP in this sample smoked regularly at both intake and follow-up.
Tobacco smoking correlates with poor physical and mental health, decreased quality of life, and
increased pain (Hooten et al., 2011). Recent literature examining use of tobacco as a coping
mechanism for individuals with CNCP found smoking correlated with higher pain ratings, greater
interference with daily living from pain, and greater fear of pain compared to non-smokers with
CNCP (Patterson, Gritzner, Resnick, Dobscha, Turk, & Morasco, 2012). In addition, Caucasian
race, lower education levels, and history of alcohol dependence or abuse were associated with
smoking among individuals with CNCP (Fishbain, Lewis, Cole, Cutler, Rosomoff, & Rosomoff,
2007). Thus, it may be that the use of tobacco is related to coping with CNCP and chronic
medical conditions and may even be a contributor to continued opioid use at follow-up (Hooten
et al., 2011).
Tobacco use remains a major hurdle, particularly in Kentucky where smoking cessation
programs are not typically provided in substance abuse treatment settings, including opiate
treatment programs (Kentucky Cabinet for Health and Family Services, 2008). The fact that
smoking is related to chronic pulmonary and respiratory diseases is not often disputed (CDC,
2004). Yet, the misguided belief that alcohol and drug use abstinence is negatively impacted by
concurrently providing smoking cessation treatment lingers (Baca & Yahne, 2009). The truth is
that smoking may contribute to ongoing substance abuse (Hooten et al., 2011; Hooten,
Townsend, Bruce, Shi, & Warner, 2009), continued behavioral and physical health problems, and
increased pain levels (Ditre et al., 2011). Sharing the findings from this and other research
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studies, while providing resources to help support both staff and clients in addressing tobacco
use at treatment facilities, could help further improve treatment outcomes, as well as the
client’s overall behavioral health.
Biopsychosocial framework for OTPs.
The framework used for this study was a biopsychosocial model. The expectation was
that biological (i.e., gender), psychological (i.e., depression and anxiety), and social (i.e.,
substance use and recovery support) aspects of individuals with CNCP would be different than
the biopsychosocial aspects of individuals without CNCP. Thus, differences in the data between
the CNCP and non-CNCP groups were expected regarding opioid dependence treatment
outcomes. Instead, the study found very similar treatment outcomes. These findings may be an
indication that OTPs are closely following the federally mandated protocol for dosing
minimum/maximum, pill counts, random observed weekly urine drug screens, substance abuse
counseling, and daily face-to-face medication consumption as the method for treating opioid
dependence (IOM, 2005; SAMHSA, 2010).
In the 1970’s the Drug Enforcement Agency (DEA) was responsible for oversight of OTPs
due to the on-site administration of a controlled substance (i.e., methadone) for management of
opioid dependence (IOM, 2005). OTPs were originally envisioned by the founders of methadone
treatment, Dole and Nyswander, within the context of mutual clinician and client respect where
individuals with opioid dependence could regain their lives through medication-assisted
treatment and client-specific support (1980). The Vincent P. Dole Research and Treatment
Institute in New York is based on an integrated biopsychosocial model of methadone treatment
(Curet, Beeder, Joseph, Alexander, Schamisso, & Rodriguez, 2007). Generally, OTPs operate
within a social control model with the goal of reducing public health risks of injection drug use
and disease (Harris & McElrath, 2012; IOM, 2005). Maintenance of social control may be the
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reason for the separation physically of OTPs from community mental health centers, which are
the primary source of all other publicly sponsored substance abuse and mental health treatment
in most states (Harris & McElrath, 2012).
In 2007, the Federal opioid treatment standards were updated by the Substance Abuse
and Mental Health Services Administration (SAMHSA). The new document included the
standard requirements for a thorough client assessment at intake, medication dosage and
safety, and teaching clients to follow policies and procedures. New additions included standards
recommended integrated care for comorbid physical and mental health conditions (42 CFR
8.12). Yet, the document leaves how integration should occur up to each state and generally
recommends referral for treatment outside of the OTP, particularly in the case of pain medicine.
The question of what OTPs should be doing with clients who have comorbid CNCP and
opioid dependence remains a pertinent issue. Chronic non-cancer pain (CNCP) and prescription
opioid abuse are public health problems that will continue to have an impact on society over the
next few decades (Clark & Treisman, 2011; IASP, 2011). An examination of best practice models
points toward integrated plans of care for concurrent treatment of comorbid conditions like
CNCP, opioid dependence, (Gatchel & Kishino, 2011; Koob, 2011) mental health issues, and
victimization history (Bennett & O'Brien, 2007; Gilbert, El-Bassel, Manuel, Wu, Go, Golder, et al.,
2006). In order to provide this model of care, the treatment program must begin with a
thorough biopsychosocial assessment covering all aspects of a client’s history including past
treatment, substance use, mental and physical health issues.
A recent survey of OTPs nationwide found wide variation in assessment surrounding
alcohol use history and case planning for ongoing alcohol use among clients (Harris, Strauss,
Katgibak, Brar, Brown, et al., 2010). If basic substance use issues are approached differently
across OTP sites, this begs the question of how much variation occurs within overall treatment
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planning, monitoring, and case management for comorbid conditions like tobacco cessation,
diabetes, hepatitis, or depression. An OTP which is going to provide integrated treatment
services needs resources and connections with other local providers in order to develop a plan
of care addressing biological, psychological, and social aspects of each unique client (Mueser,
Noorsdy, Drake, & Fox, 2003). What this study finds is a picture of an OTP model that focuses
entirely on medication-assisted treatment for opioid dependence. This does not mean in some
OTPs there are not clinicians who provide referrals for medical and emotional healthcare or that
there are not instances of brief smoking cessation groups or mental health support groups
incorporated into the service array. What it does mean is the overall picture of OTPs may not
include client-specific treatment that integrates care for all biopsychosocial aspects of an
individual into the OTP case plan.
Future Recommendations
In 2010, the Obama administration suggested the national focus shift away from the
1970’s “drug war” concept and towards harm reduction along with integrated physical and
mental health care for all individuals (Consolidated Appropriations Act; Kerlikowske, 2010).
Over the past ten years, the oversight of OTPs has shifted from the DEA to the Substance Abuse
and Mental Health Services Administration (SAMHSA) and the Center for Substance Abuse
Treatment (CSAT). This shift has allowed a move away from the DEA’s regulatory focus and a
move toward quality assurance (Pelletier & Hoffman, 2001). SAMHSA has the opportunity to
continue updating standards to ensure integrated care becomes a reality for opioid dependence
with all other comorbid conditions. This may need to be a two-way street whereby providers
outside of OTPs are educated about opioid dependence and medication assisted treatment in
order to best work with OTPs for concurrent care of clients (Clark & Treisman, 2011). Policy
updates might include requirements for case plans to denote regular check-ins and shared case
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meetings amongst pain management physicians, mental health counselors, physical health
providers, and OTPs staff. The use of telehealth and online meeting forums would be helpful for
rural and non-metropolitan areas where resources may be limited (Smalley, Yancey, Warren,
Naufel, Ryan, & Pugh, 2010). Additionally, SAMHSA might encourage OTPS to more closely
align with their strategic national initiatives for providing individualized treatment that
addresses comorbid mental and physical health issues for all clients (2011c).
With expanded healthcare options for substance abuse treatment on the legislative
agenda in Kentucky, uniformity of available resources for behavioral healthcare needs may soon
be a reality. In light of national healthcare reform, the use of a medical health home model may
be an effective tool for managing multiple conditions (American Academy of Pediatrics, 2012;
Curet et al., 2007). A medical health home provides continuity of care, particularly for
individuals who have comorbid conditions like CNCP, opioid dependence and anxiety. By using a
medical health home model, the OTP staff would collaborate with an individual’s primary care
physician, a pain management specialist, and mental health counselor to help coordinate client
meetings, services, and resources. This model reduces stress for the client and gives
professionals who work on the team the benefit of holistic case management. Chronic medical
conditions would be reviewed concurrently with opioid dependence treatment and counseling
for mental health symptoms in order to help clients manage comorbid conditions and prevent
relapse. Future research might examine the use of a medical health home model that combines
physical, mental, and social healthcare for clients with comorbid conditions like opioid
dependence and chronic non-cancer pain. In particular, the release of Medicaid funds to cover
OTP services will be important to help clients with the cost of treatment, transportation, and
other needs of individuals who are likely to have limited income and no health insurance.
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It would be ideal to conduct a pilot study within an OTP where a multi-disciplinary
arrangement is established with existing public health and CMHC services. The model would be
set up to mirror the description of treatment for methadone maintained clients at the Dole
Research and Treatment Institute (Curet et al., 2007). At admission to the OTP, a client would
receive a thorough psychosocial assessment and a physical exam including blood tests and xrays to capture history of medical problems. The team would then develop a case plan to
address not only the opioid dependence, but also physical, mental, and social issues that arose
during the assessments. The case plan would be reviewed monthly by the team and adapted as
needed in order to manage the client’s care, medication, and health. To measure the effect of
this different model of care on client treatment outcomes, similar assessment would be
conducted at a comparable OTP that was not participating in the pilot project. Clients and staff
would be interviewed at both sites to identify changes in perceived treatment effects as well as
in opioid dependence and other assessed client problems over the course of the project. One of
the key measures would be quality of life for clients who participated in the pilot
multidisciplinary treatment OTP compared to the clients in the OTP services as usual site. The
following paragraph describes more about the importance of quality of life measures in future
research.
Quality of life data elements.
Much of social work focuses on helping individuals improve quality of life while
respecting individuals and supporting non-discrimination and social justice (NASW, 2008).
Reducing harmful behaviors (i.e., drug abuse) while increasing pro-social activities (i.e.
participation in work, volunteering, peer support) and improving overall behavioral health (i.e.
coping with depression and anxiety, managing medical conditions like diabetes, weight
management) make up the core quality of life measures, which are prominent in many
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behavioral health assessments (Cummins, Lau, & Stokes, 2004; World Health Organization,
1998). The definition of quality of life used in behavioral health is in regards to the individual’s
perception of well-being and functioning in day-to-day living activities (Tiffany, et al., 2012). In a
recent article by Tiffany and colleagues (2012) a key suggestion is for outcome evaluations in
substance abuse treatment to expand beyond abstinence measures and begin incorporating
quality of life variables. Substance dependence is defined in terms of a maladaptive pattern of
behavior (APA, 1994) and improved quality of life perception may be a key predictor for clients
who will be able to sustain substance use abstinence (Laudet, Becker, & White, 2009).
Specifically because opioid dependence creates biological changes in the brain and CNS
(Compton and Volkow, 2006) and often requires long-term treatment, the focus on quality of
life factors seems particularly salient. In fact, health-related quality of life among methadone
clients in OTPs is generally very poor (Millson, Challacombe, Villeneuve, Fischer, Strike, et al.,
2004; Puigdollers, Domingo-Salvany, Brugal, Torrens, Alvaros, et al., 2004; Winklbaur, Jagsch,
Ebner, Thau, & Fischer, 2008) as seen within the sample of clients examined for this paper
where over half of those with CNCP reported comorbid physical health issues.
This exploratory study sets the stage for further research examining the quality of life
for individuals with CNCP receiving opioid treatment. For example, some scientists have found
opioid dependence, including use of opioids long-term for pain relief, increases an individual’s
sensitivity to pain (hyperalgesia) (Angst & Clark, 2006). If this is the case, we might expect to see
an overwhelming number of individuals in opioid dependence treatment reporting painful
conditions, which may be heightened in the CNS by the person’s past abuse of opioids. One of
the most difficult aspects of pain for clinicians and addiction treatment specialists is that
measurement of pain is subjective and reports of pain vary greatly from person to person (IASP,
2011). If CNCP rates continue to rise alongside the growing number of individuals who report
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abusing prescription opioids, there is much more research needed regarding these co-occurring
conditions.
There remains a limited amount of information on OTP clients with CNCP and yet the
data tell us that the problem will likely be increasing over time, therefore this is a key area of
research in the future (Ospina & Harstall, 2002). Examining in more detail the source and type
of pain and age of onset will be essential (Rashiq & Dick, 2009). Specifically, questions about a
history of victimization as the source of pain should be examined (El-Bassel, Gilbert, Wu, Go, &
Hill, 2005). Noting if the pain is unremitting or recurrent, predictable or break-through,
neuropathic or centralized can help in understanding the individual reaction to the CNCP and
coping techniques used to deal with it. Quality of life measures should be incorporated to
examine how much the pain is interfering with the individual’s life and goals along with
outcomes as treatment progresses (Laudet et al., 2009; Tiffany et al., 2012). Questions about
co-occurring physical and mental health issues, reasons for seeking opioid dependence
treatment, and what supports work best for individuals will also be important additions to
future research. In addition, the sample of OTP clients would be selected carefully to be as
representative of the wider population as possible including stratified gender, race, and age
groups.
Expansion of OTP sample.
Within the scope of a wider population of CNCP cases and opioid dependence treatment
programs, it will be important to include buprenorphine medication clients. Though only a small
number of OTPs offer buprenorphine, there are thousands of private physicians who have
received DATA 2000 authorization to prescribe within their practices or clinics
(www.buprenorphine.gov). In Kentucky, Medicaid covers the cost of buprenorphine if
purchased with a prescription from a physician for pain relief, but not for medication-assisted
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treatment for opioid dependence as administered in an OTP. Researchers need to examine how
the buprenorphine prescribing practices compare to the OTPs in relation to assessing and
treating CNCP co-occurring with opioid dependence. Are these physicians carefully monitoring
their clients or is there an increasing number of CNCP cases with opioid dependence seeking
opioids either for craving or for CNCP treatment through these private providers?
As more and more veterans return from deployment in the United States, there may be
an influx of new cases of CNCP related to combat injuries (Tanielian & Jaycox, 2008). Soldiers
may be treated with opioids during their initial healing phases and may be maintained on pain
medications while trying to get them safely home. Once home, a solider in rural Kentucky may
not be able to access pain management services as easily as a soldier who lives near the
Veteran’s Administration Hospital in Lexington. The prescription drug problem is particularly
overwhelming in the Eastern part of our state, yet there are limited numbers of OTPs in nonmetropolitan areas (SAMHSA, 2009). There may be a growing number of soldiers returning to
this region who have CNCP, opioid dependence, and who have been exposed to traumatic
events. These individuals will need an integrated plan of care for their conditions. Researchers
should examine current physician practices in relation to assessment, planning, and integration
of treatment care for clients with comorbid CNCP, opioid dependence, and other mental and
physical health conditions (Clark & Treisman, 2011). Information is needed on how physicians,
clinicians, and other behavioral health providers share information about clients with CNCP and
opioid dependence history, and how this sharing cane been done most effectively in order to
monitor progress, setbacks, and provide continuity of care.
Within each state, there is a designated person in government called the State Opioid
Treatment Authority (SOTA) whose primary responsibility is oversight of that state’s OTPs. A
recent study surveyed SOTAs across the U.S. regarding policy statements for alcohol use for

105

individuals in OTPs and found wide variation in treatment methods and requirements for clients
(Harris et al., 2010). Similar data should be collected regarding tobacco use policies and
methods found useful for providing tobacco cessation programs within OTPs. The connection
between tobacco use, poor physical health, and chronic medical conditions is strong (CDC,
2004). Moving towards a behavioral health model that addresses all biopsychosocial aspects of
the client, instead of only opioid dependence will likely be driven by policy makers, SOTAs, and
clinical providers. Surveying the practices of each state through the SOTAs and then engaging
them in a dialogue around the results would be a good start towards helping evaluate state OTP
practices in relation to national behavioral health practices. The annual American Association
for Treatment of Opioid Dependence (AATOD) conference would be an ideal location for sharing
the results so that not only the SOTAs can evaluate the research, but also the providers and
service consumers as well. Individuals with CNCP and opioid dependence in this exploratory
study highlight the need for further examination of integrated biopsychosocial treatment.

106

Appendix A: UK IRB Protocol Approval Letter

107

REFERENCES
Agency Medical Directors Group. (2010). Interagency guideline on opioid dosing for chronic non-cancer
pain (CNCP). Retrieved from http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf
Agrawal, A., & Lynskey, M. (2008). Are there genetic influences on addiction: Evidence from family,
adoption and twin studies. Addiction, 103(7), 1069-1081.
Albertson, T.E. (2007). Opiates and opioids. In K.R. Olson (Ed), Poisoning & Drug Overdose, 5e. Retrieved
from http://www.accessmedicine.com/content.aspx?aID=2678355
Alterman, A., Bovasso, G., Cacciola, J., & McDermott, P. (2001). A comparison of the predictive validity of
four sets of baseline ASI summary indices. Psychology of Addictive Behaviors, 15(2), 159-162.
Alterman, A., Mulvaney, F., Cacciola, J., Cnaan, A., McDermott, P., & Brown, L. (2001). The validity of the
interviewer severity ratings in groups of ASI interviewers with varying training. Addiction, 96 (9),
1297-1305.
American Academy of Pediatrics. (2012). National Center for Medical Home Implementation: Overview.
Retrieved from http://www.medicalhomeinfo.org/
American Pain Society. (2001). Definitions related to the use of opioids for the treatment of pain.
Retrieved from http://www.ampainsoc.org/advocacy/opioids2.htm.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.,
text rev.). Washington, DC: American Psychiatric Association.
American Society of Addiction Medicine [ASAM]. (2011). ASAM releases new definition of addiction.
Retrieved from http://www.asam.org/pdf/Advocacy/PressReleases/20110815_DefofAddictionPR.pdf
Angelino, A.F., Clark, M.R., & Treisman, G.J. (2005). Substance use disorders in patients with chronic pain:
The role of temperament in successful treatment. Technical Regional Anesthesiology and Pain
Management, 9 (4), 204-211.
Angst, M.S., & Clark, D.J. (2006). Opioid-induced hyperalgesia: A qualitative systematic review.
Anesthesiology, 104, 570–587

108

Arthritis Foundation. (2010). Rheumatoid arthritis rate rising in women. Arthritis Today, 2/26/2010.
Retrieved from http://www.arthritistoday.org/conditions/rheumatoid-arthritis/news-andresearch/rheumatoid-arthritis-women.php
Baca, C.T., & Yahne, C.E. (2009). Smoking cessation during substance abuse treatment: What you need to
know. Journal of Substance Abuse Treatment, 36, 205-219.
Banta-Green, C.J., Merrill, J.O., Doyle, S.R., Boudreau, D.M., & Calsyn, D.A. (2009). Measurement of opioid
problems among chronic pain patients in a general medical population. Drug and Alcohol
Dependence, 104 (1-2), 43-49.
Barry, D.T., Beitel, M., Cutter, C.J., Joshi, D., Falcioni, J., & Schottenfeld, R.S. (2009). Conventional and
non-conventional pain treatment utilization among opioid dependent individuals with pain
seeking methadone maintenance treatment: A needs assessment study. Journal of Addiction
Medicine, 18 (5), 379-385.
Becker, J., & Hu, M. (2008). Sex differences in drug abuse. Frontiers in Neuroendocrinology, 29 (1), 36-47.
Becker, W.C., Sullivan, L.E., Tetrault, J.M., Desai, R.A., & Fiellin, D.A. (2008). Non-medical use, abuse, and
dependence on prescription opioids among U.S. adults: Psychiatric, medical, and substance use
correlates. Drug and Alcohol Dependence, 94 (1-3), 38-47.
Belenko, S., Patapis, N., & French, M.T. (2005). Economic benefits of drug treatment: A critical review of
the evidence for policy makers. Philadelphia, PA: University of Pennsylvania, Treatment Research
Institute.
Bennett, L., & O'Brien, P. (2007). Effects of coordinated services for drug-abusing women who are victims
of intimate partner violence. Violence Against Women, 13, 395–411
Birnbaum, H.G., White, A.G., Reynolds, J.L., Greenberg, P.E., Zhang, M., Vallow, S.,…Katz, N.P. (2006).
Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal
perspective. Clinical Journal of Pain, 22, 667-676.
Boisvert, R.A., Martin, L.M., Grosek, M., & Clarie, A.J. (2008). Effectiveness of a peer-support community
in addiction recovery participation as intervention. Occupational Therapy International, 15(4),
205-220.

109

Bonica, J.J., & Loeser, J.D. (2001). History of pain concepts and theories. In J.D. Loeser, S.H. Butler, C.R.,
Chapman, & D.C. Turk (Eds.) Bonica’s Management of Pain , 3rd Edition (pp. 3-16). Philadelphia,
PA: Lippincott, Williams, & Wilkins.
Bovasso, G., Alterman, A., Cacciola, J., & Cook, T. (2001). Predictive validity of the Addiction Severity
Index’s composite scores in the assessment of 2-year outcomes in a methadone maintenance
population. Psychology of Addictive Behaviors, 15 (3), 171-176.
Bowen, S., Witkiewitz, K., Dillworth, T.M., & Marlatt, G.A. (2007). The role of thought suppression in the
relationship between mindfulness meditation and alcohol use. Addictive Behaviors, 32 (10),
2324-2328.
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2008). Survey of chronic pain in Europe:
Prevalence, impact on daily life, and treatment. European Journal of Pain, 10, 287-333.
Brown, S. (2006). Women and addiction: Expanding theoretical points of view. In S.L.A. Straussner & S.
Brown, (Eds.), The Handbook of Addiction Treatment for Women, (pp. 26-51). San Francisco, CA:
Jossey-Bass.
Bureau of Labor Statistics. (2010). Current population survey: Employment projections. Retrieved from
http://www.bls.gov/emp/ep_chart_001.htm.
Butler, S.F. (2008). Evidence of co-occurring alcohol and prescription opioid abuse in clinical populations:
Implications for screening. Tufts Health Care Institute. Retrieved from
http://www.thci.org/Opioid/nov08docs/butler.pdf.
Cacciola, J.S., Alterman, A.I., Rutherford, M.J., McKay, J.R., & Mulvaney, F.D. (2001). The relationship of
psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug and
Alcohol Dependence, 61, 271-280.
Campbell, N. (2010). Discovering Addiction: The Science and Politics of Substance Abuse Research. Ann
Arbor, MI: University of Michigan Press.
Carlson, R.G. (2006). Anthropological and cross cultural factors. In W.R. Miller & K.M. Carroll (Eds.),
Rethinking substance abuse: What the science shows, and what we should do about it (pp. 201219). New York, NY: Guildford Press.

110

Centers for Disease Control [CDC]. (2008). Kentucky: Burden of chronic diseases. Report # 122482.
Atlanta, GA: Centers for Disease Control.
Centers for Disease Control and Prevention [CDC]. (2012). Vital signs: Binge drinking prevalence,
frequency, and intensity among adults- United States, 2010. Journal of American Medical
Association, 307 (9), 14-19.
Centers for Disease Control and Prevention [CDC]. (2004). 2004 Surgeon General’s report: The health
consequences of smoking. Washington, DC: Department of Health and Human Services.
Centers for Disease Control and Prevention [CDC]. (2010). Arthritis: Data & statistics. CDC data reports
online. Retrieved from http://www.cdc.gov/arthritis/data_statistics.htm
Center for Substance Abuse Treatment. (2004). Clinical guidelines for the use of buprenorphine in the
treatment of opioid dependence. Treatment Improvement Protocol (TIP) Series 40. DHHS
Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services
Administration.
Center for Substance Abuse Treatment. (2005). Medication-assisted treatment for opioid dependence in
opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication
No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration.
Center for Substance Abuse Treatment. (2009). Incorporating alcohol pharmacotherapies into medical
practice. Treatment Improvement Protocol (TIP) Series 49. HHS Publication No. (SMA) 09-4380.
Rockville, MD: Substance Abuse and Mental Health Services Administration.
Chapman, R.C., & Turner, J.A. (2001). Psychological aspects of pain. In J.D. Loeser, S.H. Butler, C.R.
Chapman, D.C. Turk (Eds.), Bonica’s Management of Pain, 3rd Edition (pp. 180-190). Philadelphia,
PA: Lippincott, Williams, & Wilkins.
Cheng, Y.J., Hootman, J.M., Murphy, L.B., Langmaid, G.A., & Helmick, C.G. (2010). Prevalence of doctordiagnosed arthritis and arthritis-attributable activity limitation — United States, 2007–2009.
Morbidity and Mortality Weekly Report, 59 (39), 1261–1265.
Chou, R., Ballantyne, J.C., Fanciullo, G.J., Fine, P.G., & Miaskowski, C. (2009). Research gaps on use of
opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain

111

Society and American Academy of Pain Medicine clinical practice guideline. American Pain
Society, 10 (2), 147-159.
Cicero, T.J., Inciardi, J.A., & Munoz, A. (2005). Trends in abuse of OxyContin and other opioid analgesics in
the United States: 2002-2004. The Journal of Pain, 6, 662-672.
Cicero, T., Lynskey, M., Todorov, A., Inciardi, J., & Surratt, H. (2008). Co-morbid pain and psychopathology
in males and females admitted to treatment for opioid analgesic abuse. Pain, 139(1), 127-135.
Clark, M.E., Bair, M.J., Buckenmaier, C.C., Gironda, R.J., & Walker, R. (2007). Pain and combat injuries in
soldiers returning from Operations Enduring Freedom and Iraqi Freedom: Implications for
research and practice. Journal of Rehabilitation Research & Development, 44 (2), 179-194.
Clark, M., Stoller, K., & Brooner, R. (2008). Assessment and management of chronic pain in individuals
seeking treatment for opioid dependence disorder. Canadian Journal of Psychiatry, 53 (8), 496508.
Clark, M.R., & Treisman, G.J. (2011). From stigmatized neglect to active engagement. In M.R. Clark, & G.J.,
Treisman, (Eds.), Chronic pain and addiction, (pp. 1-7). New York, NY: Karger.
Clark, W.H., Power, A.K., Le Fauve, C.E., & Lopez, E.I. (2008). Policy and practice implications of
epidemiological surveys on co-occurring mental and substance use disorders. Journal of
Substance Abuse Treatment, 34 (1), 3-13. doi: 10.1016/j.jsat.2006.12.032
Cleeland, C. (1991). Research in cancer pain. What we know and what we need to know. Cancer, 67 (S3),
823-827.
Compton, W.M., & Volkow, N.D. (2006). Major increases in opioid analgesic abuse in the United States:
Concerns and strategies. Drug and Alcohol Dependence, 81, 103-107.
Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Lui, Z., Taylor, R.J.,… Taylor, R.S. (2007). Methadone
and buprenorphine for the management of opioid dependence: A systematic review and
economic evaluation. Health Technology Assessment, 11 (9), 1-171.
Crum, R. (2009). The epidemiology of substance use disorders. In R.K. Ries, S.C. Miller, D.A. Fiellin, & R.
Saitz (Eds.), Principles of Addiction Medicine (pp 13-26). Philadelphia, PA: Lippincott, Williams, &
Wilkins.

112

Cummins, R.A., Lau, A., & Sokes, M. (2004). HrQoL and subjective well-being: Noncomplementary forms
of outcome measurement. Expert Review of Pharmacoeconomics and Outcomes Research, 4,
413-420.
Curet, E., Beeder, A.B., Joseph, H., Alexander, K., Schamisso, C., & Rodriguez, H. (2007). The Vincent P.
Dole Research and Treatment Institute for Opiate Dependence: An integrated biopsychosocial
model for the treatment of methadone maintained patients. Heroin Addiction Related Clinical
Problems, 9 (1), 25-34.
Davidson, L., White, W., Sells, D., Schmutte, T., O’Connell, M., Bellamy, C., & Rowe, M. (2010). Enabling or
engaging? The role of recovery support services in addiction recovery. Alcoholism Treatment
Quarterly, 28 (4), 391-416.
Dersh, J., Gatchel, R.J., Mayer, T., Polatin, P., & Temple, O.R. (2006). Prevalence of psychiatric disorders in
patients with chronic disabling occupational spinal disorders. Spine, 31 (10), 1156-1162.
Disorbio, J., Bruns, D., & Barolat, G. (2006). Assessment and treatment of chronic pain: A physician’s guide
to a biopsychosocial approach. Practical Pain Management, 6, 11-27.
Ditre, J.W., Gonzalez, B.D., Simmons, V.N., Faul, L.A., Brandon, T.H., & Jacobsen, P.B. (2011). Associations
between pain and current smoking status among cancer patients. Pain, 152 (1), 60-65.
Dole, V.P., & Nyswander, M.E. (1980). Methadone maintenance: A theoretical perspective. In D.J. Lettieri,
M. Sayers, & H.W. Pearson (Eds.), Theories on drug abuse: Selected contemporary perspectives
(pp. 256-261). NIDA Research Monograph 30. Washington, DC: U.S. Government Printing Office.
Retrieved from http://archives.drugabuse.gov/pdf/monographs/download30.html
Doth, A.H., Hansson, P.T., Jensen, M.P., & Taylor, R.S. (2010). The burden of neuropathic pain: A
systematic review and meta-analysis of health utilities. Pain, 149 (2), 338-344.
Drug Enforcement Agency [DEA]. (2011). Drug scheduling chart. Retrieved from
http://www.justice.gov/dea/pubs/scheduling.html
Dworkin, R.H., O'Connor, A.B., Backonja, M., Farrar, J.T., Nanna, B.F., Troels, S.J.,…Wallace, M.S. (2007).
Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain,
132 (3), 237-251. doi:10.1016/j.pain.2007.08.033

113

Eccleston, C. (2010). Psychology of chronic pain and evidence-based psychological interventions. In C.F.
Stannard, E. Kalso, & J. Ballantyne (Eds.), Evidence-Based Chronic Pain Management. Oxford, UK:
Wiley-Blackwell.
Edlund, M.J., Steffick, D., Hudson, T., Harris, K.M., & Sullivan, M. (2007). Risk factors for clinically
recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer
pain. Pain, 129, 355-362.
Engstrom, M., El-Bassel, N., Go, H., & Gilbert, L. (2008). Childhood sexual abuse and intimate partner
violence among women in methadone treatment: A direct or mediated relationship? Journal of
Family Violence, 23, 605–617.
Erickson, C.K., & White, W.L. (2009). The neurobiology of addiction recovery. Alcoholism Treatment
Quarterly, 27, 338-345.
Everitt, B.J., & Robbins, T.W. (2005). Neural systems of reinforcement for drug addiction: From actions to
habits to compulsion. Nature Neuroscience, 8 (11), 1481-1490.
Fareed, A., Casarella, J., Roberts, M., Sleboda, M., Amar, R., Vayalapalli, S., & Dresxler, K. (2009). High
dose versus moderate dose methadone maintenance: Is there a better outcome? Journal of
Addictive Diseases, 28, 399-405.
Federal Register. (2006). Drug Enforcement Administration guidelines for dispensing controlled
substances for treatment of pain. Federal Register Document [E6-14517], 71(172), 52716-52722.
Retrieved from http://wais.access.gpo.gov
Field, B.J., & Swarm, R.A. (2008). Chronic pain. Toronto, ON: Hogrefe & Huber Publishers.
Fields, H.L. (2007). Understanding how opioids contribute to reward and analgesia. Regional
Anesthesiology and Pain Medicine, 32 (3), 242-246.
Fishbain, D. A., Cole, B., Lewis, J., Rosomoff, H.L., & Rosomoff, R.F. (2008). What percentage of chronic
nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction
and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine, 9
(4), 444-459.

114

Fishbain, D.A., Lewis, J.E., Cole, B., Cutler, R.B., Rosomoff, H.L., & Rosomoff, R.S. (2007). Variables
associated with current smoking status in chronic pain patients. Pain Medicine, 8 (4), 301-311.
doi: 10.1111/j.1526-4637.2007.00317.x
Garcia-Sevilla, J., Ventayol, P., Busquets, X., La Harpe, R., Walzer, C., & Guimon, J. (1997). Regulation of
immunolabelled µ-opioid receptors and protein kinase C-a and isoforms in the frontal cortex of
human opioid addicts. Neuroscience, 226 (1), 29-32.
Gardner, E.L. (2011). Addiction and brain reward and antireward pathways. Advanced Psychosomatic
Medicine, 30, 22–60. doi: 10.1159/000324065
Garland, E., Boettiger, C., & Howard, M. (2011). Targeting cognitive-affective risk mechanisms in stressprecipitated alcohol dependence: An integrated, biopsychosocial model of automaticity,
allostatsis, and addiction. Medical Hypotheses, 76 (5), 745-754.
Gatchel, R.J. (2005). Clinical essentials of pain management. Washington, D.C.: American Psychological
Association.
Gatchel, R.J., & Kishino, N.D. (2011). The biopsychosocial perspective of pain and emotion. In G.
MacDonald & L.A. Jensen-Campbell (Eds.), Social Pain: Neuropsychological and health
implications of loss and exclusion, (pp. 181- 191.). Washington, D.C.: American Psychological
Association.
Gatchel, R.J., Peng, Y. B., Peters, M.L., Fuchs, P.N., & Turk, D.C. (2007). The biopsychosocial approach to
chronic pain: Scientific advances and future directions. Psychological Bulletin, 133 (4), 581-624.
Gazzaniga, M. (1989). Organization of the human brain. Science, 245, 4921, 947-952.
Giddings, L.S., & Roy, D.E. (2008). Stigmatisation of people living with a chronic illness or disability. In E.
Chang & A. Johnson (Eds.) Chronic illness and disability: Principles for nursing care, (pp. 66-76.).
Australia: Elsevier.
Gilbert, L., El-Bassel, N., Manuel, J., Wu, E., Go, H., Golder, S.,…Sanders, G. (2006). An integrated relapse
prevention and relationship safety intervention for women on methadone: Testing short-term
effects on intimate partner violence and substance use. Violence and Victims, 21, 657–672

115

Gilson, A.M., Ryan, K.M., Joranson, D.E., & Dahl, J.L. (2004). A reassessment of trends in the medical use
and abuse of opioid analgesics and implications for diversion control: 1997-2002. Journal of Pain
Symptom Management, 28, 176-188.
Gonzalez, A., Zvolensky, M.J., Hogan, J., McLeish, A.C., & Weibust, K.S. (2011). Anxiety sensitivity and painrelated anxiety in the prediction of fear responding to bodily sensations: A laboratory test.
Journal of Psychosomatic Research, 70, 258-266.
Gossop, M., Marsden, J., Stewart, D., & Rolfe, A. (2000). Patterns of improvement after methadone
treatment: 1 year follow-up results from the National Treatment Outcome Research Study
(NTORS). Drug and Alcohol Dependence, 60 (3), 275-286. doi: 10.1016/S0376-8716(00)00109-5
Gossop, M., Marsden, J., Stewart, D., & Kidd, T. (2003). The National Treatment Outcome Research Study
(NTORS): 4–5 year follow-up results. Addiction, 98 (3), 291–303. doi: 10.1046/j.13600443.2003.00296.x
Gossop, M., Stewart, D., & Marsden, J. (2008). Attendance at Narcotics Anonymous and Alcoholics
Anonymous meetings, frequency of attendance and substance use outcomes after residential
treatment for drug dependence: a 5-year follow-up study. Addiction, 103 (1), 119-125. doi:
10.1111/j.1360-0443.2007.02050.x
Green, T.C., Serrano, J.M., Licari, A., Budman, S.H., & Butler, S.F. (2009). Women who abuse prescription
opioids: Findings from the Addiction Severity Index-Multimedia Version® Connect prescription
opioid database. Drug and Alcohol Dependence, 103 (1-2), 65-73.
Grella, C.E., Scott, C.K., Foss, M.A., & Dennis, M.L. (2008). Gender similarities and differences in the
treatment, relapse, and recovery cycle. Evaluation Review, 32 (1), 113-137.
Gureje, O., Simon, G.E., & von Korff, M. (2001). A cross-national study of the course of persistent pain in
primary care. Pain, 92, 195-200.
Haanpaa, M.L., Backonja, M., Bennett, M., Bouhassira, D., Cruccu, G., Hansson, P.T.,…Baron, R. (2009).
Assessment of neuropathic pain in primary care. The American Journal of Medicine, 122 (10),
Supplement 1, S13-S21.

116

Haas, A.L., Sorensen, J.L., Hall, S.M., Lin, C., Delucchi, K., Sporer, K., & Chen, T. (2008). Cigarette smoking in
opioid-using patients presenting for hospital-based medical services. American Journal of
Addictions, 17, 65-69.
Hamilton, L.C., Hamilton, L.R., Duncan, C.M., & Colocousis, C.R. (2008). Place matters: Challenges and
opportunities in four rural Americas. Carsey Institute, University of New Hampshire: Durham, NH.
Harrell, P.T., Montoya, I.D., Preston, K.L., Juliana, L.M., & Gorelick, D.A. (2011). Cigarette smoking and
short-term addiction treatment outcomes. Drug and Alcohol Dependence, 115 (3), 161-166.
doi:10.1016/j.drugalcdep.2010.08.017.
Harris, G.H., Strauss, S.M., Katigbak, C., Brar, B.S., Brown, L.S., Kipnis, S.S.,...Parrino, M.W. (2010).
Variation among state-level approaches to addressing alcohol abuse in opioid treatment
programs. Journal of Substance Abuse Treatment, 39, 58-64.
Harris, J. (2012). Methadone as a social control: Institutionalized stigma and the prospect of recovery.
Qualitative Health Research (online published before print), 1-15. doi:
10.1177/1049732311432718
Harrison, L.D., Martin, S.S., Enev, T., & Harrington, D. (2007). Comparing drug testing and self-report of
drug use among youths and young adults in the general population (DHHS Publication No. SMA
07-4249, Methodology Series M-7). Rockville, MD: Substance Abuse and Mental Health Services
Administration, Office of Applied Studies.
Harvey, V., & Dickenson, A. (2010). Neurobiology of pain. In C.F. Stannard, E. Kalso, and J. Ballantyne
(Eds.) Evidence-based chronic pain management. Oxford, UK: Wiley-Blackwell.
Harwood, H.J., Malhotra, D., Villarivera, C., Liu, C., Chong, U., & Gilani, J. (2002). Cost effectiveness and
cost benefit analysis of substance abuse treatment: A literature review. The Lewin Group with
the Center for Substance Abuse Treatment, NEDS Contract No. 270-00-7078. Retrieved from
http://www.lewin.com/content/publications/2485.pdf
Havens, J.R., Oser, C.B., Leukefeld, C.G., Webster, J.M., Martin, S.S., O’Connell, D.J.,…Inciardi, J.A. (2007).
Differences in prevalence of prescription opioid misuse among rural and urban probationers. The
American Journal of Drug and Alcohol Abuse, 33 (2), 309-317.

117

Henkel, D. (2011). Unemployment and substance use: A review of the literature (1990-2010). Current
Drug Abuse Review, 4 (1), 4-27.
Hettema, J.E., & Sorenson, J.L. (2009). Access to care for methadone maintenance patients in the United
States. International Journal of Mental Health Addiction, 7, 468-474. doi: 10.1007/s11469-0099204-6
Hojsted, J., Nielsen, P.R., Guldstrand, S.K., Frisch, L., & Sjogren, P. (2010). Classification and identification
of opioid addiction in chronic pain patients. European Journal of Pain, 14, 1014-1020.
Holden, J.E., Jeong, Y., & Forrest, J. (2005). The endogenous opioid system and clinical pain management.
AACN Clinical Issues: Advanced Practice in Acute & Critical Care, 16(3), 291-301.
Hooten, W.M., Shi, Y, Gazelka, H.M., & Warner, D.O. (2011). The effects of depression and smoking on
pain severity and opioid use in patients with chronic pain. Pain, 152 (1), 223-229. doi:
10.1016/j.pain.2010.10.045
Hooten, W.M., Townsend, C.O., Bruce, B.K., Shi, Y., & Warner, D.O. (2009). Sex differences in
characteristics of smokers with chronic pain undergoing multidisciplinary pain rehabilitation.
Pain Medicine, 10 (8), 1416-1425. doi:10.1111/j.1526-4637.2009.00702.x
Hyman, S.E., & Malenka, R.C. (2001). Addiction and the brain: The neurobiology of compulsion and its
persistence. Neuroscience, 2, 695-703.
Institute of Medicine [IOM]. (2005). Federal regulation of methadone treatment. Washington, DC: The
National Academies Press.
Institute of Medicine [IOM]. (2006). Improving the quality of health care for mental and substance-use
conditions. Washington, DC: The National Academies Press.
Institute of Medicine [IOM]. (2011). Relieving pain in America: A blueprint for transforming prevention,
care, education, and research. Washington, DC: The National Academies Press.
International Association for the Study of Pain [IASP]. (2011). Unrelieved pain is a major global healthcare
problem. Retrieved from http:// iasp-pain.org.
Jamison, R.N., Butler, S.F., Budman, S.H., Edwards, R.R., & Wasan, A.D. (2010). Gender differences in risk
factors for aberrant prescription opioid use. Journal of Pain, 11(4), 312-320.

118

Jamison, R.N., Kauffman, J., & Katz, N.P. (2000). Characteristics of methadone maintenance patients with
chronic pain. Journal of Pain Symptom Management, 19, 53-62.
Johannes, C.B., Le, T.K., Zhou, X., Johnston, J.A., & Dworkin, R.H. (2010). The prevalence of chronic pain in
United States adults: Results of an internet-based survey. Journal of Pain, 11(11), 1230-1239.
Jones, E.S., Moore, B.A., Sindelar, J.L., O'Connor, P.G., Schottenfeld, R.S., & Fiellin, D.A. (2009). Cost
analysis of clinic and office-based treatment of opioid dependence: results with methadone and
buprenorphine in clinically stable patients. Drug and Alcohol Dependence, 99, 132-140.
Katz, M.H. (2010). Long-term opioid treatment of nonmalignant pain: A believer loses his faith. Archives of
Internal Medicine, 170(16), 1422-1424.
Keller, S., Bann, C.M., Dodd, S.L., Schein, J., Mendoza, T.R., & Cleeland, C.S. (2004). Validity of the brief
pain inventory for use in documenting the outcomes of patients with noncancer pain. The Clinical
Journal of Pain, 20(5), 309-318.
Kentucky Cabinet for Health and Family Services. (2008). Tobacco prevention and control strategic plan,
2008-2013. Retrieved from http://chfs.ky.gov/NR/rdonlyres/AEE67B54-8E17-4EF9-9408A21F714181C0/0/StrategicPlanSummary20082013.pdf
Kerlikowske, G. (2010). Release of the Obama administration’s national drug control policy. Washington,
DC: Foreign Press Center briefing with Gil Kerlikowske, Director, Office of National Drug Control
Policy.
Koob, G.F. (2006). The neurobiology of addiction: A hedonic Calvinist view. In W.R. Miller & K.M. Carroll
(Eds.), Rethinking substance abuse: What the science shows, and what we should do about it (pp
25-45). New York, NY: Guildford Press.
Koob, G.F. (2011). Neurobiology of addiction: Toward the development of new therapies. American
Psychological Association, Focus, 9, 55-65.
Koob, G.F., & Le Moal, M. (2008). Addiction and the brain antireward system. Annual Review of
Psychology, 59, 29-53.

119

Lawrence, R.C., Felson, D.T., Helmick, C.G., Arnold, L.M., Choi, H., Deyo, R.A.,…Wolfe, F. (2008). Estimates
of the prevalence of arthritis and other rheumatic conditions in the United States: Part II.
Arthritis & Rheumatism, 58 (1), 26-35.
Laudet, A.B. (2008a). The road to recovery: Where are we going and how do we get there? Empirically
driven conclusions and future directions for service development and research. Substance Use &
Misuse, 43, 2001-2020.
Laudet, A.B. (2008b). The impact of Alcoholics Anonymous on other substance abuse related twelve step
programs. Recent Developments in Alcoholism, 18, 71-89.
Laudet, A.B., Becker, J., & White, W. (2009). Don't wanna go through that madness no more: Quality of
life satisfaction as predictor of sustained substance use remission. Substance Use and Misuse,
44, 227–252.
Laudet, A.B., Magura, S., Vogel, H., & Knight, E. (2000). Recovery challenges among dually diagnosed
individuals. Journal of Substance Abuse Treatment, 18, 321-329.
LeResche, L. (2001). Epidemiology of orofacial pain. In J.P. Lund, G.J. Lavigne, R. Dubner and B.J. Sessle
(Eds.) Orofacial pain: From basic science to clinical management. Chicago, IL: Quintessence
Publishing Company.
Lee, J.D., & Rich, J.D. (2012). Opioid pharmacotherapy in criminal justice settings: Now is the time.
Substance Abuse, 33(1), 1-4. doi: 10.1080/08897077.2011.616797
Leonhard, C., Mulvey, K., Gastfriend, D.R., & Shwartz, M. (2000). The Addiction Severity Index: A field
study of internal consistency and validity. Journal of Substance Abuse Treatment, 18 (2), 129-135.
Liu, X., Matochik, J.A., Cadet, J., & London, E.D. (1998). Smaller volume of prefrontal lobe in polysubstance
abusers: A magnetic resonance imaging study. Neuropsychopharmacology, 18(4), 243-252.
Luu, P., & Posner, M.I. (2003). Anterior cingulate cortex regulation of sympathetic activity. Brain, 126(10),
2119-2120.
Lyvers, M. (2000). "Loss of control" in alcoholism and drug addiction: A neuroscientific interpretation.
Experimental and Clinical Psychopharmacology, 8, 225-249.

120

Maldonado, R., Valverde, O., & Berrendero, F. (2006). Involvement of the endocannabinoid system in drug
addiction. Trends in Neurosciences, 29(4), 225-232.
Manchikanti, L., Cash, K.A., Damron, K.S., Manchukonda, R., Pampati, V., & McManus, C.D. (2006).
Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple
variables. Pain Physician, 9 (3), 215-225.
Manchikanti, L., Fellows, B., Damron, K.S., Pampati, V., & McManus, C.D. (2005). Prevalence of illicit drug
use among individuals with chronic pain in the Commonwealth of Kentucky: An evaluation of
patterns and trends. Journal of Kentucky Medical Association, 103, 55-62.
Mattick, R.P., Kimber, J., Breen, C., & Davoli, M. (2002). Buprenorphine maintenance versus placebo or
methadone maintenance for opioid dependence. Cochrane database of systematic reviews, 181
(2), 1-32: CD002207.
McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., & Grissom, G. (1992). The fifth edition of the
Addiction Severity Index. Journal of Substance Abuse Treatment, 9, 199-213.
McLellan, A.T., Luborsky, L., Cacciola, J., Griffith, J., Evans, F., Barr, H.L., & O’Brien, C.P. (1985). New data
from the Addiction Severity Index. Reliability and validity in three centers. The Journal of Nervous
and Mental Disease, 173(7), 412-423.
McCracken, L. M., & Vowles, K. E. (2008). A prospective analysis of acceptance and values in patients with
chronic pain. Health Psychology, 27, 215-220.
McCrady, B.S. (2006). Family and other close relationships. In Miller, W.R., & Carroll, K.M.
(Eds.), Rethinking substance abuse: What the science shows and what we should do about it. New
York: Guilford Press.
Melzack, R., & Wall, P.D. (1965). Pain mechanism: A new theory. Science, 150 (699), 971-979.
Millson, P.E., Challacombe, L., Villeneuve, P.J., Fischer, B., Strike, C.J., Myers, T.,…Pearson, M. (2004). Selfperceived health among Canadian opiate users: A comparison to the general population and to
other chronic disease populations. Canadian Journal of Public Health, 95, 99-103.

121

Mitchell, M.D., Mannino, D.M., Steinke, D.T., Kryscio, R.J., Bush, H.M., & Crofford, L.J. (2011). Association
of smoking and chronic pain syndromes in Kentucky women. Journal of Pain, 12(8), 892-899. doi:
10.1016/j.jpain.2011.02.350
Moos, R. (2006). Social contexts and substance use. In W.R. Miller & K.M. Carroll (Eds.), Rethinking
substance abuse: What the science shows, and what we should do about it (pp. 182-200). New
York, NY: Guildford Press.
Mueser, K.T., Drake, R.E., Turner, W., & McGovern, M. (2006). Comorbid substance use disorders and
psychiatric disorders. In W.R. Miller & K.M. Carroll (Eds.), Rethinking substance abuse: What the
science shows, and what we should do about it (pp. 115-133). New York, NY: Guildford Press.
Mueser, K.T., Noordsy, D.L., Drake, R.E., & Fox, L. (2003). Integrated treatment for dual disorders: A guide
to effective practice. New York, NY: Guildford Press.
National Association of Social Workers [NASW]. (2008). Code of ethics of the National Association of Social
Workers. Washington, DC: NASW Press. Retrieved from
www.socialworkers.org/pubs/code/code.asp
National Institute on Drug Abuse. (2005). Prescription drugs: Abuse and addiction. NIH Publication
Number 05-4881. Retrieved from http://www.nida.nih.gov/PDF/RRPrescription.pdf
National Institute on Drug Abuse. (2010). Drug facts: Understanding drug abuse and addiction. Retrieved
from http://www.drugabuse.gov/PDF/InfoFacts/Understanding.pdf
National Research Council. (2001). Musculoskeletal disorders and the workplace. Washington, DC:
National Academy Press.
O'Brien, C.P., & McLellan, A.T. (1996). Myths about the treatment of addiction. Lancet, 347, 237.
O'Malley, S.S., & Kosten, T.R. (2006). Pharmacotherapy of addictive disorders. In W.R. Miller & K.M.
Carroll (Eds.), Rethinking substance abuse: What the science shows, and what we should do
about it (pp 115-133). New York, NY: Guildford Press.
Passetti, F., Clark, L., Mehta, M.A., Joyce, E., & King, M. (2008). Neuropsychological predictors of clinical
outcome in opioid dependence. Drug and Alcohol Dependence, 94, 82–91.

122

Passik, S.D., Kirsh, K.L., & Webster, L. (2011). Pseudoaddiction revisited: a commentary on clinical and
historical considerations. Pain Management, 1 (3), 239-248. doi: 10.2217/pmt.11.12
Patel, N.B. (2010). Physiology of pain. In A. Kopf & N.B. Patel (Eds.), Guide to pain management in lowresource settings (pp.13-17). Seattle, WA: International Association for the Study of Pain.
Patterson, A.L., Gritzner, S., Resnick, M.P., Dobscha, S.K., Turk, D.C., & Morasco, B.J. (2012). Smoking
cigarettes as a coping strategy for chronic pain is associated with greater pain intensity and
poorer pain-related function. The Journal of Pain, 13 (3), 285-292.
Pelletier, L.R., & Hoffman, J.A. (2001). New federal regulations for improving quality in opioid treatment
programs. Journal for Healthcare Quality, 23, 29-33.
Pollack, H.A., & D’Aunno, T. (2008). Dosage patterns in methadone treatment: Results from a national
survey, 1988-2005. Health Services Research, 43 (6), 2143-2163.
Portenoy, R.K., Payne, R., & Passik, S.D. (2005). Acute and chronic pain. In J.H. Lowinson, P. Ruiz, R.B.
Millman, & J.G. Langrod (Eds.), Substance abuse: A comprehensive textbook (Fourth ed., pp. 863903). New York: Lippincott, Williams, & Wilkins.
Portenoy, R. K., Ugarte, C., Fuller, I., & Haas, G. (2004). Population-based survey of pain in the United
States: Differences among white, African American, and Hispanic subjects. Journal of Pain, 5,
317-328.
Preda, A. (2012). Opioid abuse. Medscape Reference. Retrieved from
http://emedicine.medscape.com/article/287790-overview.
Puigdollers, E., Domingo-Salvany, A., Brugal, M.T., Torrens, M., Alvaros, J., Castillo, C.,… Vazquez, J. M.
(2004). Characteristics of heroin addicts entering methadone maintenance treatment: Quality of
life and gender. Substance Use and Misuse, 39, 1353-68.
Rashiq, S., & Dick, B.D. (2009). Factors associated with chronic noncancer pain in the Canadian
population. Pain Research & Management, 14(6), 454-460.
Rikoon, S.H., Cacciola, H.S., Carise, D., Alterman, A.I., & McClellan, A.T. (2006). Predicting DSM-IV
dependence diagnoses from Addiction Severity Index composite scores. Journal of Substance
Abuse Treatment, 31, 17– 24.

123

Robinson, J.P., Leo, R., Wallach, J., McGough, E., & Schatman, M. (2010). Rehabilitative treatment. In C.F.
Stannard, E. Kalso, & J. Ballantyne (Eds.), Evidence-based chronic pain management. Oxford, UK:
Wiley-Blackwell.
Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleland, C., & Portenoy, R.K. (2003). Prevalence and
characteristics of chronic pain among chemically dependent patients in methadone maintenance
and residential treatment facilities. JAMA, 289, 2370-2378.
Sanders, S.H., Harden, R.N., & Vicente, P.J. (2005). Evidence-based clinical practice guidelines for
interdisciplinary rehabilitation of chronic nonmalignant pain syndrome patients. Pain Practice,
5(4), 303-315.
Sansone, R.A. , Whitecar, P. & Wiederman, M.W.(2009). The prevalence of childhood trauma among
those seeking buprenorphine treatment. Journal of Addictive Diseases, 28 (1), 64-67.
Savage, S.R., & Horvath, R. (2009). Opioid therapy of pain. In R.K. Ries, S.C. Miller, D.A., Fiellin, & R. Saitz
(Eds.), Principles of addiction medicine, (pp. 1329-1351). Philadelphia, PA: Lippincott, Williams &
Wilkins.
Sees, K., Delucci, K.L., Masson, C., Rosen, A., Clark, H.W., Robillard, H.,…Hall, S.M. (2000). Methadone
maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid
dependence: A randomized controlled trial. Journal of the American Medical Association, 283,
1303-1310.
Shannon, E.E., Mathias, C.W., Marsh, D.M., Dougherty, D.M., & Liguori, A. (2007). Teenagers do not
always lie: Characteristics and correspondence of telephone and in-person reports of adolescent
drug use. Drug and Alcohol Dependence, 90 (2-3), 288-291.
Sharp, J., & Keefe, B. (2006). Psychiatry in chronic pain: A review and update. Focus: Psychiatry Online, 4
(4), 573-580.
Sheu, R., Lussier, D., Rosenblum, A., Fong, C., Portenoy, J., Joseph, H., & Portenoy, R.K. (2008). Prevalence
and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol
treatment program. Pain Medicine, 9 (7), 911-917.

124

Simoens, S., Matheson, C., Bond, C., Inkster, K., & Ludbrook, A. (2005). The effectiveness of community
maintenance with methadone or buprenorphine for treating opiate dependence. British Journal
of General Practice, 55 (511), 139-146.
Skinner, M.L., Haggerty, K.P., Fleming, C.B., Catalano, R.F., & Gainey, R.R. (2011). Opioid-addicted parents
in methadone treatment: Long-term recovery, health, and family relationships. Journal of
Addictive Diseases, 30 (1), 17-26.
Smalley, K.B.,Yancey, C.T., Warren, J.C., Naufel, K., Ryan, R., & Pugh, J.L. (2010). Rural mental health and
psychological treatment: A review for practitioners. Journal of Clinical Psychology, 66 (5), 479489. doi: 10.1002/JCLP.20688.
Smith, M., Rosenblum, A., Parrino, M., Fong, C., & Colucci, S. (2010). Validity of self-reported misuse of
prescription opioid analgesics. Substance Use and Misuse, 45 (10), 1509-1524.
doi:10.3109/10826081003682107
Stannard, C. F. (2011). Opioids for chronic pain: Promise and pitfalls. Current Opinion in Supportive and
Palliative Care, 5(2), 150-157.
Staton-Tindall, M., McNees, E., Walker, R., & Leukefeld, C. (2009). Criminal Justice Kentucky Treatment
Outcome Study (CJKTOS): FY2009 follow-up report. Lexington, KY: University of Kentucky, Center
on Drug & Alcohol Research.
Stevenson, E., Cole, J., Walker, R., Logan, TK, & Mateyoke, A. (2011). Kentucky Opioid Replacement
Treatment Outcome Study annual follow-up report 2010. Lexington, KY: University of Kentucky,
Center on Drug & Alcohol Research.
Strain, E.C. (2002). Assessment and treatment of comorbid psychiatric disorders in opioid
dependent patients. Clinical Journal of Pain, 18, S14–S27.
Straussner, S.L.A., & Attia, P.R. (2002). Women’s addiction and treatment through a historical lens. In
S.L.A. Straussner, & S. Brown, (Eds.), The handbook of addiction treatment for women, (pp. 3-25).
San Francisco, CA: Jossey-Bass.

125

Substance Abuse and Mental Health Services Administration [SAMHSA], Office of Applied Studies.
(2003a). Results from the 2002 National Survey on Drug Use and Health: National findings.
NHSDA Series H-22, DHHS Publication No. (SMA) 03-3836. Rockville, MD: SAMHSA.
Substance Abuse and Mental Health Services Administration [SAMHSA], Office of Applied Studies.
(2003b). Emergency department trends from the Drug Abuse Warning Network, final estimates
1995–2002. DAWN Series D–24; DHHS Publication No. (SMA) 03–3780. Rockville, MD: SAMHSA.
Substance Abuse and Mental Health Services Administration [SAMHSA], Office of Applied Studies. (2009).
National Survey of Substance Abuse Treatment Services (N-SSATS): 2008. Data on substance
abuse treatment facilities. DASIS Series: S-49, DHHS Publication No. (SMA) 09-445). Rockville,
MD: SAMHSA.
Substance Abuse and Mental Health Services Administration [SAMHSA], Office of Applied Studies. (2010).
Results from the 2009 National Survey on Drug Use and Health: Volume I summary of national
findings. NSDUH Series H-38A, HHS Publication No. (SMA) 10-4856 Findings. Rockville, MD:
SAMHSA.
Substance Abuse and Mental Health Services Administration [SAMHSA], Office of Applied Studies.
(2011a). Treatment Episode Data Set (TEDS). 1999–2009 national admissions to substance abuse
treatment services. DASIS Series: S-56, HHS Publication No. (SMA) 11-4646. Rockville, MD:
SAMHSA.
Substance Abuse and Mental health Services Administration [SAMHSA]. (2011b). Managing chronic pain
in adults with or in recovery from substance use disorders. Treatment Improvement Protocol
(TIP) Series 54. HHS Publication No. (SMA) 12-4671. Rockville, MD: SAMHSA.

Substance Abuse and Mental Health Services Administration [SAMHSA]. (2011c). Leading
Change: A Plan for SAMHSA’s Roles and Actions 2011-2014. HHS Publication No.
(SMA) 11-4629. Rockville, MD: SAMHSA.

126

Tanielian, T., & Jaycox, L.H. (2008). Invisible wounds of war: Psychological and cognitive injuries, their
consequences, and services to assist recovery. Santa Monica, CA: Center for Military Health
Policy Research, Rand Corporation.
Teesson, M., Mills, K., Ross, J., Darke, S., Williamson, A., & Havard, A. (2008). The impact of treatment on
3 years' outcome for heroin dependence: Findings from the Australian Treatment Outcome Study
(ATOS). Addiction, 103, 80-88.
Tetrault, J.M., Desai, R.A., Becker, W.C., Fiellin, D.A., Concato, J., & Sullivan, L.E. (2008). Gender and nonmedical use of prescription opioids: Results from a national US survey. Addiction, 103 (2), 258268.
Tiffany, S.T., Freidman, L., Greenfield, S.F., Hasin, D.S., & Jackson, R. (2012). Beyond drug use: A
systematic consideration of other outcomes in evaluations of treatments for substance use
disorders. Addiction, 107 (4), 709-718. doi: 10.1111/j.1360-0443.2011.03581.x
Timko, C., Finney, J.W., & Moos, R.H. (2005). The 8-year course of alcohol abuse: Gender differences in
social context and coping. Alcoholism: Clinical and Experimental Research, 29 (4), 612–621.
Tollefson, J., Piggot, K., & FitzGerald, M. (2008). Management of chronic pain. In E. Chang & A. Johnson
(Eds.), Chronic illness and disability: Principles for nursing practice (pp. 110-125). Sydney,
Australia: Elsevier.
Torrens, M. (2008). Quality of life as a means of assessing outcome in opioid dependence treatment.
Heroin Addiction & Related Clinical Problems, 12 (1), 33-36.
Trigo, J.M., Martin-García, E., Berrendero, F., Robledo, P., & Maldonado, R. (2010). The endogenous
opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence, 108 (3),
183-194.
Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M.C.,… Watanabe, M. (2008).
Common chronic pain conditions in developed and developing countries: Gender and age
differences and comorbidity with depression-anxiety disorders. Journal of Pain, 9 (10), 883-891.
Tunks, E.R., Crook, J., & Weir, R. (2008). Epidemiology of chronic pain with psychological comorbidity:
Prevalence, risk, course, and prognosis. Canadian Journal of Psychiatry, 53 (4), 224-234.

127

Turk, D.C., Wilson, H.D., & Cahana, A. (2011). Treatment of chronic non-cancer pain. The Lancet, 377,
2226-2235.
Turner, J.A., Holtzman, S., & Mancl, L. (2007). Mediators, moderators, and predictors of therapeutic
change in cognitive-behavioral therapy for chronic pain. Pain, 127 (3), 276-286.
United States Census Bureau. (2010). United States 2010 census figures. Retrieved from
http://2010.census.gov/2010census/
Veilleux, J.C., Colvin, P.J., Anderson, J., York, C., & Heinz, A.J. (2010). A review of opioid dependence
treatment: Pharmacological and psychosocial interventions to treat opioid dependence. Clinical
Psychology Review, 30 (2), 155-166.
Verhoeven, K., Crombez, G., Eccleston, C., Van Ryckeghem, D.M.L., Nirketm, S., & Van Damme, S. (2010).
The role of motivation in distracting attention away from pain: An experimental study. Pain, 149,
229-234.
Volkow, N., & Li, T. (2004). Drug addiction: the neurobiology of behaviour gone awry. Nature Reviews
Neuroscience, 5, 963-970.
Walker, R., Cole, J., Logan, TK, Mateyoke-Scrivner, A., & Stevenson, E. (2011). Kentucky Treatment
Outcome Study 2011. Lexington, KY: University of Kentucky, Center on Drug & Alcohol Research.
Wetherell, J.L., Afari, N., Rutledge,T., Sorrell, J.T., Stoddard, J.A…..Atkinson, J.H. (2011). A randomized,
controlled trial of acceptance and commitment therapy and cognitive-behavioral therapy for
chronic pain. Pain, 152 (9), 2098-2107. doi: 10.1016/j.pain.2011.05.016
White House. (2011). Epidemic: Responding to America’s prescription drug abuse crisis. Retrieved from
http://www.whitehousedrugpolicy.gov
Whittle, S.L., Richards, B.L., Husni, E., & Buchbinder, R. (2011). Opioid therapy for treating rheumatoid
arthritis pain. Cochrane Database System Review, 11, Article Number, CD003113. doi:
10.1002/14651858.CD003113.pub3
Williams, V.S., Smith, M.Y., & Fehnel, S.E. (2006). The validity and utility of the BPI interference measures
for evaluating the impact of osteoarthritic pain. Journal of Pain and Symptom Management, 31
(1), 48-57.

128

Wilson, D.B., Zakkak, J.M., & Lanier, J.O. (2009). The association between body mass index and arthritis
among US adults: CDC’s surveillance case definition. Preventing Chronic Disease, 6 (2), A56.
Winklbaur, B., Jagsch, R., Ebner, N., Thau, K., & Fischer G. (2008). Quality of life in patients receiving opioid
maintenance therapy. A comparative study of slow-release morphine versus methadone
treatment. European Addiction Research, 14, 99-105.
Younger, J.W., Chu, L.F., D'Arcy, N.T., Trott, K., Jastrzab, L.E., & Mackey, S.C. (2011). Prescription opioid
analgesics rapidly change the human brain. Pain, 52 (8),1803-1810.
doi: 10.1016/j.pain.2011.03.028
Zacny, J., Bigelow, G., Compton, P., Foley, K., Iguchi, M., & Sannerud, C. (2003). College on Problems of
Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position
statement. Drug and Alcohol Dependence, 69, 215-232.
Ziedonis, D.M., Amass, L., Steinberg, M., Woody, G., Krejci, J., Annon, J.J.,…Ling, W. (2009). Predictors of
outcome for short-term medically supervised opioid withdrawal during a randomized,
multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug
and alcohol dependence. Drug and Alcohol Dependence, 99, 28-36.

129

Vita
Date and Place of Birth
24 March 1972 in Princeton, Indiana
Educational Institutions Attended and Degrees Already Awarded
Masters of Social Work from University of Kentucky, May 2002
Bachelor of Arts in Elementary Education from Centre College, June 1994
Professional Positions Held
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Principal Investigator- October 2011 to present
• Joint SAMHSA and BJA Drug Court Enhancement Project Evaluation Grant, Pike County
• BJA Second Chance Family Based Prisoner Treatment Evaluation Grant, Johnson County
• BJA Co-occurring Treatment Evaluation Grant, Johnson County
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Principal Investigator- February 2011 to present
• Kentucky’s Opioid Treatment Program Outcome Study (KORTOS)
• SAMHSA Assertive Adolescent and Family Treatment Evaluation Grant , Floyd County
• BJA Grant Second Chance Family Based Prisoner Treatment Evaluation Grant, Floyd
County
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Co-Principal Investigator – January 2010 to present
• Kentucky Substance Abuse Treatment Outcome Project (KTOS)
• Adolescent Substance Abuse Treatment Outcome Study (AKTOS)
• Kentucky Opioid Replacement Treatment Outcome Study (KORTOS)
• Recovery Kentucky KTOS
• DCBS-Initiative KTOS
• KIDS NOW Project
• IMPACT Project
• Independence House Pregnant and Postpartum Women Project Evaluation
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Principal Investigator – March 2007 to November 2009 (project funding ended)
• Kentucky Youth First Project
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Project Director- July 2005 to January 2010
• Kentucky Substance Abuse Treatment Outcome Project (KTOS)
• Adolescent Substance Abuse Treatment Outcome Study (AKTOS)

130

•
•
•
•

State Data Infrastructure Project (SDI)
KY Youth First Project
Kentucky’s Opioid Treatment Program Outcome Study (KORTOS)
Family Futures Drug Court Project

Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Study Coordinator - March 2003 to July 2005
• Kentucky Substance Abuse Treatment Outcome Project (KTOS)
• State Data Infrastructure Project (SDI)
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky
Research Associate - May 2002 to March 2003
• NIAAA Study on Protective Orders and Intimate Partner Violence
University of Kentucky, College of Social Work, Lexington, Kentucky
Project Coordinator - February 2001 to May 2002
• Pilot Project Effects of Intimate Partner Violence on Women’s Employment
Lexington Fayette Urban County Government, Lexington, Kentucky
Project Coordinator - February to December 2001
• Studies on Workplace Violence and Work life Issues
Scholastic and Professional Honors
• Kentucky Coach, Network for Improvement of Addiction Treatment (NIATx) – Jan 2010 present
• Research Article Reviewer for The Journal of Rural Health - 2009 to present
• University Of Kentucky, College of Social Work, Lexington Campus Instructor
SW124 Introduction to Social Work
SW222 Undergraduate History of Social Welfare
SW430 Policy
SW450 Introduction to Social Work Research
SW750 Research Design
SW751 Research Implementation

Professional Publications
Journal Articles
Stevenson, E., & Cole, J. (2012). Variance in substance use among a among communitybased substance use treatment sample with chronic non-cancer pain. Paper in progress.
Abstract submitted to SSWR 2013 conference for oral paper presentation.
Cole, J. & Stevenson, E. (2012). Victimization, mental health, and substance use among

131

adolescents in substance abuse treatment. Paper in progress.
Stevenson, E., Cole, J., Walker, R., & Logan, TK. (2011). Association of persistent non-cancer pain
with substance abuse treatment outcomes among a Community Mental Health Center
sample. Paper being revised for resubmission.
Cole, J., & Stevenson, E. (2011). Tobacco use and psychiatric comorbidity among adolescents in
substance abuse treatment. Journal of Substance Abuse Treatment, in press.
Logan, T., Evans, L., Stevenson, E., & Jordan, C. (2005). Barriers to services for rural and urban
rape survivors. Journal of Interpersonal Violence, 20(5), 591-616.
Logan, T., Stevenson, E., Evans, L., & Leukefeld, C. (2004). Rural and urban women’s
perceptions of barriers to health, mental health, & criminal justice services: Implications
for victim’s services. Violence and Victims, 19(1), 37-62.
Professional Reports
Cole, J., Scrivner, A., Logan, TK, & Stevenson, E. (2012). Differences in substance use by
geographical region. KY Treatment In Focus, 4(2), 1-4. Center on Drug & Alcohol
Research: Lexington, KY.
Stevenson, E., Mateyoke-Scrivner, A., Cole, J., Walker, R., & Logan, TK. (2012). Kentucky’s
Opiate Replacement Treatment Outcome Study – 2011 Annual report. Center on Drug &
Alcohol Research, University of Kentucky.
Scrivner, A., Walker, R., Stevenson, E., Cole, J. & Logan, TK. (2011). Regional differences in
substance use. KY Treatment In Focus, 3(5), 1-4. Center on Drug & Alcohol Research,
University of Kentucky.
Scrivner, A., Walker, R., Stevenson, E., Cole, J. & Logan, TK. (2011). Substance abuse risk during
pregnancy: An overview of the KIDS NOW Plus Evaluation- Birth Event Characteristics.
KY Treatment In Focus, 3(4), 1-4. Center on Drug & Alcohol Research, University of
Kentucky.
Scrivner, A., Walker, R., Stevenson, E., Cole, J. & Logan, TK. (2011). Substance abuse risk during
pregnancy: An overview of the KIDS NOW Plus Evaluation- Characteristics at the
beginning of care. KY Treatment In Focus, 3(3), 1-4. Center on Drug & Alcohol Research,
University of Kentucky.
Cole, J., Stevenson, E., Mateyoke-Scrivner, A., Logan, T., & Walker, R. (2010). Tobacco use
among individuals in substance abuse treatment in Kentucky. KY Treatment In Focus,
3(2), 1-4. Center on Drug & Alcohol Research, University of Kentucky.
Mateyoke-Scrivner, A., Walker, R., Cole, J., Stevenson, E., Logan, TK, & Shannon, L. (2009).
Examining prescription opioid abuse in Kentucky: A look at an emerging trend. KY
Treatment In Focus, 2(3), 1-4. Center on Drug & Alcohol Research, University of
Kentucky.
Cole, J., Stevenson, E., Scrivner, A., Newell, J., & Walker, R. (2010). Adolescent KTOS Follow-up
Report 2010. Lexington, KY: University of Kentucky, Center on Drug & Alcohol Research.
Stevenson, E., Walker, R., Logan, TK., Cole, J., & Mateyoke-Scrivner, A. (2009). Supporting
medication assisted treatment outcomes research: An overview of Kentucky’s Opioid
Replacement Treatment Outcome Study. KY Treatment In Focus, 2(2), 1-4. Center on
132

Drug & Alcohol Research, University of Kentucky. Lexington, KY: University of Kentucky,
Center on Drug & Alcohol Research.
Cole, J., Walker, R., Logan, TK., Stevenson, E., & Mateyoke-Scrivner, A. (2009). Following
substance abuse treatment clients over time: Tips from the front lines. KY Treatment In
Focus, 2(1), 1-6. Center on Drug & Alcohol Research, University of Kentucky.
Stevenson, E., Shannon, L., Walker, R., Mateyoke-Scrivner, A., Logan, TK., & Cole, J. (2008).
Kentucky women in substance abuse treatment: Rural Appalachia. KY Treatment In
Focus, 1(2), 1-4. Center on Drug & Alcohol Research, University of Kentucky.
Stevenson, E,. Walker, R., Cole, J., Logan, TK, Mateyoke-Scrivner, A., & Corrigan, J. (August,
2008). Substance use treatment clients with traumatic brain injury. KY Treatment In
Focus, 1(1), 1-4. Center on Drug & Alcohol Research, University of Kentucky.
Walker, R., Mateyoke-Scrivner, A., Cole, J., Logan, TK., Stevenson, E., Leukefeld, C., & Jackson, T.
(2008). Fiscal year 2007 follow-up findings from the Kentucky Substance Abuse
Treatment Outcome Study. Lexington, KY: University of Kentucky, Center on Drug &
Alcohol Research.
Walker, R., Mateyoke-Scrivner, A., Cole, J., Logan, TK., Stevenson, E., Leukefeld, C., & Jackson, T.
(2007). Kentucky substance abuse treatment outcome study: Fiscal Year 2005 follow-up
findings and summary report (CDAR Technical Reports 2007-1, 2). Lexington, KY:
University of Kentucky, Center on Drug & Alcohol Research.
Walker, R., Mateyoke-Scrivner, A., Cole, J., Logan, TK., Stevenson, E., & Leukefeld, C. (2006).
Kentucky substance abuse treatment outcome study: FY2004 follow-up findings and
summary report (CDAR Technical Reports 2006-3, 4). Lexington, KY: University of
Kentucky, Center on Drug & Alcohol Research.
Walker, R., Mateyoke-Scrivner, A., Bradshaw, G., Logan, TK., Stevenson, E., Leukefeld, C., &
Goltz, M. (2006). Kentucky substance abuse treatment outcome study: FY2003 followup findings and summary report. (CDAR Technical Reports 2006-1, 2). Lexington, KY:
University of Kentucky, Center on Drug & Alcohol Research.
Walker, R., Logan, TK, Bradshaw, G., Leukefeld, C., Goltz, M., & Stevenson, E. (2005). Kentucky
substance abuse treatment outcome study: FY2002 regional summary reports of
statewide follow-up findings (CDAR Technical Reports 2005-1.1-14). Lexington, KY:
University of Kentucky, Center on Drug & Alcohol Research.
Walker, R., Logan, TK, Bradshaw, G., Leukefeld, C., Goltz, M., & Stevenson, E. (2004). Kentucky
substance abuse treatment outcome study: FY2002 summary report of statewide followup findings (CDAR Technical Report 2004-4). Lexington, KY: University of Kentucky,
Center on Drug & Alcohol Research.
Walker, R., Logan, TK, Bradshaw, G., Leukefeld, C., Goltz, M., & Stevenson, E. (2004). Kentucky
substance abuse treatment outcome study: FY2002 follow-up findings (CDAR Technical
Report 2004-3). Lexington, KY: University of Kentucky, Center on Drug & Alcohol
Research.
Walker, R., Logan, T., Leukefeld, C., & Stevenson, E. (2004). Kentucky traumatic brain injury
prevalence study (CDAR Technical Report No. 2004-1). Lexington, KY: University of
Kentucky, Center on Drug & Alcohol Research.
133

Recent Research Presentations
Stevenson, E., & Cole, J. (2012). Variance in substance use among a among communitybased substance use treatment sample with chronic non-cancer pain. Abstract
submitted to SSWR 2013 conference for oral paper presentation.
Cole, J. & Stevenson, E. (2012). Victimization, mental health, and substance use among
adolescents in substance abuse treatment. Accepted for oral paper presentation at
Council on Social Work Education (CSWE) conference in Washington, D.C., November 912, 2012.
Stevenson, E. (2012). Chronic pain among individuals in treatment for opiate dependence:
Preliminary findings. Presentation of oral paper at Society for Social Work Research
(SSWR) annual conference in Washington, DC, January 14, 2012.
Cole, J., & Stevenson, E. (2011). Persistent tobacco use among adolescents in substance abuse
treatment. Presentation of oral paper at Council on Social Work Education (CSWE)
conference in Atlanta, GA, October 27-30, 2011.
Stevenson, E., & Cole, J. (2011). Overview of addiction and chronic pain: Examining outcomes
among substance abuse treatment clients with chronic pain. Kentucky Association of
Social Work Education (KASWE) conference in Louisville, KY, April 7, 2011.
Stevenson, E. (2011). Gender differences in chronic pain among opiate treatment clients.
Presentation of oral paper at Society for Social Work Research (SSWR) annual
conference in Tampa, FL, January 14, 2011.
Typed Name of Student on Final Copy
Jennifer Erin Stevenson

134

